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A common pathological feature of various neurodegenerative disorders is the 
accumulation of misfolded proteins in the brain. Neurodegenerative disorders 
associated with protein misfolding include Alzheimer’s disease (AD), Parkinson’s 
disease (PD), dementia with Lewy bodies (DLB), fronto-temporal lobar degeneration 
(FTLD), motor neuron disease (MND), Huntington’s disease and the prion diseases.  
The incidence and prevalence of most of these diseases is rising, especially those 
that cause dementia, due to an increase in the average human life span. 
 
The diagnosis of neurodegenerative disorders is heavily reliant on physical 
examinations and assessment of clinical symptoms.  The clinical symptoms of many 
of these neurodegenerative diseases overlap, which poses a huge difficulty for 
accurate diagnosis, especially in the early stages.  This has led to an interest in 
identifying reliable and robust discriminatory molecular biomarkers.  A successful 
biomarker test will not only provide a more accurate means of diagnosis, but will 
allow efficient tracking of disease progression, benefitting the process of developing 
therapeutic strategies. 
 
In this project, the development and validation of a bead based assay system that 
has multiplexing capabilities (simultaneously measure multiple analytes in a single 
sample via a single assay) has been described.  This assay system uses the 
Luminex technology and has been developed to quantitatively measure 
phosphorylated α-synuclein, total α-synuclein, total DJ-1 and LRRK2 in human CSF 
and plasma.  These proteins are predominantly implicated in diseases collectively 
termed α-synucleinopathies.  The initial aim of the project was to develop assays for 
proteins that span a range of neurodegenerative disorders, however, for reasons 
discussed in the final chapter of this thesis, this was not possible.  
ii 
 
This project provides evidence on how the use of plasma as a possible matrix for 
potential markers associated with brain diseases can be justified, since levels of 
phosphorylated α-synuclein in matched plasma and CSF samples positively 
correlated with each other.   Plasma would be an ideal sample source for biomarker 
studies, since it is less invasive than obtaining CSF, thus allowing longitudinal studies 
to be performed. 
 
It was also shown how the DJ-1 protein in plasma may carry diagnostic potential by 
allowing differentiation between PD patients and healthy controls (p=0.004) as well 
as between PD and MSA patients (p=0.005).  The discrimination between PD and 
MSA is vital since the two diseases are symptomatically very similar, thus posing a 
greater issue with accurate diagnosis. 
 
There has been minimal research discussing the presence of LRRK2 in human 
biological fluids such as plasma and CSF.  This thesis presents the use of western 
blotting, high performance liquid chromatography (HPLC) and the Luminex 
technology as a means of detecting this protein in human CSF and plasma.  The 
data related to LRRK2 in this thesis, opens up avenues for further research into this 
protein; to definitively show whether it can be detected in such biological fluids and 
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1.1  Project Overview 
 
The general goal of this project was to develop and validate a biomarker multiplex 
assay system utilising the bead based Luminex technology (refer to Chapter 2b for 
details on this method).  The multiplex system was used to analyse a range of 
plasma/CSF samples associated with various neurodegenerative diseases.  
 
α-Synuclein and DJ-1 are amongst the most sought after biomarkers related to α-
synucleinopathies and interest in LRRK2 has risen dramatically too.   
 
It was initially thought that α-synuclein exists solely as an intracellular protein due to 
the lack of a “signal sequence” directing the protein to the endoplasmic reticulum 
(ER) for secretion into the extracellular space.  However, revelations showing the 
presence of α-synuclein in CSF and blood plasma have now led to the theory that 
neurones secrete α-synuclein into the circulatory system (El-Agnaf et al, 2003; Lee et 
al, 2006a).  Although the mechanisms involved in the secretory pathway of α-
synuclein are not yet fully understood, the possibility and interest for using α-
synuclein as a biomarker for various neurodegenerative diseases has since 
intensified. 
 
Research into DJ-1 levels in CSF has been performed on cross sectional samples 
taken from Parkinson’s disease (PD) and healthy control samples (Waragai et al, 
2006; Hong et al, 2010, Herbert et al, 2014).  Fewer studies investigating DJ-1 levels 
in plasma have been reported (Waragai et al, 2007; Shi et al, 2010).  In this project, 
plasma and CSF samples from individuals with a range of neurodegenerative 
disorders, including  PD, multiple system atrophy (MSA),  dementia with Lewy bodies 




1 has the potential to differentiate the various disease groups from healthy 
individuals, as well as to differentiate between clinically similar diseases. 
 
LRRK2 is a relatively novel protein – its use as a biomarker has not been determined 
so far.  Its physiological role is not fully understood but a lot of interest into the protein 
has been generated from findings that multiple mutations in LRRK2 are associated 
with the onset of PD.  The initial aim of this project regarding this protein is to see if 
LRRK2 is detectable and thus measurable in human biological fluids such as CSF 
and plasma. 
 
By developing a multiplex assay in which biomarkers such as α-synuclein, DJ-1 and 
LRRK2 are included, the aim is to ascertain whether there is a trend in certain 
biomarker levels that will allow differentiation between clinically similar 
neurodegenerative disorders. Furthermore, by analysing these protein levels in both 
CSF and plasma, this project will show whether there is a correlation between 








1.2  Chapter Overview 
 
The formation and accumulation of insoluble protein aggregates has been implicated 
in the pathogenesis of many diseases, including, sickle cell disease (Horwich, 2002), 
α-1-antitrypsin deficiency (Gregersen et al, 2005) and neurodegenerative diseases 
(Aguzzi et al, 2010).  These disorders are collectively termed “amyloidoses”, due to 
protein aggregates presenting themselves as highly ordered cross-β-spine structures 
named amyloid fibrils (Aguzzi et al, 2010).  
 
In order to design and implement therapeutic strategies for the management of 
protein aggregation diseases, it is important to understand why protein aggregates 
occur, the mechanisms leading to their formation and what pathological changes they 
exert.  This chapter commences with an overview on the current theories related to 
how protein aggregates occur, including a discussion on the role of Molecular 
Chaperones and the Ubiquitin Proteasome System (UPS). 
  
The chapter continues with particular focus on protein aggregation in 
neurodegenerative disease.  Neurodegenerative diseases include AD, PD, DLB, 
fronto-temporal lobar dementia (FTLD), motor neurone disease (MND) and prion 
disease (Kokalj et al, 2005).  PD, DLB, and MSA will be the main disorders discussed 
in this report, with a description on the role of some of the major proteins implicated 
in their pathogenesis; α-synuclein (PD, DLB, MSA), DJ-1 (PD) and LRRK2 (PD). 
 
The report concludes by highlighting the potential use of these proteins as 







1.3  Protein Aggregation and Disease 
 
The human body contains approximately 100,000 different types of proteins which all 
have a vital role to play in virtually every chemical process upon which our lives 
depend (Dobson, 2004).   
 
Post translation, each polypeptide chain adopts a unique folded tertiary structure.  
The biological activity and flawless functionality of each protein is dependent on the 
act of protein folding.  The importance of protein folding has encouraged a great 
interest into this phenomenon.  Dobson (2004) has summarised very effectively the 
proposed ideas on how proteins fold and what factors influence the final protein 
structure.  Protein folding does not involve a simple cascade of events that take place 
in a step by step fashion; instead, evidence has indicated that protein folding involves 
a “stochastic/random” search of the many conformations available to a newly 
synthesised polypeptide chain.  Amongst these various structures, the fold that 
achieves the most stability under physiological conditions is the fold that is most 
favoured.  This stochastic approach is also referred to as the “new view” and 
employs the concept of “energy landscapes”, where the final structure of a protein is 
the conformation that requires the least free energy (Dobson, 2005). 
 
The number of different conformations available to a newly synthesised polypeptide 
chain is vast and complex, thus the prospect and occurrence of misfolding is 
inevitable.  The cause of many diseases, including some important 
neurodegenerative diseases, has been attributed to the occurrence of misfolded 
proteins (Wolozin, 2012).  In various diseases misfolding of the protein can diminish 
or alter its normal functionality, leading to some of the symptomatic effects 




Furthermore, the misfolded proteins can also form aggregates within cells in the form 





Figure 1.1: Image of an amyloid fibril:  A molecular model of an amyloid fibril derived from 
cryo-EM analysis.  The fibril consists of four protofilaments twisted around one another, 
forming a hollow tube with a diameter of 6 nm (Dobson, 2004). 
 
Each amyloid disease (amyloidosis) involves the aggregation of one or more specific 
proteins, protein fragments or peptides.   Studies have revealed important features of 
protein aggregates that have allowed scientists to theoretically piece together the 
steps leading up to protein aggregation.  The core structure of amyloid fibrils is found 
to be stabilised by hydrogen bonds, primarily involving the protein “main 
chain/backbone” that is common amongst all proteins – this explains why protein 
fibrils with very different amino acid sequences can form fibrils that are ultra-
structurally very similar.  The protein aggregation process can be split into three 
major stages: 
 
 Stage 1:  Formation of oligomers – involves monomeric proteins binding to one 
another.  They are often described as being disorganised structures that expose 
hydrophobic areas of the protein that would normally be hidden.  In some cases, 





 Stage 2:  Formation of protofibrils or protofilaments – the oligomeric structures 
enjoin to form short, thin, sometimes curly fibril like species. 
 
 Stage 3:  Formation of mature fibril – the protofilaments associate laterally and 
twist around each other to form a mature fibril that constitutes the main 






Figure 1.2: Protein Aggregation Process:  Diagram illustrating the stages leading to 
amyloid fibrilisation. 
 
It is yet debatable at which stage the aggregate elicits its toxic effect, i.e. is it the final 
fibril or the prior structures? 
 
In the overall scheme of things, the process of protein synthesis is highly complex.  
Its efficiency is a testament to evolutionary biology, where the physiologically 
favoured protein structures have been passed through generations via natural 
selection.  Furthermore, the human body is equipped with quality control 
mechanisms in order to minimise the risk and occurrence of misfolded proteins and 
their undesired effects.  Unfortunately, the existence of misfolded protein diseases 
makes it clear that misfolding still occurs, and it has been proposed that in diseased 
states, such quality control mechanisms may be faulty or inadequate.  The 
combinatory actions of molecular chaperones, the ubiquitin proteasome system 
(UPS) and the autophagy lysosomal pathway (ALP) form the major quality control 
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1.4  The Ubiquitin Proteasome System 
 
Molecular chaperones act to prevent the actual misfolding of proteins and are defined 
as proteins that aid other proteins in reaching their native stable conformational state.  
They are also known as “heat shock proteins” (HSPs).  The name originates from the 
fact that their levels are abundantly increased in response to stressed conditions 
such as increase in temperature, and more relevantly, during an increase in the 
concentration of protein intermediates prone to aggregation (Frydman, 2001).   
 
In brief, chaperones/HSPs perform their role by binding to the protein being 
synthesised on a temporary basis until the protein folding is complete.  It has already 
been established that proteins undergo a search for the conformation that suits them 
in terms of their physiological stability.  During this search, the protein passes 
through a stage where it exists in a partially folded state. These partially folded 
proteins expose hydrophobic amino acid residues which can encourage misfolding 
and aggregate formation.  Chaperones/HSPs bind to these hydrophobic amino acid 
residues to prevent this misfolding.  If however, misfolding has already occurred, 
Chaperone/HSPs have the ability to direct the offending protein to either be refolded 
or undergo protein degradation (Hartl et al, 2011).  The latter activity, involving 
protein degradation, is when the UPS comes into play.   
 
Muchowski et al (2005) and Lecker et al, (2006) have very elegantly and simply 
highlighted the role of the UPS in proteolytic degradation.  The UPS involves a series 
of ATP-dependent enzymatic reactions.  These enzymatic activities link chains of a 
polypeptide co-factor, ubiquitin (Ub), onto proteins that are destined to be degraded.   
It has been mentioned previously, that protein aggregates associated with different 
diseases share many morphological features (Dobson, 2004).  Another similar trait is 




chaperones/HSPs (Huang et al, 2010).  This suggests that the functionality of these 
two systems may be defective to some extent.   
 
Many amyloid diseases including those involved in neurodegeneration are diseases 
of old age.  Soti et al (2002) define ageing as “a multicausal process leading to a 
gradual decay in self defensive mechanisms” (Soti et al, 2002).  The slow breakdown 
of self-defensive mechanisms that normal cells rely on for homeostasis results in an 
accumulation of damage at a molecular level.  In relation to protein misfolding, such 
damage reflects stressful conditions in which the demand for chaperone/HSPs and 
UPS activity is greatly increased.  It is proposed by Soti et al (2002), that 
chaperones/HSPs and UPS struggle with this sudden high demand, as ageing 
progresses, the need for these protective systems increases even more.  In addition, 
Huang et al (2010), state that proteasome function declines with age.  Studies with 
Drosophila Melanogaster have revealed reduced ATP levels in old flies when 
compared to levels in young flies.  The 26S proteasome degradation unit is ATP 
driven, thus supporting the theory that ageing decreases the quality control 
mechanisms associated with maintaining cell homeostasis and preventing diseased 
states (Soti et al, 2002).  This could be one of the reasons why protein misfolding 
diseases often occur in old age. 
 
1.5  Autophagy Lysosomal Pathway 
 
The UPS and ALP are two independent but complementary degradation systems - 
when one system fails the other compensates.  The term “autophagy” is greek for 
“self-eating” and involves degrading and decomposing target components using the 





I. Chaperone mediated autophagy (CMA):  as the name suggests, the actions of a 
chaperone; specifically cytosolic hsc70, is pivotal to this system (Chiang et al, 
1989).  The CMA pathway is unique since it only degrades proteins that have a 
specific amino acid sequence – KFERQ, this motif is found in approximately 30% 
cytoplasmic proteins (Dice, 1990).  Hsc70 binds to proteins with this particular 
amino acid sequence which is then directed to the lysosomal membrane where it 
interacts with LAMP-2A to initiate a series of downstream events leading to the 
degradation of the protein (Cuervo et al, 1996; Agarraberes et al, 1997; Eskelinen 
et al, 2005).  
 
II. Macroautophagy: this system is defined by the formation of de novo double 
membrane bound vesicles, called autophagosomes,  as a way of isolating and 
taking components to be degraded to the lysosomes (Noda et al, 2002; Kraft et 
al, 2012).  The outer membrane of the autophagosomes then fuses with the 
lysosome to receive its constituents, including, lysosomal hydrolase.  Lysosomal 
hydrolase degrades the autophagosomal membrane and its contents. 
 
III. Microautophagy: first proposed by de Duve and Wattiaux around 50 years ago 
(de Duve and Wattiaux, 1966).  In contrast to macroautophagy, the components 
to be degraded are directly engulfed by the lysosomes as opposed to being 
isolated and delivered to lysosomes via autophagosomes. 
 
Amongst the many proteins destined to be degraded by the ALP is α-synuclein.  The 
importance and relevance of this protein to disease is discussed in subsequent 
sections, but in summary, the aggregates of this protein are the pathological 
hallmarks of a range of diseases that fall under the “synucleinopathies” group.  
Monomeric α-synuclein can be degraded by both the UPS and ALP (Liu et al, 2003; 




predominantly degraded by the ALP (Lee et al, 2004).  Studies by Cuervo et al 
(2000) have shown that LAMP-2A down regulation, decreasing CMA activity is 
observed in ageing. In addition, certain genetic mutations, namely A53T, in the α-
synuclein gene SNCA associated with the onset of PD have been shown to block the 
CMA pathway (Xilouri et al, 2009).  There is not much evidence linking α-synuclein to 
microautophagy but overexpression of α-synuclein has been shown to interfere with 
macroautophagy (Winslow et al, 2010) and its aggregates have been shown to inhibit 
it (Tanik et al, 2013).   
 
1.6  Protein Aggregation and Neurodegenerative Diseases 
 
Neurodegenerative diseases involve the degeneration of a specific subpopulation of 
nerve cells in the CNS, which lead to the disease related clinical symptoms. Many 
neurodegenerative diseases are associated with an accumulation of abnormally 
folded proteins.  Table 1.1 lists the neurodegenerative disease and the 
corresponding misfolded protein: 
 
Neurodegenerative disease Protein(s) implicated 
AD* β-amyloid (Aβ),  tau 
PD** α-synuclein 
FTLD* TDP-43,  FUS,  tau  
MND* TDP-43,  FUS,  SOD-1 
DLB** α-synuclein 
Huntington’s disease (HD)* Huntingtin 
Prion diseases*** Prion protein (PrP) 
 
Table 1.1:  Misfolded proteins associated with neurodegenerative diseases:  




1.7  α-Synucleinopathies 
 
The neurodegenerative diseases studied for the purpose of this project are referred 
to as the “synucleinopathies”.   As the name suggests and as briefly mentioned in 
section 1.5, this disease group is comprised of disorders that share a common 
pathological feature – protein aggregates formed of α-synuclein.  PD, DLB and MSA 
are amongst the disorders included in this group.  α-Synuclein was first described in 
1988 by Maroteaux et al, but the defining studies strongly implicating the protein in 
neurodegenerative disease came from genetic findings showing that genetic 
mutations in the SNCA coding for α-synuclein lead to disease (Polymeropoulos et al, 
1996; Polymeropoulos et al, 1997; Kruger et al, 1998; Zarranz et al, 2004) and that 
this protein is found in the inclusions that have become the pathological hallmarks for 
these disorders (Spillantini et al, 1997; Iwatsubo et al, 1996; Spillantini et al, 1998; 
Wakabayashi et al, 1998a; Wakabayashi et al, 1998b).  The role of α-synuclein in 
PD, DLB and MSA are discussed in the following sections.  
 
1.8  Overview of Parkinson’s Disease 
 
Neurodegenerative diseases can be broadly categorised into three groups; 
movement disorders, neuromuscular disorders and dementing disorders.  
Parkinson’s disease (PD) falls primarily under the movement disorder category. 
 
The classical features of PD include tremors, rigidity, bradykinesia (slow, reduced 
movement) and postural instability.  Although, PD is often classified as a movement 
disorder, during the advanced stages, affected individuals can exhibit episodes of 
depression or anxiety and develop dementia (Aarsland et al, 2003; Hely, 2008). 
   
PD is the second most common neurodegenerative disease following AD.  Statistics 




Age has been shown to be a major risk factor for the disease, with the percentage of 
affected individuals within a population rising from 1% at 65 years old to 5% at 85 
years old.  Most cases are idiopathic, but some cases show a clear genetic 
correlation.  Many gene mutations have been revealed to be strongly linked to the 
onset of PD (Wood-Kaczmar et al, 2006) and some of them are associated with 
protein misfolding and aggregation, key examples of which are PARKIN (Kitada et al, 
1998), which encodes a ubiquitin protein ligase. 
 
1.8.1  History and Aetiology of Parkinson’s Disease 
 
References to this disease date back to AD175, where it is referred to as the 
“shaking palsy syndrome”, by a Physician known as Galen.  Post this citation; there 
is no mention of the disease in any western literature until 1817, when a London 
physician called James Parkinson authored a detailed medical essay, adeptly titled 
“An essay on the shaking palsy”.  The publication revolves around individuals from 
the doctor’s neighbourhood who presented with the disease.  The intention of the 
essay was and is fairly transparent - to encourage and highlight the need for 
research in to the disease and have it recognised as a specific medical condition.  It 
wasn’t until approximately 60 years later that these intentions proved fruitful.  A 
French neurologist, Jean Martin Charcot, built upon Parkinson’s case studies and 
promoted recognition of the condition to an international level.  Charcot renamed the 
“shaking palsy syndrome” as Parkinson’s disease in reverence to the immense work 
that Dr. James Parkinson performed in order to bring medical attention to this 
debilitating condition (www.parkinsons.org). 
 
For many decades, it was believed that the sole pathological feature and cause of 




of the brain, which decreased the level of neurotransmission into the basal ganglia, 
causing the movement disorders typical of PD.   
 
Advances in the PD research field have now revealed that as well as the loss of 
dopaminergic neurones in the SN, surviving neurones within the SN and other brain 
regions contain insoluble protein inclusions.  These protein inclusions are found in 
the neuronal cell body and/or neuronal processes.  Inclusions in the cell body are 
referred to as Lewy bodies (LBs) and those enclosed in the neuronal processes are 
called Lewy neurites (LNs).  The terminology originates from the first founder of this 
pathological feature, Friedrich Lewy (Lewy, 1912).  LBs appear as spherical globules, 
consisting of a dense core surrounded by a pale stained halo of radiating filaments.  
LNs appear as a thread-like structure (Forno, 1996).  Both LBs and LNs have been 
found to be enriched with filaments of a protein called α-synuclein, as well as other 
proteins and they are often highly ubiquitinated (Shimura et al, 2001; Hasegawa et al, 
2002).  
 
1.8.2  Diagnosis and Treatment of Parkinson’s Disease 
 
The diagnosis of PD is heavily reliant on patient history and examination of visible 
symptoms (Savitt et al, 2006).  A scoring device named The United Parkinson’s 
Disease Rating Scale (UPDRS) has been generated in order to provide a 
standardized assessment tool and a means of tracking and documenting disease 
and treatment progression. The scale is subdivided into four categories - mental 
effects, limitations in activities of daily living, motor impairment and treatment 
complications. A diagnosis of PD is attained if the following cardinal signs are visible 






 Distal or resting tremor of 3 to 6 Hz 
 Rigidity 
 Bradykinesia 
 Asymmetrical onset 
 
The clinical manifestations of PD are very similar to some other neurological 
disorders.  For instance, resting tremor is the most common feature amongst PD 
patients, yet, 20% of patients with autopsy confirmed PD fail to display this clinical 
feature (Suchowersky et al, 2006).  Furthermore, even after careful examinations, the 
level of PD misdiagnosis is stated to be at approximately 25% (Hughes et al, 2001; 
Savitt et al, 2006).  Thus, the clinical heterogeneity of PD compromises accurate 
diagnosis.  There are certain factors that aid in ruling out PD, such as lack of 
response to PD treatments and presence of dementia.  Advances in brain imaging 
techniques have not provided much advantage since a specific pattern that can be 
assigned to PD has not been established, but can aid in ruling out or confirming other 
ailments such as brain tumours (Rao et al, 2006). 
 
The discovery that PD is due to a loss of dopaminergic neurones has led to treatment 
strategies aimed at replacing the lost dopamine levels.  Unfortunately, dopamine 
does not cross the blood brain barrier and therefore cannot be administered directly 
as a form of therapy.  However, the dopamine precursor Levadopa (L-Dopa) does 
cross the blood brain barrier and has become the gold standard mode of treating PD.  
During the early years of using Levadopa, extremely high doses were required to 
have significant effects.  These high doses led to undesired side effects such as 
nausea and vomiting.  It was made apparent that these adverse effects were due to 
the rapid breakdown of L-Dopa by the enzyme dopa-decarboxylase (DDC), in the 
periphery of the body before it enters the brain.  Administering Levadopa in 




L-Dopa by 70%.  Unfortunately, by inhibiting DDC, another enzyme was found to 
breakdown dopamine, called Catechol-O-methyl transferase (COMT).  Thus, 
currently, L-Dopa is administered together with both a peripheral DDC inhibitor and 
peripheral COMT inhibitor.  This drug cocktail increases the levels of L-Dopa 
reaching the brain where it can be metabolised into dopamine and utilised as a 
neurotransmitter (www.epda.eu.com).  
 
There is no cure for PD but treatment methods are aimed at relieving symptoms in 
order to make lives more comfortable for patients.  Treatment strategies are flexible 
and are designed for various stages of the disease (Savitt et al, 2006; 
www.parkinsons.org). 
 
Early stage treatment involves using L-Dopa with DCC and COMT inhibitors.  
Dopamine agonists that stimulate dopamine receptors and mimic its actions are also 
used. The enzyme Monoamine Oxidase B (MAO-B) degrades dopamine at the nerve 
terminals, thus (MAO-B) inhibitors have also been used to alleviate mild symptoms 
seen in the very early stages of PD and reduce motor disabilities without the need for 
L-Dopa treatment.  Patients are categorised into the early stage group if they have 
been diagnosed with the disease for less than five years (Rao et al, 2006). 
 
Patients already receiving the L-Dopa treatment are grouped into the “late stage 
phase” of the disease.  Approximately 40% of patients receiving L-Dopa treatment 
develop a “wearing off” effect, where the benefits of therapy dwindle and PD 
symptoms, such as motor complications reappear.  Some patients also experience 
an “on and off” effect from L-Dopa therapy, where unpredictable fluctuations in the 
symptoms occur.  Such late stage phase patients are given dopamine agonists or 
higher doses of the DDC and COMT inhibitors as an attempt to relieve the “wearing 




Patients within the advanced stages of the disease do not only contend with motor 
complications but may suffer from depression, anxiety and psychosis.  Depression is 
treated with selective serotonin reuptake inhibitors.  Psychosis is a side effect from 
the use of dopamine agonists and high doses of L-Dopa, therefore decreasing the 
dose of administration is a common way of managing these non-motor related 
symptoms.  Surgical procedures have also become an option.  Deep Brain 
Stimulation of the subthalamic nucleus has been shown to improve motor related 
symptoms associated with PD (Rao et al, 2006). 
 
There are only a few options available for the treatment, and as explained these do 
not offer a consistent improvement in the quality of life for the patients.  They also do 
not treat the on-going loss of dopaminergic neurones.  This highlights the importance 
of continuing research into the underlying pathology behind PD.  Further research 
may lead to more effective, reliable strategies as well as potential preventative 
measures. 
 
1.9  Overview of Multiple System Atrophy 
 
MSA is a progressive neurodegenerative disorder with patients experiencing 
symptoms that affect the autonomic nervous system and/or movement (Rehman, 
2001).  The disease is believed to affect 3 in 100000 persons worldwide and is 
considered as being rare, but this figure may not be accurate, since the symptoms of 
MSA in the early stages are very similar to PD and thus prone to misdiagnosis 
(www.patient.co.uk/doctor/multiple-system-atrophy).  MSA is often categorised into 






 MSA-P : also known as the Parkinsonian type.  As the subtype name suggests, 
the dominating symptoms within this group are very similar to PD i.e. rigidity, 
tremors, gait and speech issues. 
 
 MSA-C : referred to as the cerebellar type.  The main symptoms are due to the 
degeneration of an area of the brain called the cerebellum and include the 
progressive loss of coordination and balance (Gilman et al, 2008 and 
www.multiplesystematrophy.org/about-msa/types-symptoms). 
 
1.9.1  History and Aetiology of Multiple System Atrophy 
 
The varying nature of the symptoms associated with MSA, originally resulted in the 
invention of three distinct diseases – Shy Drager syndrome, striatonigral 
degeneration and sporadic olivopontocerebellar atrophy  - these terms are no longer 
used and all three diseases are now defined as MSA.  Bearing this in mind, the first 
case of MSA may have been described in 1925 by Bradbury and Eggleston. The 
current terminology of MSA was not invented until 1969 (www.parkinsons.ie/Atypical-
MSA). 
 
The key pathological feature of MSA is the presence of α-synuclein aggregates in the 
form of cytoplasmic inclusions in the glial cells of the basal ganglia, primary motor 
cortices and the protocellebellar, giving rise to the aforementioned symptoms 









1.9.2  Diagnosis and Treatment of Multiple System Atrophy 
 
Diagnosis of MSA is challenging since symptoms are very similar to PD and there 
are no tests that are specific to MSA.  Thus, diagnosis is heavily reliant on the 
physical examination of visible symptoms, medical history and ruling out other 
possible causes of symptoms.  MRI scans are often performed to dismiss other brain 
lesions as the source of symptoms.  Tests designed to investigate the blood pressure 
control system and autonomic nervous system can aid with diagnosis too  
(Gilman et al, 2008 and www.mayoclinic.org/diseases-conditions/multiple-system-
atrophy/basics/tests-diagnosis/con-20027096). 
 
There is no cure for MSA, but treatments directed at alleviating symptoms are 
available.   
 
Table 1.2 lists a few medications for some symptoms.   The diverse range in 
symptoms involved in MSA means that a multidisciplinary team approach is required 
to ensure MSA patients are treated effectively whilst improving their quality of life 















Used for treating PD symptoms.  
Response to L-Dopa has been 





















Antimuscarinic drugs can reduce 
the urgency and frequency. 
 
DDAVP have the ability to 
reduce the amount of urine 
produced overnight – thus, may 





Caution must be taken with 
these drugs as they may cause 




These drugs work to increase 
blood pressure, since dizziness 
is often attributed to low blood 
pressure. 
 
Table 1.2:  MSA symptoms and medications: common clinical symptoms associated with 
MSA and the medications given to alleviate such symptoms.  Taken from 
(msatrust.org.uk/living-with-msa/newly-diagnosed/treatment-management-of-msa). 
 
1.10  Overview of Dementia with Lewy Bodies 
 
DLB accounts for approximately 25% of dementia cases and is usually found in 
people aged 60 – 90 years.  It presents itself with a mixture of AD and PD like 
symptoms (Breitve et al, 2014).  In addition to dementia and movement disorders, 
DLB patients exhibit symptoms such as hallucinations, delusions, sleeping problems 





1.10.1  History and Aetiology of Dementia with Lewy Bodies 
 
As the name suggests, the pathological feature for DLB is the presence of Lewy 
bodies (LB) and Lewy neurites (LN) similar to those found in PD, in the cortical and 
limbal regions of the brain.  The distribution of these abnormal α-synuclein 
aggregates differ slightly between PD and DLB.  In DLB affected brains, the LBs and 
LNs are more concentrated in the cortical area, as opposed to the substantia nigra 
where they are prominent in PD affected individuals (Armstrong, 2014). 
 
DLB is sporadic, with a very low genetic association.  A study investigating risk 
factors for DLB revealed that depression and low caffeine intake increases the risk 
for developing DLB (Boot, 2013), however there is no one definitive cause for DLB. 
 
1.10.2  Diagnosis and Treatment of Dementia with Lewy Bodies 
 
A single test to conclusively diagnose an individual with DLB is non-existent.  As 
discussed for other neurodegenerative disorders, diagnosis is reliant on physical 
assessments of visible symptoms and careful judgement by the specialists involved.  
The heavy overlap of DLB symptoms with AD and PD has led to criteria designed to 
help differentiate between the clinically similar conditions.   
 
To distinguish between DLB and PD the following rules are used (McKeith et al, 
2005a and www.alz.org/dementia/dementia-with-lewy-bodies-symptoms.asp): 
 
 Diagnosis is PD if movement issues present themselves at least 1 year before 
the onset of dementia. 
 Diagnosis is DLB if dementia develops at least 1 year before or simultaneously 




The following guidelines are adopted to help differentiate between DLB and AD 
(www.emedicine.medscape.com/article.com/article/1135041-overview): 
 
 Memory loss is a dominating symptom in the early stages of AD compared to 
DLB 
 Visual hallucinations are more frequent in the early stages of DLB compared to 
AD 
 RBD is more common in early DLB patients compared to AD.  Ferman et al 
(2011) followed 234 neurodegenerative patients until autopsy and suggested that 
RBD could be used as a core clinical feature to improve diagnostic accuracy for 
DLB. 
 
There is no cure for DLB, but treatments designed to manage symptoms do exist.  
Medications used for alleviating AD and PD symptoms are obviously ideal for treating 
DLB.  Medicines include acetylcholinesterase inhibitors to help with hallucinations, 
Memantine to improve cognitive functions, L-Dopa to ease movement and 





1.11  α-Synuclein 
 
α-Synuclein belongs to a family of proteins known as “the synucleins”.  Other 
members of the family include β- and γ-synuclein.  The genes coding for α-, β- and 
γ-synuclein proteins are located on chromosome 4q.21.3 - q22 and are referred to as 
the SNCA, SNCB and SNCG genes, respectively (Goedert, 2001; George, 2002). 
 
α-Synuclein is a much conserved, acidic, 140 amino-acid residue long protein, with 
an approximate molecular weight of 14 kDa.  It is abundantly found residing in 
neuronal presynaptic terminals and in close proximity to synaptic vesicles.  In some 
diseased states, it has been hypothesised that the synuclein inclusions appear early 
in the disease process and follow a sequence of ascension, commencing from the 
lower brainstem and then spreading up towards to the central and wider cortical 
areas (Braak et al, 2003; Mckeith et al 2005a; Kovacs et al, 2014; Vekrellis et al, 
2011). 
 
The fact that an aggregated form of α-synuclein is a key feature of the 
aforementioned neurodegenerative disorders has encouraged research into the 
physiological role of this protein.  Since the functionality of a particular protein is 
closely related to its structure, many studies have been conducted in order to deduce 
the structure of α-synuclein.  The primary structure of α-synuclein has been shown to 
consist of seven, 11-residue repeat sequences that form five amphiphatic α-helices 
within the amino terminal region of the protein.  Helices 1 to 4 are predicted to be 
involved with binding to lipid vesicles and helix 5 appears to be responsible for 
protein-protein interactions.  The acidic carboxyl terminal region is believed to remain 
unstructured and may have a role in hindering fibril formation (Eliezer et al, 2001; 




most hydrophobic region that is hypothesised to be the aggregate-prone area (Beyer, 
2006). 






Figure 1.3: α-Synuclein structure:  Diagram showing the three sections of α-synuclein; N-
terminal, Central and C-terminal regions (Bisaglia et al, 2009) 
 
There are different opinions with regard to the structural state of α-synuclein 
intrinsically under physiological conditions.  α-Synuclein is described to be an 
intrinsically unstructured protein lacking a well-defined secondary or tertiary structure 
(Bisaglia et al, 2009).  It is widely accepted that α-synuclein resides in an unfolded 
state until it binds to or comes into contact with the acidic phospholipids on 
membranes and synaptic vesicles (Yates, 2011).    However, findings by Bartels et al 
(2011) challenge this opinion.  They have proposed that α-synuclein actually exists 
as a tetramer made up of four α-helical structures bound together.  In normal 
conditions these tetramers do not aggregate, but in pathological cases these 
tetramers are somehow destabilised and then become prone to aggregation.  Bartels 
et al (2011) state that the protein may have been unfolded in other scientific studies 
due to the harsh conditions used during the experiments or due to the proteins being 
expressed in E. coli bacterium.  Bartels et al (2011) claim to have studied α-synuclein 
protein purified from human cells using gentler methods.  The native structure of α-
synuclein is therefore debatable, but the link between α-synuclein aggregation and 
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1.11.1  Normal Physiological role of α-synuclein  
 
α-Synuclein is heterogeneously expressed in the human brain, with highest levels 
found in the SN and is normally a presynaptic protein.  It is synthesised in the cell 
body and transported to the nerve terminals via axonal transport (Lykkebo, 2002).  
The normal physiological role for α-synuclein is poorly understood, but structural 
studies in conjunction with transgenic mouse models have resulted in a few 
suggestions, which will be discussed (Vekrellis et al, 2011; Beyer, 2006; Bisaglia et 
al, 2009). 
 
Proteins with a disordered structure possess key features such as the ability to bind 
to distinct partners with high potential binding strength and increased speed of 
interaction.  Such features are found in many chaperones.  The disordered structure 
of α-synuclein suggests that this protein may also serve as a chaperone.  It has been 
found that α-synuclein shares homology with the phospho-dependent signalling 
chaperone protein 14-3-3 (Ostrerova, 1999).  14-3-3 is known to bind to tyrosine 
hydroxylase – an enzyme involved in the rate limiting synthesis of dopamine.  
Similarly, α-synuclein has been shown to bind to tyrosine hydroxylase and regulate 
the concentration of cytoplasmic dopamine (Bisaglia et al, 2009; Recchia et al, 2004). 
 
α-synuclein knockout mice demonstrate a lacklustre neurological phenotype.  In 
particular, the mice show a reduction in the number of vesicles in the presynaptic 
pool.  Thus, α-synuclein may play a role in the trafficking of synaptic vesicles 
(Lashuel et al, 2013; Bellani et al, 2010).  Synaptic vesicles are mainly composed of 
lipids and store various neurotransmitters.  From structural studies, the N-terminal 
region of α-synuclein has been shown to bind to lipid membranes, strengthening the 
possibility of this role for α-synuclein.  Burre et al (2010) have provided further 




series of tightly co-ordinated reactions that involves generating a membrane fusion 
complex.  The core component of this membrane fusion complex is Soluble NSF 
Attachment Protein (SNARE).  During each neurotransmitter release, the protein 
fusion complex undergoes assembly followed by disassembly. It is suggested that α-
synuclein plays a vital role in promoting the assembly of the membrane fusion 
complex by interacting with SNARE.  More specifically, the N-terminal region of α-
synuclein may bind to the phospholipid membrane and the C-terminal region to the 
SNARE protein synaptobrevin-2 (Burre et al, 2010). Furthermore, a genome wide 
screening in yeast reveal that approximately one third of the genes that enhance the 
toxicity of α-synuclein are involved in vesicle trafficking (Bisaglia et al, 2009).   
 
A novel physiological role for α-synuclein has emerged recently, implicating α-
synuclein in the sustenance of nerve terminals and protecting them from cell death.  
It has already been mentioned that the protein 14-3-3 is a chaperone that binds to 
tyrosine hydroxylase.  14-3-3 has additional jobs as a participant in neuronal 
development, cell growth control and regulating apoptosis.  Xu et al (2002) have 
claimed that α-synuclein binds to 14-3-3, forming a 54 to 83kDa protein complex.  It 
is suggested that α-synuclein binds to 14-3-3 as an attempt to prevent apoptosis and 
give the cell a chance to recuperate from the damage it has undergone or deal with 
the stress it is under. 
 
In summary, while the exact physiological function of α-synuclein is still work in 
progress, its conformational flexibility and disordered structure has shed light onto 
the possible roles it may play. It is not entirely necessary for synaptic formation and 







1.11.2  The α-synuclein aggregation model 
 
Under certain conditions, α-synuclein misfolds into a β-sheet conformation and 
gradually assembles into fibrils with a typical amyloid like morphology.  This 
conformational change is referred to as the “aggregation” process and is believed to 
be the causal factor behind the neuronal toxicity typical of PD and other 
α-synucleinopathies. (Vekrellis et al 2011).  Amyloid fibrils are structurally classed 
into two groups: 
 
I. Fibrils generated from already folded proteins via the refolding mechanism or the 
gain of interaction model. The refolding mechanism is adopted by proteins that 
natively exist as folded proteins.  These proteins unfold and then refold into a β-
sheet enriched secondary structure that resembles the amyloid fibril 
configuration.  Fibrils generated from the gain of interaction method are rather 
more complicated. This model involves proteins with regions that are natively 
disordered, exposing a previously inaccessible region of its structure and binding 
to the surfaces of other proteins to gradually build an amyloid fibril (Breydo et al, 
2011). 
 
II. Fibrils generated from intrinsically unfolded/disordered proteins.  Fibrils 
composed of α-synuclein belong to this structural class.  α-synuclein exposes a 
hydrophobic region that interacts with other α-synuclein  proteins to form a well-
defined β-sheet containing secondary structure (Serpell, 2000). 
 
The review by Breydo et al (2012) summarises a collection of structural studies 
performed to elucidate a more detailed structural picture of the α-synuclein amyloid 
fibril.  These studies have used x-ray crystallography and x-ray diffraction methods to 




parallel to one another.  Furthermore, the side chains protruding from any two β-
sheets within the fibril, interlock with one another to form “steric zippers”.  These 
steric zippers prevent water from reaching the interface between the two strands, 
which explains the insoluble property of amyloid fibrils (Breydo et al, 2012). 
 
The aggregation process of α-synuclein is nucleation dependent, requiring the 
formation of “fibril nuclei” in order to generate the finalised fibrillar aggregate (Wood, 
1999).  The fibril nuclei are the oligomeric intermediates that are randomly formed 
from partial folding and interactions between individual monomers.  Following the 
formation of fibril nuclei, a fibril literally grows by adopting a “dock and lock” 
mechanism, in which free α-synuclein  monomers bind to (dock onto) previously 
buried and now exposed regions of the oligomer in an irreversible manner (lock) 
(Esler et al, 2000).  
 
The aggregation of α-synuclein is a multistep process, thus in order to direct 
therapeutic strategies onto a successful pathway it is important to identify which part 
of the process is actually eliciting the neurotoxic effects and how.  Three mechanism 
of how aggregation may lead to neurotoxicity have been proposed: 
 
The first proposed mechanism is “toxic gain of function”, where in simple terms, 
α-synuclein adopts a neurotoxic property. α-synuclein has been shown to undergo 
cytotoxic modifications when exposed to metals such as iron and copper as well 
dopamine metabolites.  The significance of copper interactions is yet to be identified, 
but the environment in which α-synuclein is largely present, i.e. presynaptic terminals 
of the SN, is high in iron and dopamine metabolite content (Dickson, 2001). 
 
The second proposed mechanism is “toxic loss of function”.  The possible loss of the 




previous sections.  In addition to these systems being dysfunctional, it is proposed 
that in pathological conditions where α-synuclein is sequestered in an aggregated 
form, it is no longer available to perform its normal duties.  One of the roles of 
α-synuclein is to control dopamine levels by acting as a negative regulator for 
tyrosine hydroxylase.  A failure to suspend the activities of tyrosine hydroxylase 
results in an increase in dopamine levels.  Cell death due to high levels of dopamine 
is believed to be caused by the formation of highly reactive oxygen species that 
create an environment of oxidative stress leading to neuronal cell death (Dickson, 
2001). 
 
The final suggested mode of neurotoxicity is “mechanical disruption”.  Oligomers also 
known as fibril nuclei, have been shown to have the ability to penetrate through 
cellular membranes and create pore-like channels.  The formation of these pores 
abnormally increases the membranes ionic permeability and cause cell death 
(Bennett, 2005; Breydo et al, 2011). 
 
1.11.3  The α-synuclein “prion-like” hypothesis 
 
The possibility that proteins implicated in the pathogenesis of various 
neurodegenerative disorders behave in a “prion-like” manner has been proposed.  A 
prion is a type of misfolded protein that can recruit and trigger normal proteins to fold 
abnormally via a self-templating model.  Prion proteins also have the ability to 
transfer from cell to cell and thus act as an infectious agent that confers disease 
onset and its progression (Griffith 1967; Prusiner, 1982).  Prion diseases include 
scrapies, bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob 





The protein α-synuclein has been proposed to behave in a prion-like manner.  This 
prion-like behaviour originated from findings that embryonic dopaminergic neurones 
transplanted into the putamen of PD patients developed α-synuclein positive 
inclusions; 11-16 years post transplantation.  It was suggested that this time period 
was not enough for such inclusions to be generated naturally, and thus the possibility 
of α-synuclein spreading from diseased areas to non-diseased areas was proposed 
(Kordower et al, 2008; Brundin et al, 2008).  The possible mechanism for α-synuclein 
self-templating and transmitting from cell to cell is as follows: 
 
 Misfolded α-synuclein can access the extracellular space via exocytosis or 
nanotubes (Emmanouilidou et al, 2010).  This is consistent with detectable levels 
of α-synuclein in extracellular fluids such as plasma and CSF (discussed in 
chapters 5 and 6). Alternatively, misfolded α-synuclein may also be transmitted 
via direct synaptic contact  
 Neighbouring cells internalize the α-synuclein via passive diffusion, endocytosis 
and/or nanotubes (Hansen et al, 2011). 
 Within the cells, α-synuclein acts as a seed and induces normal α-synuclein to 
undergo a conformational change and conjoin with the misfolded protein to 
generate amyloid like fibrils. 
 
Evidence for α-synuclein being a prion is still in its infancy.  The most compelling 
evidence includes the research reported by Luk et al (2012), where non-transgenic 
mice, inoculated with preformed α-synuclein fibrils, generated a clear time and 
connectivity spread of α-synuclein inclusions with abundant pathology in the 
dopaminergic neurones of the substantia nigra.  This pathology was not observed in 
mice lacking α-synuclein – suggesting that host α-synuclein is necessary for α-




of α-synuclein being a prion, but, it is important to stress that this prion-like behaviour 
for α-synuclein is still in its infancy. It is still not clear whether, the results observed in 
transgenic mice is translatable into humans and furthermore, there is no evidence of 
α-synuclein being contagious which is a feature that prion proteins responsible for 
BSE, CJD and scrapies, possess (Irwin et al, 2013). 
 
1.12  DJ-1 
 
The DJ-1 gene was initially identified as a novel oncogene by Nagakubo et al (1997).  
Later, in 2003, research by Bonifati et al (2003) revealed data that linked the DJ-1 
gene with the onset of PD.  Bonifati et al (2003) showed a 4 kD homozygous 
chromosomal deletion and a homozygous L166P missense mutation (Baulac et al, 
2004), in Italian and Dutch PD patients, attributing DJ-1 as a causative gene for 
familial PD with recessive inheritance.  The link between DJ-1 and PD has directed 
research into the physiological and pathological role of the DJ-1 protein.   
 
DJ-1 is a 189 amino acid long protein that exists as a dimer (Cookson, 2003).  The 
protein is comprised of seven β-strands and nine α-helices in total and is expressed 
in most cells and tissues, including neurones and glial cells of the brain (Ariga et al, 
2013).  Oxidative stress is amongst the various hypothesis associated with the cause 
of PD.  It has been proposed that DJ-1 plays a neuroprotective role against oxidative 
stress and its loss of function may lead to PD pathogenesis (Baulac et al, 2004).  
Ariga et al (2013) have reviewed the physiological and pathological roles of DJ-1 









1.12.1  DJ-1: Physiological and Pathological role in disease 
 
DJ-1 is a multifunctional protein involved in reducing the level of damage caused by 
oxidative stress.  Its activity is highly dependent on the reduction of cysteine residue 
106 (C106).  During oxidative stress, the level of C106 reduction is proportional to the 
intensity and exposure time of oxidative stress, where C106 is first oxidised to SOH, 
then SO2H, followed by SO3H.  DJ-1 is rendered inactive when C106 is oxidised to 
SO3H, and it is this form of DJ-1 that is found in PD and AD patients (Bandopadhyay 
et al, 2004).   This suggests that DJ-1 protects cells against oxidative stress by 
oxidising itself.  Other protective measures against oxidative stress include 
transcriptional regulation, mitochondrial regulation as well as exercising chaperone 
activity (Lin et al, 2012).   
 
DJ-1 has been shown to regulate the transcription of nuclear factor erythroid-2-
related factor 2 (Nrf2), p53 and polypyrimidine tract binding protein associated 
splicing factor (PSF).  The regulation of all three factors is important during anti-
oxidative stress response (Ariga et al, 2013).  Nrf2 normally resides in the cytoplasm 
as a protein complex with Keap1, which is then degraded by the UPS.  However, 
under oxidative stress conditions, DJ-1 sequesters Keap1, resulting in the 
translocation of Nrf2 to the nucleus where it activates anti-oxidative stress genes with 
the aim to reduce ROS levels (Clements et al, 2006).  p53 is a tumour suppressor 
gene and has the role of inducing apoptotic events in response to oxidative stress.  
DJ-1 binds to p53 in order to prevent apoptosis and give the affected cells time to 
repair themselves against damage (Kato et al, 2013).  The PSF protein is involved in 
reducing transcription of the tyrosine hydroxylase (TH) gene.  This gene encodes for 
the enzyme tyrosine hydroxylase which plays a vital role in dopamine synthesis.  
Tyrosine hydroxylase converts tyrosine to L-DOPA, which is then converted to 




regulates TH transcription during oxidative stress by sequestering PSF (Zhong et al, 
2006).  Researchers have shown that when SOH and SO2H forms of DJ-1 exceed 
50%, TH transcription is increased (Shendelman et al, 2004). 
 
An interesting example of DJ-1 chaperone activity involves inhibiting α-synuclein 
aggregation during oxidative stress.  Zhou et al (2006) showed that native DJ-1 does 
not affect α-synuclein aggregation.  However upon oxidation of C106 to SO2H, 
significant anti-aggregation of α-synuclein was detected.  Thus, DJ-1 is an oxidative 
stress induced chaperone that prevents α-synuclein aggregation. 
 
Dysfunctional mitochondria are a feature observed in PD patients as well as in DJ-1 
knockout mice.  DJ-1 has been found to be translocated into the mitochondria during 
oxidative stress when C106 is oxidised to SO2H.  The detailed mechanism of how 
DJ-1 performs its anti-oxidative stress response within mitochondria is not yet clearly 
understood, but the role of mitophagy has been proposed, where DJ-1 clears 
damaged mitochondria (Thomas et al, 2011). 
 
The identified physiological roles of DJ-1 makes it easier to comprehend how a loss 
of DJ-1 activity can lead to oxidative stress induced diseases such as PD.  The loss 
of DJ-1 functionality in familial PD is attributable to the mutations associated with 
DJ-1.  Continuous exposure to oxidative stress that renders DJ-1 inactive provides a 











1.13  LRRK2 
 
Mutations identified in certain genes implicated in the onset of familial 
neurodegenerative diseases, have paved the way in understanding the role of the 
encoded protein in disease pathogenesis.   
 
Missense mutations in LRRK2 have been linked to autosomal dominant and sporadic 
PD (Li et al, 2014, Mata et al, 2006).  This section summarises the current knowledge 
on the normal physiological functions of LRRK2 as well as its pathological 
implications in PD. 
 
LRRK2 is a large protein; 286 kDa, made up of 2527 amino acids (Mata et al, 2006b, 
Li et al, 2014).  Figure 1.4, illustrates the structure of LRRK2, showing a few 
mutations known to cause PD.  As depicted in the diagram, LRRK2 is a multidomain 
protein; these domains give a good indication on the normal physiological role of the 
protein, and, the mutations promote understanding on the possible role of LRRK2 in 








Figure 1.4: LRRK2 structure:  diagram depicting the multidomains making up the LRRK2 
protein structure.  ARM =   armadillo repeats, ARK = ankyrin repeats, LRR = leucine rich 
repeat sequence.  A few known LRRK2 mutations are also highlighted.  The G2019S 










1.13.1  LRRK2: Physiological and Pathological role in disease 
 
The absolute physiological role for LRRK2 is still research ongoing.  However, 
revelations into the structural components of this large protein indicate the potential 
roles it may undertake. 
 
LRRK2 has two enzymatic domains – a kinase domain and a ROC GTPase domain 
(Cookson, 2010 and Kawakami, 2015).  The kinase domain suggests a role for 
LRRK2 in catalysing phosphorylation reactions.  Amongst the substrates found for 
this kinase domain, include the microtubule associating protein tau – which is 
interesting since tau has been linked to many neurodegenerative disorders including 
PD and AD.   The physiological relevance of the ROC-GTPase domain is largely 
unknown.  However, it structurally resembles the Rab GTPase family that has been 
shown to play a role in vesicular trafficking.  The presence of repetitive sequences 
within the LRRK2 protein structure confers a protein-protein interaction functionality, 
where it may play a role in bringing together a multiprotein signalling pathway (Mata 
et al, 2006b). 
 
Amongst the many mutations found in LRRK2, pG2019S has been studied the most.  
This particular mutation is situated in the kinase domain, resulting in hyperactive 
kinase activity.  It has been hypothesised that hyperphosphorylation of LRRK2 
substrates initiates pathways that are ultimately toxic to cells.  Experimental evidence 
from C.elegans and Drosophilia has shown that the pG2019S mutation leads to loss 
of dopaminergic neurones and locomotor activity in an age-dependent manner 






The role of α-synuclein in the pathogenesis of certain neurodegenerative disorders 
has already been discussed in Section 1.9.2.  The finding that mutations in both 
LRRK2 and SNCA are associated with the onset of autosomal dominant PD and 
sporadic PD, has initiated an interest into whether the roles of these two proteins in 
disease are related. 
 
α-synuclein inclusions, which are characteristic features for PD, DLB and MSA, are 
predominantly phosphorylated at S129 (Fujiwara et al, 2002; Anderson et al, 2006; 
Wakabayashi et al, 1998).  The most common LRRK2 mutation involves a 
hyperactive kinase domain.  Thus, the question arises as to whether α-synuclein is a 
substrate for LRRK2.  Guerreiro et al (2013) set out to investigate this possibility.  
Their research showed that the two proteins do interact with one another but this 
interaction was not affected by the presence/lack of LRRK2 G2019S mutation; 
suggesting that the kinase domain is not an essential requirement for the interaction.  
However, co-localization experiments showed that LRRK2 levels positively correlated 
with the level of α-synuclein phosphorylation and aggregation in PD affected brain 
regions.   This finding leads to the conclusion that the presence of LRRK2 rather than 
LRRK2 kinase activity may play a role in disease pathogenesis involving α-synuclein 
phosphorylation, accumulation and aggregation (Guerreiro et al, 2013). 
 
Another possible relationship between LRRK2 and α-synuclein has been elegantly 
described by Orenstein et al (2013).   Orenstein et al (2013) have published a role for 
LRRK2 in the lysosomal degradation pathway.   As previously described, the 
lysosomal pathway, is chaperone mediated and is classified into various forms.  The 
specific form of lysosomal degradation which highlights a possible relationship 
between LRRK2 and α-synuclein is called the CMA form mediated by the chaperone 




CMA is a pathway that is responsible for delivering up to 30% of cytosolic proteins to 
the lysosome for degradation.  LRRK2 is amongst this 30%, possessing structural 
motifs that are specific for binding with hsc70.  This LRRK2-hsc70 complex is then 
recognised by the LAMP-2A protein present on the outer membranes of lysosomes.  
This binding activates a series of events leading to the importation of LRRK2 into the 
lysosomes for degradation.   
 
Orenstein et al (2013) showed that wild type LRRK2 utilises the UPS and CMA 
degradation pathways.  However, the mutant forms rely on the UPS pathway; 
furthermore – these mutant forms are poorly degraded by the CMA system.  This 
finding has led the researchers to hypothesise that mutant LRRK2 may be blocking 
the CMA pathway i.e. upon binding to the LAMP-2A; the subsequent series of events 
are not initiated.  This blockage means that other cytosolic proteins destined to be 
degraded cannot be degraded either.    Interestingly, α-synuclein also uses the CMA 
system for degradation, therefore, blockage of the CMA by mutant LRRK2 means 
poor degradation of α-synuclein that should be removed – resulting in its 
accumulation and aggregation which is a hallmark characteristic of various 





1.14  Biomarkers 
 
Biomarkers are defined as characteristics that can be used as an indicator of normal 
biological processes as well as pathological processes.  Additionally, biomarkers can 
directly show the nature of a pharmacological response upon therapeutic 
interventions (Michell et al, 2004). Biomarkers can be in various forms, such as, 
genetic and biochemical markers as well as data obtained from imaging techniques.   
This section discusses the potential use of biomarkers in the field of 
neurodegenerative diseases. 
 
As echoed in previous sections of this report, diagnosis of neurodegenerative 
disease is difficult and heavily reliant on physical examinations with little or no 
laboratory/clinical data to support or aid the diagnosis.  Furthermore, symptoms of 
neurodegenerative conditions present themselves once neuronal cell death and 
damage has already occurred.  Nerve cells do not have the ability to regenerate, 
therefore, once cell death has occurred there is no going back.  Biomarkers may 
serve to allow diagnosis of neurodegenerative diseases in their earlier stages. They 
may also allow us to predict the probability of an individual developing the disease in 
the future.  Furthermore, symptoms experienced by patients with neurodegenerative 
diseases are very similar amongst the various conditions, thus the ability to 
differentiate between the different diseases, and their subtypes, is a feat that might 
be achieved via the measurement of specific biomarkers. 
 
Post diagnosis, the potential role for biomarkers extends into the field of 
pharmaceutical clinical trials.  Surrogate biomarkers are often adopted during 
longitudinal clinical trials.  Surrogate biomarkers aim to substitute the use of clinical 
end points.  In neurodegenerative trials, a successful surrogate biomarker must be 




To summarise, biomarkers carry the potential to aid and improve diagnosis, 
Furthermore, they open up avenues for monitoring disease progression and 
therapeutic effects, more accurately.  In order to be classed as a “good” biomarker, 
its measurements need to be precise and reliable.  The data obtained from the 
measurement must be distinguishable between normal and diseased cases and 
allow differentiation between the subtypes of the same disease (Rachakonda et al, 
2004). 
 
1.15 Project Aims 
 
The specific aims of this project are as follows: 
 
1. To develop and validate a singleplex Luminex assay for measuring phosphorylated 
α-synuclein in human plasma and CSF. 
 
2.  To develop and validate a multiplex assay to measure total α-synuclein, total DJ-1 
and LRRK2 in human plasma and CSF. 
 
3.  To analyse cross sectional plasma and CSF samples from individuals with various 
neurodegenerative disorders and age matched healthy controls, using the developed 
and validated Luminex assays.  
 
4.  To measure total α-synuclein, total DJ-1 in longitudinal plasma samples taken 






5.  To screen human plasma and CSF samples for the presence of LRRK2, using the 
Luminex assay, HPLC and western botting. 
 
By meeting the above aims it will be deduced whether α-synuclein, DJ-1 and LRRK2 
carry the potential to be biomarkers for differentiating between various 
neurodegenerative disorders and healthy individuals.  The subsequent chapters of 
this thesis describe the development and validation of Luminex assays in detail 










2a.1  Antibodies and recombinant proteins 
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2a.2  Buffers and additional reagents 
 








Triton activation buffer 
 
 






0.1 M sodium phosphate pH 6.1 
 
Triton coupling buffer 
 
 
























Proprietary buffer from Surmodics® 
9924 West 74th Street 

















5 tablets of PBS (Sigma, P4417) in 1L deionised water 















































Thermo Scientific Fisher 
Brand, IL, US 
 
 






Thermo Scientific Pierce, 
IL, US 
 

























30.3 g TRIS + 144 g glycine dissolved in 950 mL dH20 + 
50 mL 20% (v/v) SDS 
 
 
4 x Stacking gel stock  
 
 
6g TRIS dissolved in 40 mL dH20. 
Solution titrated to pH 6.8 with 1M HCL. 




10% (w/v) Ammonium 
persulfate 
 








Supplied by Thermo Scientific; product code 34080. 
 











Product code/Buffer composition 
 




10006D, from Life Technologies-Invitrogen, 
Paisley, UK 
 
SDS sample buffer 
 
 
0.125 M TrisHCl, pH 6.8, 2% (v/v) SDS, 10% 
(w/v) glycerol, 0.01% (v/v) bromophenol blue, 



















1% (v/v) TFA in water 
 
 
100 mL TFA + 900 mL dH20  
 
1% (v/v) TFA in acetonitrile 
 
 
100 mL TFA + 900 mL acetonitrile 
 
 



























































Charles Austen Pumps 








Manufactured by:  Thermo 

















2a.4  CSF samples 
 
The CSF samples analysed in this project were collected at the Department of 
Neurology, University College Hospital, London (UCL), courtesy of Dr Nadia 
Magdalinou.  CSF samples were collected via lumbar puncture into sterile 
polypropylene tubes and immediately centrifuged at 4000 rpm for 10 minutes at 4oC.  
The samples were then aliquoted and stored at ≤70 oC.  The CSF samples used in 










Mean age ± SD 
(years) 
HC 26 14 12 61 ± 9 
MSA 28 15 13 64 ± 6 
PD 22 15 7 68 ± 8 
PSP 31 19 12 69 ± 6 
CBS 13 4 9 68 ± 7 
 
The age of the patients’ enrolled in the UCL study was significantly lower for the HC 
and MSA groups in comparison to the PD, PSP and CBS categories (p value ≤0.05 
as per Mann-Whitney test).  Gender distribution within each disease group was even 
except for the PD and CBS groups, where more males were recruited in the PD 
category and more females within the CBS group.  The gender distribution was 
statistically insignificant between all disease groups (p value ≥0.05 as per Mann 
Whitney test).    
 
2a.5  Plasma samples 
 
The plasma samples used in this project were obtained from two individual sites -  
Out-patient clinics at Greater Manchester Neurosciences Centre (GMNC) at Salford 
Royal Hospital and Department of Neurology, University College Hospital, London 




The blood was collected in EDTA tubes and stored at 4°C prior to centrifugation 
(within 20 hours of collection).  The samples were then centrifuged at 2000 rpm 
(1000 x g) for 10 minutes at 4°C.  The resultant plasma was pipetted off into sterile 
cryogenic vials prior to storage at ≤ -70°C.  The table below show the demographics 
of the plasma samples from GMNC only followed by GMNC and UCL combined.  The 












Mean age ± 
SD (years) 
HC 72 30 42 68 ± 9 
MSA 18 9 9 64 ± 8 
PD 61 37 24 69 ± 12 
PSP 36 21 15 66 ± 11 
CBS 16 8 8 65 ± 10 
AD 79 49 30 64 ± 10 
DLB 59 44 15 68 ± 11 
 










Mean age ± 
SD (years) 
HC 98 44 54 65 ± 11 
MSA 46 24 22 65 ± 7 
PD 83 52 31 66 ± 10 
PSP 67 40 27 70 ± 7 
CBS 29 12 17 68 ± 8 
AD 79 49 30 64 ± 10 
DLB 59 44 15 68 ± 11 
 
The age (GMNC + UCL samples combined) of the patients sampled did not 
significantly differ between the HC, MSA, PD, CBS, AD and DLB disease groups (p 




PSP and DLB groups in comparison to the remaining disease groups.  The gender of 
patients sampled was evenly distributed within individual disease groups except for in 
DLB.  The difference in gender distribution between the disease groups was not 
significant except for between HC vs PD, HC vs DLB, CBS vs DLB and MSA vs DLB, 
where the p value was ≤ 0.05 as per Mann Whitney tests. 
 
Only 8 samples from the UCL site have been pathologically and longitudinally 
followed up post 2 years.  None of the samples from the GMNC site have undergone 
pathological confirmation; these samples are from an ongoing study thus longitudinal 
visits have been planned.  Information regarding disease duration upon sampling 
was recorded for all  samples from UCL, but only a selected few samples from the 
GMNC site had this information readily available.  The samples for which disease 
duration data was available ranged from 1.5 – 20 years for the PD samples (n = 20), 
2 – 12 years for PSP patients (n = 33), 1.5 – 10 years for MSA (n = 28) and 1 – 11 
years for CBS/CBD patients (n = 13). 
 
All samples from GMNC were obtained with informed consent and ethical approval 
was received from the Oldham Local Research Ethics Committee. Samples from 
UCL were also obtained with informed consent and ethical approval from London, 
Queen Square Ethical Committee.  Diagnoses of the patients from whom samples 
were collected were based on internationally established operational criteria (Hughes 
et al, 1992; Litvan et al, 1996; Bak et al, 2008; McKhann et al, 1984; Gilman et al, 
2008).  Patients with PSP, PD and CBS had additional assessments including 
UPDRS, Mini Mental State Examination (MMSE), PSP rating scale (PSPRS) and 
Mattis Dementia Rating Scale (Schmidt et al, 2005).  Healthy control samples were 
usually spouses and friends of the diseased patients and underwent clinical and 








2b.1 Luminex Technology 
 
The Luminex analyser utilises a combination of scientific technologies involving flow 
cytometry, microspheres and lasers to offer a versatile platform for developing and 
performing immunoassays.   
 
The Luminex system is based on the availability of unique Luminex microsphere 
bead sets. At present, there are 100 bead sets available with each set being colour 
coded with varying intensities of red and infra-red fluorophores.  This internal dye 
mixture generates the unique characteristic of each bead set and is referred to as the 
‘spectral signature’. The Luminex analyser has an inbuilt laser component that 
identifies the varying nature of the spectral signature and thus the individuality of 
each bead set.   
 
The availability of 100 unique bead sets allows the ability to multiplex assays, where 
several analytes can be quantified from a single sample well simultaneously.   
 
2b.1.1   Luminex sandwich immunoassay protocol summary 
 
The Luminex is an open platform, meaning that a range of assay formats can be 
performed using the technology, e.g. competitive immunoassays, sandwich 
immunoassays and nucleic acid bioassays.  For the purpose of this project we 
developed, validated and used sandwich immunoassays.   A summary of the 
Luminex sandwich immunoassay protocol is described as follows: 
 
Step 1:  The analyte of interest was captured using a specific antibody conjugated to 
the chosen bead set.  The surface chemistry of each bead is designed to allow bead 




Step 2:  The captured analyte was detected using analyte specific detection 
antibodies.  The detection antibodies were biotinylated. 
 
Step 3:  Streptavidin-R-phycoerythrin (Streptavidin-RPE) was added. Streptavidin 









Figure 2b.1: Luminex sandwich assay format: sandwich immunoassay format utilised for 
the assays in this project.  The capture and detection reagents are specific to the analyte of 
interest.  Streptavidin-RPE acts as a reporter molecule. 
 
The actual immunoreaction was carried out in a 96 well filter microtitre plate.  
 
Step 4:  The Luminex analyser was used to quantify the reaction and yield results. 
Upon transfer of the microtitre plate into the instrument, the fluidics system of the 
application aligns the microspheres into a single file and moves them into a flow cell. 
Within the flow cell each microsphere is exposed to two types of lasers: 
 
Laser 1: 635nm laser – red “classifier” laser, this excites the infra-red and red 
fluorophore internal dye mixture to identify and classify the bead set. 
 
 Bead 








Laser 2: 532nm laser – green “assay” laser, which excites the R-phycoerythrin linked 
to the streptavidin to determine the level of analyte captured onto the microsphere 
and generate a quantifiable result. 
 
During the multiplexing step of this project, various bead sets were used.  Each bead 
set was conjugated to a different analyte specific capture antibody.   
 
A cocktail of analyte specific biotinylated detection antibodies were then utilised to 






Figure 2b.2: Luminex beads in a multiplex format:  Each bead set attached to a different 









2b.1.2   Surmodics® buffer for all assays to reduce matrix effects 
 
The Luminex assays developed for use in this project involved the use of a special 
buffer from Surmodics®.  This buffer was chosen to eliminate any non-specific 
binding from heterophilic antibodies.  Figure 2b.3 summarise how heterophilic 
antibodies can create false negative and false positive results.  The buffer is protein 
free to avoid any protein cross-reactivity problems within the assays, such as with 



















Figure 2b.3: Heterophilic Ab interference:  heterophilic Abs have been reported to be 
present in complex matrices such as plasma.  Heterophilic Abs can interfere with the assay 






The heterophilic antibody acts 
as a bridge between the 
capture Ab and detection Ab, 









The heterophilic antibody 
prevents any analyte present 
in the sample from binding to 
the capture antibody, thus 


























2b.1.3    Luminex bead antibody coupling 
 
The Luminex technology requires the capture antibody to be coupled to Luminex 
microspheres/beads.  The coupling process involved a two-step carbodiimide 
reaction, where the primary amine group of the capture antibody was covalently 
bonded to free carboxyl groups on the surface of Luminex microspheres.  Briefly, 
500,000 beads were washed three times with triton/activation buffer via centrifugation 
at 9,300 x g for 1 min and removal of the supernatant.  The washed beads were then 
activated using 10 µL of 50 mg/mL EDC and 10 µL of 50 mg/mL Sulfo-NHS in 80 µl 
of activation buffer.  After a 30 min incubation and three washes with triton/coupling 
buffer, the antibody to be coupled was added.  Coupling buffer was added to make 
the volume up to 500 µl.  This mixture was incubated for 2 h at room temperature 
(RT) with end-over-end mixing.  Post incubation, the beads were washed three times 
with wash buffer, and blocked with 150 µL PBS/1% BSA.  The coupled beads were 
















Figure 2b.4:  Antibody coupling to Luminex microspheres: the figure does not represent 
the order in which the reagents are added.  Sulfo NHS was added before the EDC. EDC is 
unstable once dissolved therefore adding it post the Sulfo NHS allows efficient coupling.  The 




2b.1.4    Antibody biotinylation 
 
The detection antibody to be used in the Luminex technology needs to be 
biotinylated.  The biotinylation was performed using EZ-Link™ NHS-LC-LC-Biotin 
(Thermo Scientific Pierce).  The procedure involved following the manufacturer’s 
recommended protocol.  Briefly, 20 – 100 µL of 1 mg/mL of antibody was reacted 
with 50 mM biotin solution at a 50:1 ratio and sodium bicarbonate at 10:1 ratio.  The 
reaction was allowed to take place at RT for 30 mins with continuous end-over-end 
mixing.  Post incubation, unbound biotin was removed using Zeba desalting columns 
(Thermo Scientific Pierce) with PBS as the exchange buffer.  The biotinylated 
antibodies were stored at -20oC after the addition of 0.08% (w/v) NaN3. 
 
2b.1.5    Antibody concentrating 
 
In order to maximise bead coupling and biotinylation efficiency, the antibodies 
destined for such purposes were used at 1mg/mL concentration.  Many of the 
antibodies used in this project were readily available at this concentration.  
Antibodies that were only available at < 1mg/mL were concentrated up using one of 
the following devices: 
 
 Pierce protein concentrators, PES, 3K MWCO, 0.5mL. 
 Amicon® Ultra 4mL centrifugal filters. 
 
Both devices work using similar principles; the Pierce 0.5 mL concentrator was used 
for small volumes of antibodies and the Amicon® filter tubes were used for 







2b.1.6    Antibody purification 
 
Prior to undergoing bead coupling and biotinylation, all antibodies had to be free from 
azide and amine containing substances.  The purification step involved using Protein 
A/G columns (Thermo Scientific Pierce) and ultracentrifugal filter tubes (Merck 
Millipore). 
 
The manufacturer’s protocol was followed for the Protein A/G purification, utilising the 
immobilised protein columns (Thermo Scientific Pierce).  All centrifugation steps were 
performed at 5,000 x g at RT.  400 µL of binding buffer (Thermo Scientific Pierce) 
was added to the resin packed column, followed by 500 µL of antibody.  After two 
washes with binding buffer, the bound antibody was eluted using 400 µL elution 
buffer (Thermo Scientific Pierce) in tubes containing neutralising buffer (Thermo 
Scientific Pierce).  
 
The eluted antibody solution was purified using the ultra-centrifugal filter tubes, with 
PBS as the exchange buffer.  This involved adding the eluted antibody solution with 
PBS and centrifuged three times at 4,000 x g for 8 min.  The final centrifugation 
yielded approximately 150 µL of purified antibody solution.  The final concentration of 
this antibody was determined using the Nanodrop (Thermo Fisher Scientific) at 280 
nm absorbance.  
 
2b.2    Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
A tris-based gel was used which involved preparing a resolving gel for protein 
resolution and a stacking gel for sample addition.  SDS-PAGE can be performed with 




gel preparation.  Table 2b.1 shows the buffer recipe used for the generation of 2 x 





12.5% gel Stacking Gel 
 
Acrylamide/Bis mix 30% 
(v/v) 
 
8.3 mL 1.7 mL 
 
Stacking Gel Buffer 
 
na 2.5 mL 
 
Resolving Gel Buffer 
 




6.3 mL 5.6 mL 
 
10% (v/v) SDS 
 
200 µL 100 µL 
 
10% (w/v) Ammonium 
persulfate 
 




20 µL 10 µL 
 
Table 2b.1:  SDS-PAGE buffer recipe: 12.5% resolving gel and stacking gel buffer recipe. 
 
The resolving gel was prepared and allowed to set before pouring the stacking gel on 
top.  Once the stacking gel had been set, sample wells were generated using a 






















Samples were prepared by adding SDS sample buffer (0.125 M TrisHCl, pH 6.8, 2% 
(v/v) SDS, 10% (w/v) glycerol, 0.01% (v/v) bromophenol blue, 0.1 M dithiothreitol 
(DTT)) and heating at 98oC for 3 mins.  Prepared samples plus a molecular weight 
marker (Kaleidoscope) were then loaded into the sample wells created within the 
stacking gel and electrophoresed at 125V for 45 mins with TRIS-glycine running 
buffer, using BioRad equipment. 
 
2b.3 Western blotting 
 
A wet transfer method was used to transfer the proteins resolved via the SDS-PAGE 






















Figure 2b.5: Transfer step for western blot: the gel and membrane were sandwiched 
between filter papers and sponges within a transfer cassette and placed into the X Cell Blot 
module (Invitrogen Inc. and electrophoresed at 25V for 1.5 h. The resolved negatively 
charged proteins from the gel were therefore migrated towards the positive electrode and thus 
transferred onto the nitrocellulose membrane.  
+ - 




Once the transfer step was complete, the membrane was blocked (2% (w/v) milk 
powder in PBST) for 1 hr at room temperature (RT) whilst shaking.  The membrane 
was then washed 3 x with PBST, then incubated with primary antibody (1:5000 of 
protein specific antibody), overnight at 4oC whilst shaking.  After another series of 
washes with PBST, the membrane was then incubated with a secondary antibody 
conjugated to HRP (1:5000, antibody dependant on the primary antibody type used), 
for 1 hr at RT, again with shaking. The membrane was developed using an ultra-




2b.4  Immunoprecipitation 
 
Dynabeads® Protein A Immunoprecipitation Kit was used to purify and obtained a 
concentrate of the protein of interest from plasma samples.  Manufacturer’s protocol 
was used; in summary an analyte specific antibody (5 µg) was conjugated to 
Dynabeads® (supermagnetic beads) coated with Protein A.  The sample to be 
immunoprecipitated was then added (100 µL – 500 µL) to this Dynabeads®-Ab 
complex – at this stage any analyte of interest present in the sample would be 
captured onto the beads.  After a series of washes with the washing buffer provided 
in the kit, any captured analyte was eluted using the kit elution buffer and denatured 
for use with the SDS-PAGE and western blot by adding SDS sample buffer. 
 
2b.5  HPLC 
 
Reversed phase HPLC was used using the Dionex HPLC system.  100 µL of sample 
was injected into a C18 or C4 hydrophobic columns; 250 x 4.6 mm with 5 microns 
particles (supplied by Phenomenex).  The mobile phase used in this methodology 




eluent gradient was started at 0% then to 60% after 30 minutes, with all samples 
analysed at 25 oC. 
 
2b.6  Luminex Assay Validation  
 
There are no government based guidelines such as FDA documentation dictating 
how biomarker ligand binding assays are to be validated.  However, there are 
publications that discuss how to conduct a “fit for purpose” validation.  We have used 
the papers listed below as guidance when validating the Luminex assays described 
in this project: 
 
  Lee et al. (2006b) Fit-for-Purpose Method Development and Validation for 
Successful Biomarker Measurement, Pharmaceutical Research, 23 (2) 
 
 Lee, (2009) Method validation and application of protein biomarkers: basic 
similarities and differences from biotherapeutics, Bioanalysis, 1(8), 1461-1474. 
  
This section describes the parameters tested and how: 
 
2b.6.1  Parallelism 
 
This parameter was tested to determine whether sample matrix interference affected 
the assay system.  It was also used to determine the minimum required dilution 
(MRD) for the samples, i.e. the dilution at which the recovery of analyte of interest is 
acceptable.  This was assessed in two ways: 
 
(i) analysing samples containing high amounts of the protein of interest and 




(ii) spiking in the protein of interest into the sample matrix, conducting a series of 
dilutions and assessing whether the recovery at the different dilution levels is 
acceptable. 
 
The dilution level at which the % difference of protein recovery was ≤ 20% was used 
as the proposed MRD.  
 
2b.6.2  Spike Recovery 
 
To ensure that matrix interference was not having an effect on the assay and that the 
chosen MRD was suitable for use in our assay systems, the spike recovery test was 
performed. 
 
Six matrix samples were spiked with low and high levels of the protein of interest, 
diluted at the proposed MRD and analysed using the Luminex test system.  The % 
recovery (RE) was calculated for each test samples.  The acceptance criteria were 
for the % RE and % CV to be ≤ 20%. 
 
2b.6.3  Limit of Detection (LOD) 
 
LOD is the concentration at which the signal can be significantly distinguished from 
the background signal i.e. signal obtained from the zero calibrator.  In order to 
determine this, the zero calibrator for each assay developed was analysed 20 times.  
The concentration obtained from the mean of these 20 signals +3 SD was then 








2b.6.4  Dilutional Linearity 
 
This test was used to show that samples with protein levels above the ULOQ can be 
diluted within the quantifiable range.  This test was done by spiking protein of interest 
above the ULOQ into matrix then diluted at various levels.  The protein recovery was 
then calculated.  Acceptance criteria were for % difference and % CV to be ≤ 20%. 
 
2b.6.5  Hook effect 
 
The hook effect is also known as the “prozone effect”.  False negative results can be 
obtained when samples contain very large concentrations of the analyte of interest.  
The phenomenon occurs due to the large concentration of analyte saturating the 
amount of capture antibody present in the immunoassay system.  For the developed 
assays, this was assessed by spiking in a very large amount of the protein of interest 
in the sample matrix and analysed.  If the signal obtained reduced then hook effect 
was taking place.  The spiked concentrations varied for each assay developed and 
are mentioned in their respective results chapters. 
 
2b.6.6  Accuracy and Precision 
 
Accuracy refers to the “trueness/bias” of an assay, i.e. how close the results obtained 
are to the actual true concentration of the analyte being quantified.  To assess this, 
we performed at least five analytical runs, on separate days.  Each analytical run 
consisted of quantifying five “validation samples (VS)”.  Each VS comprised of matrix 








 VS1 – spiked to proposed lower limit of quantification (LLOQ) 
 VS2 – spiked to represent the lower end of the calibration curve, generally 3 x the 
proposed LLOQ. 
 VS3 – spiked to represent the middle part of the calibration curve 
 VS4 – spiked to represent the high end of the calibration curve 
 VS5 – spiked to the proposed upper limit of quantification (ULOQ) 
 
The inter and intra assay % difference was calculated for each VS sample throughout 
the five analytical runs as a means of assessing the accuracy of the assay.  
Acceptable accuracy was defined by % difference ≤ 20% for VS2, VS3, VS4 samples 
and ≤ 25% for VS1, VS5. 
 
Precision/consistency was also assessed using the data collected from the five 
analytical runs with the five VS % CV were calculated as used to determine inter and 
intra assay precision.  The acceptance criteria for assay precision were ≤ 20% at 
VS2, VS3, VS4 and ≤ 25% for VS1 and VS5. 
 
2b.7 Sample analysis run acceptance criteria 
 
Each assay performed for this project involved analysing a calibration curve per 
assay plate and three levels of Quality controls (LQ, MQ and HQ), straight after the 
calibration curve and at the end of the plate.   These QCs were either spiked samples 
or actual samples that had been pre-screened and found to contain a suitable 
amount of protein that can be used as QC.  For each assay it was ensured that the 
QCs span the whole calibration curve.  LQ = at least 3 x LLOQ level, MQ = middle of 





Each assay was accepted as long as 4 out 6 QCs passed.  The acceptance range for 
each QC was determined from the validation runs; mean ± 3 SD. 
 
Each test sample was diluted three times to its MRD level and analysed in three 
separate wells.  The test result was accepted if the % CV was ≤ 20%. 
 
The statistical analysis on the sample test data performed has been described in the 
respective results chapters. 
  
 
Chapter 3:    
Phosphorylated α-synuclein: 







An assay for the quantification of phosphorylated α-synuclein in human plasma and 
CSF has been established previously in ELISA format, utilising N-19 goat anti-α/β-
synuclein pAb (Santa Cruz Biotechnology Inc.) as the capture reagent and a 
phospho-dependent EP1536Y rabbit anti-α-synuclein (phospho S129) mAb 
(Epitomics) as the detection component.  A goat anti-rabbit secondary antibody 
conjugated to horseradish peroxidase (HRP) plus TMB substrate complex was used 
as the detection system (Foulds et al, 2011).  An attempt was made to transfer this 
assay on to the Luminex system, with the view of developing a more sensitive and 
specific assay, that could then be multiplexed with other neurodegenerative disease 
related molecular biomarkers.   
 
This chapter presents the developmental and validation data obtained for the new 
phosphorylated α-synuclein Luminex assay. 
 
3.2 Luminex assay development 
 
In order to develop a phosphorylated α-synuclein assay on the Luminex bead based 
system, it was rational to start with the antibody pairings that worked in the ELISA 
system, where the N-19 pAb was coupled to beads and the EP1536Y mAb was 
biotinylated in order to function as the detection component.  Unfortunately, the N-19 
pAb + EP1536Y mAb combination was not successful on the Luminex system and so 
alternative antibody combinations were tested in order to find a working antibody 
pair.  The successful antibody pairings underwent concentration titration experiments 
in order to optimise the assay.  Once optimal concentrations of antibodies were 






3.2.1 Antibody combinations 
 























































Table 3.1: Phosphorylated α-synuclein antibodies:  Antibodies tested for phosphorylated 





Each capture antibody (2 µg/mL = 1 µg in 500 µL coupling buffer) was coupled to 
33 µL beads.  The biotinylated goat anti-α-synuclein pAb was supplied already 
biotinylated, but the biotinylated P-syn/81A mouse anti-α-synuclein phospho-specific 
(Ser129) mAb was biotinylated in house. 
 
The data obtained from these combinations are displayed in Figure 3.1: 
 
 
Figure 3.1: Testing different antibody combinations:  Luminex beads coupled with 
2 µg/mL of each capture Ab were used to capture 1000, 500, 250, and 0 ng/mL of 
recombinant phosphorylated α-synuclein.  2 µg/mL of biotinylated detection Ab and 4 µg/mL 
of streptavidin-RPE were used as the detection system for the assay.  The figure shows the 
raw MFI signals (n=2), achieved with the various antibody combinations. 
 
Beads coupled with the P-syn/81A mouse anti-α-synuclein phospho-specific (Ser129) 
mAb from Covance, with biotinylated goat anti-α-synuclein pAb from R&D Systems 
for detection, generated the best MFI signals.  This antibody combination was, 
therefore, taken into the assay optimisation stage. 
 
Key: 
Cov = Covance 
SC = Santa Cruz 
Inv = Invitrogen 




3.2.2 Assay optimisation 
 
Capture Ab and detection Ab titration experiments were performed in order to 
determine the concentrations of these antibodies required, for optimal assay 
performance. 
The capture antibody titration experiment involved coupling beads to varying 
concentrations of the P-syn/81A mouse anti-α-synuclein phospho-specific (Ser129) 
mAb.  The concentrations tested were; 1, 2 and 3 µg/mL of antibody in coupling 
buffer.  The raw MFI obtained are displayed in Figure 3.2 and the signal to noise ratio 




Figure 3.2: Capture antibody titration:  Luminex beads coupled with 1, 2 and 3 µg/mL of 
P-syn/81A mouse anti-α-synuclein phospho-specific (Ser129) mAb were reacted with 
recombinant phosphorylated α-synuclein at 1000, 500, 250, 125, 62.5, 31.3, 15.6 and 0 
ng/mL.  2 µg/mL of biotinylated detection Ab and 4 µg/mL streptavidin-RPE were used as the 
detection system for the assay.  The figure shows the mean (n=2) MFI signals achieved with 







Figure 3.3: Capture antibody titration – signal to noise ratio:  Luminex beads coupled 
with 1, 2 and 3 µg/mL of P-syn/81A mouse anti-α-synuclein phospho-specific (Ser129) mAb 
were reacted with recombinant phosphorylated α-synuclein at 1000, 500, 250, 125, 62.5, 
31.3, 15.6 and 0 ng/mL.  2 µg/mL of biotinylated detection Ab and 4 µg/mL streptavidin-RPE 
were used as the detection system for the assay.  The figure shows the mean (n=2) MFI 
signal achieved with the various capture antibody concentrations. 
  
The data indicated that the best signal to noise ratio was achieved using beads 
coupled with 2 µg/mL of P-syn/81A mouse anti-α-synuclein phospho-specific 
(Ser129) capture mAb. 
 
The detection antibody titration experiments involved performing an assay using 
2 µg/mL of P-syn/81A mouse anti-α-synuclein phospho-specific (Ser129) capture 
mAb beads, and the biotinylated goat anti-α-synuclein pAb at varying concentrations. 
 






Figure 3.4: Detection antibody titration – signal to noise ratio:  Luminex beads coupled 
with 0.5 µg/mL of P-syn/81A mouse anti-α-synuclein phospho-specific (Ser129) mAb were 
reacted with recombinant phosphorylated α-synuclein at 1000, 200, 40, 8, 1.6, 0.32, 0.064 
and 0 ng/mL.  1 or 0.5 µg/mL of biotinylated detection Ab with 4 µg/mL streptavidin-RPE was 
used as the detection system for the assay.  The figure shows the mean (n=2) MFI signal 
achieved with the two different detection antibody concentrations. 
 
Using capture antibody beads coated with 0.5 µg/mL P-syn/81A mouse anti-α-
synuclein phospho-specific (Ser129) mAb and the biotinylated goat anti-α-synuclein 
pAb at 0.5 µg/mL, generated the best data with recombinant phosphorylated 
α-synuclein protein.  Therefore, this system was taken into the assay validation 
stage. 
 
Prior to validating the assay, two additional assessments were performed.  Firstly, an 
isoform specificity test was performed to ensure that the assay was specific for 
phosphorylated α-synuclein and did not detect monomeric and/or oligomeric non-






Figure 3.5: Isoform specificity:  Luminex beads coupled with 2 µg/mL of P-syn/81A mouse 
anti-α-synuclein phospho-specific (Ser129) mAb were reacted with recombinant 
phosphorylated, monomeric non-phosphorylated or oligomeric non-phosphorylated 
α-synuclein at 1000, 500, 100 and 0 ng/mL.  0.5 µg/mL of biotinylated detection Ab with 
4 µg/mL streptavidin-RPE was used as the detection system for the assay.  The figure shows 
the mean (n=2) of the raw MFI achieved with the different forms of the protein isoforms. 
 
The assay was found to be predominantly specific for phosphorylated α-synuclein. 
 
Secondly, all assay development experiments displayed so far were performed in 
assay buffer (SM01:PBS).  The final stage in assay development was to deduce what 
buffer would be suitable for use as an assay diluent for preparing calibration curves 
and diluting samples, when analysing human plasma and CSF.  To deter matrix 
effects and obtain the best spike recoveries during assay validation, it is advised to 
prepare assay calibration curves in matrix that closely matches, or is identical, to the 






















Published literature shows that some researchers use FBS as a surrogate matrix for 
human plasma for preparing calibrators and diluting samples – we therefore tried 
FBS at 5% (w/v) and 10% (w/v).  In addition to FBS we tested BSA and analyte free 
human serum and compared assay performance with analyte free human plasma.  
The data obtained are shown in Figure 3.6. 
 
 
Figure 3.6: Diluent choice:  Luminex beads coupled with 2 µg/mL of P-syn/81A mouse anti-
α-synuclein phospho-specific (Ser129) mAb were reacted with recombinant phosphorylated 
α-synuclein at 1000, 200, 1.6 and 0 ng/mL prepared in various buffers.  0.5 µg/mL of 
biotinylated detection Ab with 4 µg/mL streptavidin-RPE was used as the detection system for 
the assay.  The figure shows the raw MFI achieved with the different buffers (n=2). 
 
It was apparent from the data obtained that FBS, BSA and human serum do not 
behave in the same manner as human plasma in the assay.  Thus using analyte-free 
human plasma for the calibration curve and sample dilutions was chosen.   We opted 
to use plasma diluted in SM01:PBS, to generate 1% (v/v) plasma for use as sample 
diluent and 1% (v/v) plasma spiked with recombinant phosphorylated α-synuclein for 


















Recombinant phosphorylated α-synuclein (ng/mL) 
SM01 + 1% BSA
SM01 + 0.1% BSA
SM01 + 10% FBS






In order to continue the theme of using assay diluents that are identical to the sample 
type; for the CSF assay we decided to use 20% (v/v) analyte free human CSF as 
sample diluent and 20% (v/v) CSF spiked with recombinant phosphorylated α-
synuclein as the calibrator diluent. 
 
The decision on using these diluents were initially based on obtaining good assay 
signal:noise ratio, since the addition of matrix to the assay reduced MFI signals 
vastly.  The final decision for using these diluents was based on the subsequent 
validation data.  If the validation data achieved was unacceptable, the choice of 
diluents would have been re-assessed. 
 
3.3  Assay Validation: assay for analysing plasma samples 
 
Currently, there are no official Government-based guidelines dictating how to validate 
biomarker assays.  However, scientific white-papers have been published providing 
in-depth guidance on qualifying biomarker assays fit for their purpose. For the 
purpose of this project, the following papers have been used for validating our 
assays: 
 
 Lee et al. (2006b) Fit-for-Purpose Method Development and Validation for 
Successful Biomarker Measurement, Pharmaceutical Research, 23 (2) 
 
 Lee, (2009) Method validation and application of protein biomarkers: basic 
similarities and differences from biotherapeutics, Bioanalysis, 1(8), 1461-1474. 
 




3.3.1   Parallelism: plasma assay 
 
Three plasma samples from patients with suspected neurodegenerative disorders 
were assayed at multiple dilutions; 1/20, 1/40, 1/50, 1/75 and 1/100.  The samples 
were diluted using assay diluent (1% (v/v) plasma in SM01:PBS).  The data are 



















Plasma from Individual 1 
1/20 0.050 12.3 0.40 3.2 246 256 -3.9 
1/40 0.025 5.96 0.22 3.6 239  -6.6 
1/50 0.020 5.66 0.22 3.8 283  10.8 
1/75 0.013 3.43 0.04 1.2 257  0.7 
1/100 0.010 2.53 0.09 3.4 253  -1.0 
Plasma from Individual 2 
1/20 0.050 39.5 5.54 14.0 789 844 -6.5 
1/40 0.025 22.0 0.98 4.4 880  4.3 
1/50 0.020 17.3 0.60 3.5 864  2.4 
1/75 0.013 10.9 0.52 4.7 820  -2.8 
1/100 0.010 8.66 0.40 4.6 866  2.6 
Plasma from Individual 3 
1/20 0.050 12.8 0.22 1.7 256 224 14.0 
1/40 0.025 5.46 0.11 2.0 218  -2.6 
1/50 0.020 4.52 0.29 6.5 226  0.7 
1/75 0.013 2.74 0.04 1.6 206  -8.3 
1/100 0.010 2.16 0.02 1.0 216  -3.8 
 
Table 3.2: Plasma Parallelism: Precision (%CV) and % Difference for three plasma samples 
at 1/20, 1/40, 1/50, 1/75 and 1/100 dilutions with 1% (v/v) plasma assay buffer.  % difference 





Figure 3.7: Plasma Parallelism: three plasma samples reacted with Luminex beads coupled 
with 2 µg/mL of P-syn/81A mouse anti-α-synuclein phospho-specific (Ser129) mAb at various 
dilutions. 0.5 µg/mL of biotinylated detection Ab with 4 µg/mL streptavidin-RPE was used as 
the detection system for the assay.   
 
The % difference was shown to be between -8.3% and 14.0%, with precision (% CV) 
between 0.97% and 14.0%. 
 
Remaining validation experiments were performed using a calibration curve 
generated by spiking recombinant phosphorylated α-synuclein into 1% (v/v) plasma 
diluent at 0, 0.469, 0.938, 1.876, 3.752, 7.50, 15.0, 30.0, and 60.0 and 120 ng/mL 
(120 ng/mL was used as an anchor calibrator).  All plasma samples were diluted x50 
with 1% (v/v) plasma diluent.  The range of quantitation for the assay was therefore 







3.3.2   Spike Recovery: plasma assay 
 
Six patient samples were analysed with 1000 ng/mL of recombinant protein spiked 
into it.  An additional six patient samples were spiked with 90 ng/mL of recombinant 
phosphorylated α-synuclein and analysed.  Each sample was also analysed alone 












295 2.0 1212 1.8 1295 93.6 
Plasma 2 
986 0.9 1846 6.1 1986 93.0 
Plasma 3 
599 2.2 1447 2.8 1599 90.5 
Plasma 4 
1885 6.1 3042 1.3 2885 105.4 
Plasma 5 
213 2.9 1000 3.5 1213 82.5 
Plasma 6 












0.00 na 85.0 8.5 90 94.8 
Plasma 2 
0.00 na 90.0 3.9 90 99.4 
Plasma 3 
0.00 na 93.0 11.6 90 103.3 
Plasma 4 
0.00 na 97.0 1.3 90 108.0 
Plasma 5 
0.00 na 84.0 9.5 90 93.7 
Plasma 6 
0.00 na 85.0 10.3 90 93.9 
 
Table 3.3: Plasma Spike Recovery: % recovery and precision (%CV) for six plasma 





The % recovery for the spiked samples ranged between 82.5% and 105.4% at the 
high level spikes with a precision between 1.3% and 6.1%.  The low spike recoveries 
ranged between 93.7% and 108.0% with a precision of 1.3% to 11.6%. 
 
3.3.3   Dilutional linearity and Hook Effect: plasma assay 
  
A pooled plasma sample (made up of several healthy donors from Blood Transfusion 
Unit, Manchester, UK) was spiked with 20000 ng/mL of recombinant phosphorylated 
α-synuclein.  This spiked sample was diluted 1/50, 1/100, 1/200, 1/400, 1/800, 
1/1600 and 1/3200.  Each diluted sample was analysed in triplicate on the Luminex 
and the data obtained are shown in Table 3.4 
 









1/50 0.02 > ULOQ > ULOQ > ULOQ > ULOQ na na 
1/100 0.01 > ULOQ > ULOQ > ULOQ > ULOQ na na 
1/200 0.005 > ULOQ > ULOQ > ULOQ > ULOQ na na 
1/400 0.0025 16404 16892 16692 16663 20000 -16.7 
1/800 0.00125 17496 17792 18704 17997 20000 -10.0 
1/1600 0.000625 18000 18416 16800 17739 20000 -11.3 
1/3200 0.0003125 16736 17440 17984 17387 20000 -13.1 
 
Table 3.4: Plasma Dilutional Linearity: % difference for a pooled plasma sample diluted at 
1/50, 1/100, 1/200, 1/400, 1/800, 1/1600 and 1/3200 with 1% (v/v) plasma assay buffer.   
 
The difference between the expected result and the obtained result was ≤ -16.7 %, 
showing that samples can be diluted up to 3200 times without compromising the 
achieved result.  To further show the linearity of the dilutions, a regression plot was 





Figure 3.8: Plasma Dilutional Linearity: pooled plasma sample underwent a series of 
dilutions.  Each diluted sample was reacted with Luminex beads coupled with 2 µg/mL of P-
syn/81A mouse anti-α-synuclein phospho-specific (Ser129) mAb.   0.5 µg/mL of biotinylated 
detection Ab with 4 µg/mL streptavidin-RPE was used as the detection system for the assay.   
 
The R2 value was 0.9979, showing that the sample diluted in a linear fashion. 
 
This experiment was also used to assess hook effect for the assay (refer to Chapter 
2b for the definition of hook effect).  The results (Table 3.5 and Figure 3.9) showed 
that the MFI signal at 20000 ng/mL of recombinant phosphorylated α-synuclein does 











Dilution 1/Dilution Raw MFI Result 
Mean MFI 
Result 
1/50 0.02 5017 4802 4847 4889 
1/100 0.01 4156 4132 4059 4116 
1/200 0.005 2711 2969 3053 2911 
1/400 0.0025 1688 1731 1713 1711 
1/800 0.00125 968 983 1029 993 
1/1600 0.000625 524.5 536 492 518 
1/3200 0.0003125 256.5 266.5 274.5 266 
 
Table 3.5: Plasma Hook Effect: Raw Luminex MFI data for pooled plasma sample spiked 




Figure 3.9: Plasma Hook Effect: pooled plasma sample underwent a series of dilutions.  
Each diluted sample was reacted with Luminex beads coupled with 2 µg/mL of P-syn/81A 
mouse anti-α-synuclein phospho-specific (Ser129) mAb.   0.5 µg/mL of biotinylated detection 
Ab with 4 µg/mL streptavidin-RPE was used as the detection system for the assay.  Raw MFI 
data are plotted to deduce if the signal was reduced in the presence of high levels of 




3.3.4  Accuracy and Precision: plasma assay 
 
A total of six assays were performed on different dates to assess the accuracy and 
precision of the assay.  Five samples; ULOQ, HVS, MVS, LVS and LLOQ, were 
generated and used for this assessment.   
 
The ULOQ sample was generated by spiking 3000 ng/mL of recombinant 
phosphorylated α-synuclein into neat blank plasma to yield a MFI assay reading in 
the region of 60 ng/mL after the x 50 assay dilution. 
 
A number of plasma samples from patients with various neurodegenerative disorders 
were screened in order to select samples that would serve as the HVS, MVS and 
LVS.  Three samples were identified and used for assessing the precision of the 
assay at different regions of the calibration curve.  The approximate concentrations of 
these samples were 2000 – 2500 ng/mL, 750 – 1000 ng/mL and 50 – 75 ng/mL, 
respectively.  These equated to 40 – 50 ng/mL, 15 – 25 ng/mL and 1 – 1.5 ng/mL 
post the x 50 assay dilution.  
 
The LLOQ sample was generated by spiking 25 ng/mL of recombinant 
phosphorylated α-synuclein into neat blank plasma to yield a MFI assay reading in 
the region of 0.5 ng/mL after the x50 assay dilution. 
 
Each sample was assayed in three wells on each assay plate.  Both Inter-assay and 
Intra-assay precision and accuracy was determined.   Table 3.6 shows the inter-






Assay Date ULOQ HQ MQ LQ LLOQ 
27-Mar-14 
63.0 40.8 18.7 1.12 0.42 
61.5 37.9 19.0 0.99 0.45 
59.4 40.2 17.7 1.11 0.40 
28-Mar-14 
60.6 38.7 18.1 1.12 0.50 
61.4 37.7 18.6 1.13 0.53 
54.3 37.6 19.7 0.95 0.41 
01-Apr-14 
57.0 39.0 16.4 1.19 0.51 
59.7 41.2 18.5 1.16 0.54 
62.5 43.9 16.7 1.09 0.46 
03-Apr-14 
57.3 41.7 18.8 1.29 0.43 
53.5 30.4 17.9 1.20 0.38 
55.9 42.0 18.1 1.12 0.56 
05-Apr-14 
66.4 34.3 16.9 1.16 0.45 
60.1 34.7 17.4 1.23 0.46 
65.6 39.9 15.5 1.17 0.57 
11-Apr-14 
52.3 37.8 16.6 1.07 0.34 
64.0 43.5 18.8 1.10 0.42 
65.1 46.1 19.0 1.04 0.43 
Inter-assay data 
Mean 60.0 39.3 17.9 1.12 0.459 
SD 4.218 3.770 1.129 0.082 0.064 
CV% 7.0 9.6 6.3 7.3 13.9 
% 
Difference/Bias 
0.0 na na na -8.2 
 
Table 3.6: Plasma Inter-assay Accuracy and Precision: ULOQ, HVS, MVS, LVS and 
LLOQ samples were analysed on the Luminex for the quantification of phosphorylated α-
synuclein.  The precision was calculated using %CV (SD/mean %) and the bias for ULOQ 




Assay Date Intra-assay data ULOQ HQ MQ LQ LLOQ 
27-Mar-14 
Mean 61.3 39.6 18.5 1.07 0.42 
SD 1.79 1.57 0.71 0.07 0.03 
CV% 2.9 4.0 3.9 6.7 5.9 
%Difference/Bias 2.2 na na na -15.3 
28-Mar-14 
Mean 58.7 38.0 18.8 1.07 0.48 
SD 3.90 0.60 0.81 0.10 0.06 
CV% 6.6 1.6 4.3 9.5 13.0 
%Difference/Bias -2.1 na na na -4.0 
01-Apr-14 
Mean 59.7 41.4 17.2 1.15 0.50 
SD 2.80 2.48 1.14 0.05 0.04 
CV% 4.7 6.0 6.6 4.5 8.0 
%Difference/Bias -0.5 na na na 0.7 
03-Apr-14 
Mean 55.6 38.0 18.2 1.20 0.46 
SD 1.91 6.64 0.46 0.09 0.09 
CV% 3.4 17.5 2.5 7.1 20.3 
%Difference/Bias -7.4 na na na -8.7 
05-Apr-14 
Mean 64.0 36.3 16.6 1.19 0.49 
SD 3.45 3.12 1.00 0.04 0.07 
CV% 5.4 8.6 6.0 3.2 13.5 
%Difference/Bias 6.7 na na na -1.3 
11-Apr-14 
Mean 60.5 42.5 18.1 1.07 0.40 
SD 7.08 4.20 1.37 0.03 0.05 
CV% 11.7 9.9 7.6 2.8 12.4 
%Difference/Bias 0.8 na na na -20.7 
       
Intra-assay data Intra-CV% 5.8 7.9 5.1 5.6 12.2 
 
Table 3.7: Plasma Intra-assay Accuracy and Precision: ULOQ, HVS, MVS, LVS and 
LLOQ samples were analysed on the Luminex for the quantification of phosphorylated α-
synuclein.  The precision was calculated using CV% (SD/mean %) and the bias for ULOQ 
and LLOQ was calculated using %difference ((observed-expected)/expected * 100). Intra 
assay precision was calculated from the average CV% from each individual assay.  
 
The average inter assay precision was shown to be ≤ 13.9% and the bias based on 




The assay intra assay precision averaged at ≤ 12.2%, and the bias of the spiked 
known concentrations ranged from -20.7 to 6.7%. 
 
3.3.5  Limit of detection: plasma assay 
 
As defined by Armbruster et al (2008), the limit of detection (LOD) is the lowest 
analyte concentration that may be reliably distinguished from a blank sample.  The 
method used to ascertain this limit entailed analysing a blank sample 20 times, 
determining the mean value and then using the mean + 3SD as the LOD.   
 
The mean MFI reading from 20 replicates of the blank sample for this assay was 
measured at 7.5 with a standard deviation of 0.6.  Therefore, the mean MFI + 3*SD 
was calculated to be 9.39.  
 
The Luminex software cannot be manipulated in order to generate a value for the 
mean blank + 3SD MFI signal, therefore, a readily available software program called 
“Elisa analysis” (available at http://elisaanalysis.com/app) was used for this task.  
According to this program, a MFI signal of 9.39 correlates to a concentration of 0.02 
ng/mL of phosphorylated α-synuclein.  Correcting this value for the proposed 
minimum dilution of x 50 for the assay, the LOD was calculated to be 1 ng/mL (0.02 * 
50). 
 
3.4  Assay Validation: assay for analysing human CSF samples 
 
The Luminex assay for the quantification of phosphorylated α-synuclein was also 
used to measure phosphorylated α-synuclein levels in CSF.  The assay underwent 
slight modifications and a similar validation procedure as described in previous 





The assay modifications included determining the minimum required dilution of 
samples.  This was determined by performing spike recovery experiments at a series 
of sample dilutions.  The minimum required dilution was x5 and the spike recovery 
data obtained at this dilution are shown in section 3.4.2.   
 
The calibration curve was performed using 20% (v/v) blank human CSF spiked with 
recombinant phosphorylated α-synuclein at 200, 80, 32, 12.8, 5.12, 2.05, 0.819, 
0.327, 0 ng/mL.  The complete validation data obtained are displayed in this section. 
 
3.4.1  Parallelism: CSF assay 
 
One sample was used to assess this parameter due to very low detectable levels of 
phosphorylated α-synuclein present in CSF.  The data from this one sample are 


















CSF from Individual 1 
1/5 0.000 197 4.64 2.4 197 213 -7.3 
1/10 0.500 114 5.15 4.5 228  7.0 
1/20 0.250 53.4 1.80 3.4 214  0.4 
1/40 0.125 27.3 0.49 1.8 218  2.6 
1/80 0.063 12.9 0.79 6.1 207  -2.7 
 
Table 3.8: CSF Parallelism: Precision (%CV) and % Difference for one CSF sample 
Analysed at various dilutions with 20% (v/v) CSF assay buffer.  % difference calculated form 








Figure 3.10: CSF Parallelism: a CSF sample analysed at various dilutions; 1/5, 1/10, 1/20, 
1/40 and 1/80.    
 
The % difference was shown to be between -7.3% and 7.0%, with precision between 
1.8% and 6.1%. 
 
3.4.2  Spike Recovery: CSF assay 
 
Patient CSF samples were spiked with various concentrations of phosphorylated 
























CSF sample 1 
1.11 16.1 106 98.4 104 103 3.7 101 101.6 
CSF sample 2 
0.3 0.0 109 115 112 112 2.7 100 111.9 
CSF sample 3 














CSF sample 4 
0.0 0.0 144 183 174 167 12.2 150 111.4 
CSF sample 5 
0.18 50.4 144 152 135 144 5.7 150 95.6 
CSF sample 6 














CSF sample 7 
1.11 16.1 2.23 2.68 2.68 2.53 10.3 2.61 96.8 
CSF sample 8 
0.3 0.00 1.28 1.90 1.59 1.59 19.5 1.76 90.3 
CSF sample 9 














CSF sample 10 
1.1 16.1 14.2 13.0 13.6 13.6 4.5 16.1 84.4 
CSF sample 11 
0.18 50.4 12.8 14.4 16.5 14.6 12.5 15.2 95.9 
CSF sample 12 
0.48 0.0 14.0 13.1 11.5 12.9 9.9 15.5 83.0 
 
Table 3.9: CSF spike recovery: % recovery and precision (%CV) for a total of 12 CSF 
samples spiked with 100, 150, 2 or 15 ng/mL of recombinant phosphorylated α-synuclein 
 
The  % recovery for the spiked samples ranged between 95.6% and 114.7% at the 
high level spikes (100 and 150 ng/mL) with a precision between 0.7% and 12.2%.  
The low spike recoveries (2 and 15 ng/mL) ranged between 83.0% and 101.8% with 




3.4.3  Dilutional linearity and Hook Effect: CSF assay 
 
Three CSF samples taken from individuals with various neurodegenerative disorders 
were spiked with 2000 ng/mL of recombinant phosphorylated α-synuclein.   
 
The spiked samples were then diluted 1 in 5, 1 in 25, 1 in 125, 1 in 625, and 1 in 
3125 with 20% (v/v) CSF assay diluent.  Each diluted sample was analysed on the 
Luminex and the data obtained are shown in Table 3.10. 
Dilutional linearity sample 1 





1/5 0.02 na <ULOQ na 
1/25 0.04 76.2 81.3 -6.4 
1/125 0.008 16.0 16.3 -1.6 
1/625 0.0016 3.3 3.3 2.4 
1/3125 0.00032 0.9 <LLOQ na 
Blank 0 1.3 Na na 
Dilutional linearity sample 2 





1/5 0.02 na <ULOQ na 
1/25 0.04 76.9 80.8 -4.8 
1/125 0.008 15.8 16.2 -2.3 
1/625 0.0016 3.6 3.2 11.7 
1/3125 0.00032 0.8 <LLOQ na 
Blank 0 0.8 Na na 
Dilutional linearity sample 3 





1/5 0.02 na <ULOQ na 
1/25 0.04 79.4 80.5 -1.4 
1/125 0.008 16.4 16.1 1.6 
1/625 0.0016 3.6 3.2 11.5 
1/3125 0.00032 0.8 <LLOQ na 
Blank 0 0.5 0 na 
 
Table 3.10: CSF Dilutional Linearity: % Difference for three CSF samples diluted at 1/5, 






The % difference between the expected result and actual result was ≤ 11.7%, 
showing that samples can be diluted up to 3125 times without compromising the 
result.   To further show the linearity of sample dilution, a regression plot for each of 




Figure 3.11: CSF Dilutional Linearity: three CSF samples underwent a series of dilutions.  
Each diluted sample was reacted with Luminex beads coupled with 2 µg/mL of P-syn/81A 
mouse anti-α-synuclein phospho-specific (Ser129) mAb.   0.5 µg/mL of biotinylated detection 
Ab with 4 µg/mL streptavidin-RPE was used as the detection system for the assay. 
 
This experiment was also used to assess hook effect for the assay.  The results in 
Table 3.11 and Figure 3.12 show that the MFI signal at 2000 ng/mL of recombinant 
phosphorylated α-synuclein does not reduce.  A reduction in the signal would have 
indicated hook effect.  Only data for sample 1 have been displayed, the other two 




Sample 1: R 
2
 = 0.9999 
Sample 2: R 
2
 = 1 
Sample 3: R 
2






Table 3.11: CSF Hook Effect: Raw Luminex MFI data CSF sample 1 spiked with 2000 





Figure 3.12: CSF Hook Effect: three CSF were spiked with 2000 ng/mL of recombinant 
phosphorylated α-synuclein and then underwent a series of dilutions.  The spiked sample and 
the each diluted sample was analysed.  Raw MFI data are plotted to deduce if the signal was 
reduced in the presence of high levels of recombinant phosphorylated α-synuclein.  Data for 




Dilution 1/Dilution Raw MFI Result Mean MFI Result 
1/5 0.2 3052 3055 3196 3101 
1/25 0.04 692 688 697 693 
1/125 0.008 124 130 133 129 
1/625 0.0016 28 25 28 27 




3.4.4  Accuracy and Precision: CSF assay 
 
Assays were performed on different dates to assess the accuracy and precision of 
the assay using five prepared samples; ULOQ, HVS, MVS, LVS and LLOQ. 
 
CSF samples, both from individuals with suspected neurodegenerative disorders and 
healthy individuals were screened in order to find and select samples that could 
serve as the ULOQ, HVS, MVS, LVS and LLOQ samples.  Unfortunately, no samples 
were suitable for this purpose; therefore, all samples were generated by spiking 
recombinant phosphorylated α-synuclein into blank CSF. 
 
The ULOQ sample was generated by spiking 200 ng/mL of recombinant 
phosphorylated α-synuclein into neat blank CSF and then diluted x 5.  The HVS, 
MVS, LVS and LLOQ samples were generated in a similar fashion by spiking 150, 
50, 12.5 and 1.2 ng/mL of recombinant phosphorylated α-synuclein into the blank 
CSF.   
 
Each sample was assayed in three wells on each assay plate.  Both Inter-assay and 
Intra-assay precision and accuracy has been determined from ≥ 7 different assay 












Assay Date ULOQ HQ MQ LQ LLOQ 
12-Sep-14 
192 138 49.9 na na 
169 136 52.5 na na 
193 142 50.0 na na 
13-Sep-14 
179 145 47.0 13.4 0.97 
x 133 49.6 13.0 0.97 
192 144 51.0 12.8 0.97 
18-Sep-14 
188 136 55.1 13.7 1.23 
185 157 45.2 14.2 1.07 
209 146 45.7 12.9 1.18 
06-07 Oct 2014 
210 167 64.0 14.8 1.45 
220 154 62.9 13.4 1.58 
163 160 56.0 10.4 1.13 
07-08 Oct 2014 
184 155 51.2 12.5 1.41 
na 170 52.9 11.1 1.64 
na 171 57.1 11.3 1.04 
10-11 Oct 2014 
200 176 48.9 12.2 na 
196 151 54.2 12.2 na 
196 148 46.6 11.3 na 
15-16 Oct 2014 
215 159 52.8 11.9 1.72 
201 169 55.8 11.0 na 
216 162 58.2 11.8 na 
15-16 Oct 2014 b 
na 181 56.6 11.5 1.24 
na 186 55.7 12.3 1.27 
na 171 46.1 12.2 1.35 
18-19 Oct 2014  
na 175 55.1 13.7 1.52 
na 173 66.7 12.2 1.36 
na 173 58.3 13.8 1.36 
21-22 Oct 2014 b 
na 170 64.7 13.3 1.28 
na 197 52.2 15.3 1.02 
na 173 57.8 11.7 1.15 
Inter-assay data 
Mean 195 161 54.0 12.6 1.27 
SD 15.667 16.360 5.723 1.197 0.223 
CV% 8.0 10.2 10.6 9.5 17.6 
% Difference/Bias -2.6 7.0 8.0 0.6 5.7 
 
Table 3.12: CSF Inter-assay Accuracy and Precision: ULOQ, HVS, MVS, LVS and LLOQ 
samples were analysed on the Luminex for the quantification of phosphorylated α-synuclein.  
The precision was calculated using %CV (SD/mean %) and the accuracy was calculated 









Assay Date Intra-assay data ULOQ HQ MQ LQ LLOQ 
12-Sep-14 
Mean 185 139 50.8 na na 
SD 13.29 3.41 1.48 na na 
CV% 7.2 2.5 2.9 na na 
%Difference/Bias -7.6 -7.6 1.6 na na 
13-Sep-14 
Mean 185 140 49.2 13.0 0.97 
SD 9.29 6.87 1.99 0.30 0.00 
CV% 5.0 4.9 4.1 2.3 0.0 
%Difference/Bias -7.4 -6.4 -1.6 4.2 -19.2 
18-Sep-14 
Mean 194 146 48.7 13.6 1.16 
SD 12.69 10.36 5.56 0.62 0.08 
CV% 6.54 7.09 11.42 4.56 7.06 
%Difference/Bias -3.0 -2.6 -2.6 8.8 -3.3 
06-07 Oct 2014 
Mean 198 161 61.0 12.86 1.39 
SD 30.27 6.37 4.32 2.27 0.23 
CV% 15.3 4.0 7.1 17.6 16.7 
%Difference/Bias -1.2 7.1 na* 2.9 15.6 
07-08 Oct 2014 
Mean 184 166 53.7 11.6 1.4 
SD na 9.17 3.04 0.74 0.30 
CV% na 5.54 5.66 6.41 22.2 
%Difference/Bias -8.2 10.3 7.5 -7.2 13.6 
10-11 Oct 2014 
Mean 197 158 49.9 11.9 na 
SD 2.68 15.42 3.87 0.51 na 
CV% 1.4 9.8 7.7 4.3 na 
%Difference/Bias -1.4 5.4 -0.2 -4.8 na 
15-16 Oct 2014 
Mean 211 163 55.6 11.5 1.7 
SD 8.33 5.24 2.72 0.51 0.70 
CV% 3.9 3.2 4.9 4.5 40.7 
%Difference/Bias 5.4 8.9 11.2 -7.7 43.3 
15-16 Oct 2014 b 
Mean na 179 52.8 12.0 1.3 
SD na 7.82 5.80 0.42 0.06 
CV% na 4.36 10.98 3.50 4.42 
%Difference/Bias na na* 5.6 -3.8 7.2 
18-19 Oct 2014 b 
Mean na 173 60.0 13.2 1.4 
SD na 1.01 6.01 0.86 0.09 
CV% na 0.6 10.0 6.5 6.5 
%Difference/Bias na 15.6 na* 5.7 17.8 
21-22 Oct 2014 b 
Mean na 180 58.3 13.4 1.2 
SD na 14.88 6.25 1.77 0.13 
CV% na 8.3 10.7 13.2 11.3 
%Difference/Bias na na* 16.5 7.4 -4.2 
       
Intra-assay data Intra-CV% 6.6 5.0 7.6 7.0 13.6 
 
Table 3.13: CSF Intra-assay Accuracy and Precision: ULOQ, HVS, MVS, LVS and LLOQ 
samples were analysed on the Luminex for the quantification of phosphorylated α-synuclein.  
The precision was calculated using CV% (SD/mean %) and the accuracy was calculated 
using %difference ((observed-expected)/expected * 100). Intra assay precision was 
calculated from the average CV% from each individual assay. na* represents data exclusion 




The average inter assay precision ranged between 8.0% and 17.6% and the bias, 
based on the spiked known concentrations, was between -2.6% and 8.0%. 
 
The assay mean intra assay precision was between 5.0% and 13.6%, and the bias of 
the spiked known concentrations (ULOQ to LLOQ levels) ranged from -19.2% and 
17.8% (43.3% bias was achieved in one assay at LLOQ). 
 
3.4.5  Limit of detection: CSF assay 
 
The method used to ascertain the LOD entailed analysing a blank sample (20% (v/v) 
CSF) 20 times, determining the mean value and then using the mean + 3SD as the 
LOD.   The mean MFI for the 20 blank sample replicates was 5.63 with a standard 
deviation of 0.78.  The mean MFI + 3*SD was therefore calculated to be 7.95. 
 
The “Elisa anlaysis” program (available at http://elisaanalysis.com/app) was used for 
converting the Luminex MFI signal into a concentration value of CSF phosphorylated 
α-synuclein in the blank CSF sample.  According to this program, a MFI signal of 
7.95 correlates to a concentration of 0.32 ng/mL of phosphorylated α-synuclein. 
 
3.5  Discussion 
 
This chapter presented the development and validation of a Luminex assay for the 
quantification of phosphorylated α-synuclein levels in human plasma and CSF.   An 
ELISA assay for this purpose was already developed in house, but the purpose of 
this project was to transfer this assay onto a more sensitive platform and then use 
this for subsequent sample analysis.  Unfortunately the antibodies used in the 
original ELISA assay; N-19 (capture antibody) and EP1536Y (detection antibody), did 
not work well with the Luminex technology and as a result alternative antibodies were 




Two possible reasons can be offered as to why the original ELISA antibodies did not 
work on the Luminex platform.  It should be noted that these possible reasons were 
not proven experimentally but may serve to explain the possible causes for the assay 
transfer failure: 
 
1.  Inefficient coupling of the capture antibody to the beads:  the N-19 pAb was 
supplied at 200 µg/mL with 0.1 % gelatin and sodium azide.  For optimal bead 
coupling, it is recommended that the antibody is free from BSA, glycine, sodium 
azide and other TRIS or amine containing additives.  The antibody did undergo a 
buffer exchange step and was concentrated to 1 mg/mL prior to the coupling 
reaction, but it is possible that some of the interfering components remained and thus 
compromised the bead coupling reaction.  Also, procedures such as buffer exchange 
can lead to loss of antibody and this may have contributed to the fact that the assay 
failed to work with N-19 as the capture antibody (http://www.bio-
rad.com/webroot/web/pdf/lsr/literature/4110012B.pdf). 
 
2.  Poor biotinylation of the detection antibody:  the EP1536Y antibody was supplied 
in 50% glycerol.  The biotinylation technique adopted in this project involved 
biotinylating the antibody via the formation of a NHS ester.  The presence of high 
levels of glycerol interferes with this reaction.  Again, as with the N-19 antibody, a 
buffer exchange step was performed prior to biotinylation, but this may not have been 
effective at removing such large concentrations of glycerol, thus leading to poor 
biotinylation (https://www.lifetechnologies.com/order/catalog/product/20217).  The 
original ELISA assay that utilised the EP1536Y antibody for detection did not require 
being biotinylated, thus the buffer constituents and interference with biotinylation 





The guidelines (Lee et al, 2006b and 2009) used for validating the phosphorylated 
α-synuclein Luminex assay provide detailed descriptions of the parameters to 
validate and how, but do not provide acceptance criteria for the various assessments.  
Cummings et al (2010) have published a set of guidelines with acceptance criteria to 
support biomarker assessments for anti-cancer drug clinical trials.  These 
acceptance criteria are summarised (Table 3.14): 
 
Validation Parameter Acceptance criteria 
Inter assay bias 
 
≤ 20% recovery at HQ, MQ and LQ level 




Intra assay bias 
 
≤ 20% recovery at HQ, MQ and LQ level 
≤ 25% recovery at LLOQ and ULOQ 
 
Inter assay precision 
 
≤ 20% CV at HQ, MQ and LQ level 
≤ 25% CV at LLOQ and ULOQ 
 
Intra assay precision 
 
≤ 20% CV at HQ, MQ and LQ level 
≤ 25% CV at LLOQ and ULOQ 
 
Parallelism 
≤ 20% bias 
≤ 30% precision 
Dilutional linearity 
≤ 20% bias 
≤ 30% precision 
Spike Recovery 
Not specified, but we have adopted the same 
criteria as Parallelism and Dilutional linearity 
 
Table 3.14: Assay validation acceptance criteria: parameters assessed for the Luminex 





The validation data obtained for the quantification of phosphorylated α-synuclein in 
human plasma and CSF met all the criteria outlined by Cummings et al (2010).  A 
“Draft – not to be implemented Guidance for Industry” document was released in 
September 2013 by the FDA in the US and includes acceptance criteria that closely 
relate to those summarised in table 3.14 (US Department of Health and Human 
Services, 2013).  Therefore, if this draft document becomes an official document, the 
data shown in this chapter will meet the Government based requirements.  
 
One of the aims for developing a Luminex assay was to improve the sensitivity at 
which levels of phosphorylated α-synuclein can be detected and measured in human 
plasma and CSF.  The LOD for the ELISA assay was calculated prior to the 
commencement of this project, by Dr Penny Foulds. The ELISA for quantifying 
phosphorylated α-synuclein in human plasma had a LOD of 40 ng/mL and 3 ng/mL in 
CSF.  The Luminex assay for quantifying phosphorylated α-synuclein was found to 
have a LOD of 1 ng/mL for human plasma and 0.3 ng/mL for CSF.  Thus the 
Luminex assay provided a much more sensitive assay than the original ELISA.  
  
 
Chapter 4:    
Phosphorylated α-synuclein: 






Chapter 3 described the development and validation of a Luminex assay for 
quantifying phosphorylated α-synuclein in human plasma and CSF.  This assay was 
used to analyse a series of plasma and CSF samples taken from individuals affected 
by various neurodegenerative disorders such as AD, PD, MSA, PSP and CBD. 
 
Samples obtained from two independent sites were analysed.  One set of samples 
was obtained from patients attending out-patient clinics at Greater Manchester 
Neurosciences Centre (GMNC) at Salford Royal Hospital; a total of 269 plasma 
samples, taken from patients with AD, PD, MSA, PSP and CBD were received.  
Additionally, 94 matched plasma and CSF samples were obtained from the 
Department of Neurology, University College Hospital, London (UCL), courtesy of Dr 
Nadia Magdalinou.  These matched plasma and CSF samples were collected from 
patients with MSA, PD, PSP and CBS.  Both sites also provided a set of samples 
taken from healthy controls; 72 from GMNC and 26 from UCL.   
 
All samples were analysed in triplicate (3 wells) against a standard curve and 
minimum three levels of quality controls at the beginning and end of each assay plate 
as described in the Methods section (Chapter 2b) and Appendix 1.  Data from 
samples were only used if they met the acceptance criteria outlined in Chapter 2b. 
 
The aim was to see if levels of phosphorylated α-synuclein show significant 
differences between the different disease groups.  The availability of matched plasma 
and CSF samples also provided the opportunity to assess whether levels of 





This chapter displays the data obtained from the sample analysis and the outcomes 
from this investigation. 
 
4.2  Phosphorylated α-synuclein levels in plasma samples from GMNC 
 
The data for phosphorylated α-synuclein levels collected from the plasma samples 
from GMNC were analysed statistically using IBM SPSS Statistics 21 package.  Data 
obtained from the Luminex software were sorted into the different disease groups 
and then checked for normality using Kolgomorov-Smirnov test.  The data was not 
normally distributed; therefore the non-parametric Kruskal-Wallis (K-W) test (with 
post-hoc Mann-Whitney test when K-W was significant) was used in order to 
determine whether phosphorylated α-synuclein levels were significantly different 
between the different disease groups.  A summary of the data obtained is tabulated 
in Table 4.1. 






AD 66 335 15 1344 
PD 58 456 13 2378 
DLB 63 518 12 1362 
MSA 18 60 4 206 
PSP 32 702 21 2173 
CBD 15 83 13 248 
Healthy Controls 69 236 24 461 
 
Table 4.1: Plasma samples from GMNC data summary:  mean, median and SD calculated 
using Microsoft Excel 2010.  Each sample was analysed in triplicate. 
 
By K-W test, the levels of phosphorylated α-synuclein between AD, PD, DLB, MSA, 




4.3   Relationship between APOE genotype and phosphorylated α-synuclein 
levels in plasma samples from GMNC 
 
An independent t-test was performed in order to investigate whether phosphorylated 
α-synuclein levels in plasma were influenced by the APOE genotype. This involved 
stratifying the phosphorylated α-synuclein levels according to the presence of at least 
one APOE ε4 allele, i.e. individuals who were heterozygous or homozygous for 
APOE ε4 allele, versus individuals without APOE ε4 allele. The test was done for 
each of the individual disease groups to see if the presence of APOE ε4 allele 
influenced phosphorylated α-synuclein levels in individuals with a particular disorder, 




with APOE E4 
n 
without APOE E4 
P value 
AD 54 12 0.947 
PD 42 16 0.422 
DLB 30 33 0.207 
MSA 12 6 0.546 
PSP 25 7 0.547 
CBD 6 8 0.273 
Healthy Controls 56 12 0.525 
 
Table 4.2: Independent t-test data summary: phosphorylated α-synuclein levels stratified 





The P-value for each group was > 0.05, therefore it can be concluded that the 
presence of APOE ε4 allele has no influence on the levels of phosphorylated α-
synuclein in plasma. 
 
4.4  Phosphorylated α-synuclein levels in plasma samples from UCL 
 
Data obtained from the UCL plasma samples were also analysed using the IBM 
SPSS Statistics 21 package.  Again, the data were grouped according to disease 
type and checked for normality using the Kolgomorov-Smirnov test.  The data was 
not normally distributed; therefore the K-W test was used to determine whether the 
levels of phosphorylated α-synuclein in plasma differed between disease groups.  
Table 4.3 summarises the data. 
 






PD/DLB 22 297 43 728 
MSA 28 211 25 392 
PSP 31 320 39 616 
CBS 13 92 15 140 
Healthy controls 26 229 23 355 
 
Table 4.3: Plasma samples from UCL data summary:  mean, median and SD calculated 
using Microsoft Excel 2010.  Each sample was analysed in triplicate. 
 
There was no significant difference in phosphorylated α-synuclein levels between 







4.5  Phosphorylated α-synuclein levels in samples from GMNC and UCL 
combined 
 
The data obtained from GMNC and UCL were combined and then analysed as 
described previously.   
 
Table 4.4 summarises the combined data: 
 






AD 66 335 15 1344 
PD/DLB 143 294 43 728 
MSA 46 211 25 391 
PSP 63 322 29 636 
Healthy controls 95 238 23 359 
 
Table 4.4: Plasma samples from GMNC and UCL combined, data summary:  mean, 
median and SD calculated using Microsoft Excel 2010. 
 
There was no significant difference in the levels of plasma phosphorylated α-
synuclein between the various neurodegenerative disorders (p=0.508 by K-W test). 
 
4.6  Phosphorylated α-synuclein levels in CSF samples from UCL 
 
The UCL plasma samples had matched CSF samples, and these were also analysed 














PD/DLB 21 0.48 0.38 0.46 
MSA 28 0.61 0.44 0.61 
PSP 31 1.32 0.38 2.77 
CBS 13 0.54 0.26 0.93 
Healthy controls 26 0.62 0.30 0.95 
 
Table 4.5: CSF samples from UCL data summary:  mean, median and SD calculated using 
Microsoft Excel 2010.  Each sample was analysed in triplicate. 
 
There was no significant difference in the levels of phosphorylated α-synuclein in 
CSF between the different disease groups and healthy controls (p=0.245 by K-W 
test). 
 
4.7 Correlation between phosphorylated α-synuclein levels in plasma and 
matched CSF samples from UCL 
 
The availability of matched plasma and CSF samples allowed us to investigate 
whether levels of phosphorylated α-synuclein measured in plasma of a particular 
individual, correlated with levels quantified in the CSF sample collected from that 
same individual.  This was initially determined by combining the phosphorylated α-
synuclein plasma and CSF data from all patient groups.  
 
The data set was checked for normality using the Kolgomorov-Smirnov test and was 
found to be non-normally distributed.  Therefore, the Spearman rank correlation test 
was adopted to test for any correlation between plasma and CSF measures of 











Sig (2 tailed) na 0.000 






Sig (2 tailed) 0.000 na 
n 119 119 
 
Table 4.6: Matched plasma vs CSF samples from UCL correlation:  spearman rank 



















Figure 4.1: Scatter plot for matched plasma vs CSF samples: all disease groups.  A) full 
scatter plot, B) data concentrated in the lower end of full plot 
 
Overall, the levels of phosphorylated α-synuclein in plasma correlated with the levels 
in CSF (p<0.05 by Spearman rank correlation test).  In order to determine whether 
the overall positive correlation was driven by any particular patient group, correlation 





Table 4.7 and Figure 4.2 represent the results from PD/DLB samples: 
 
 






Sig (2 tailed) na 0.000 






Sig (2 tailed) 0.000 na 
n 21 21 
 
Table 4.7: PD/DLB matched plasma vs CSF samples from UCL correlation:  spearman 
























Figure 4.2: PD/DLB matched plasma vs CSF samples from UCL correlation:  scatter plot 
depicting the spearman rank correlation. A) full scatter plot, B) data concentrated in the lower 
end of full plot. 















Sig (2 tailed) na 0.000 






Sig (2 tailed) 0.000 na 
n 28 28 
 
Table 4.8: MSA matched plasma vs CSF samples from UCL correlation:  spearman rank 






















Figure 4.3: MSA matched plasma vs CSF samples from UCL correlation:  scatter plot 
depicting the spearman rank correlation. A) full scatter plot, B) data concentrated in the lower 


















Sig (2 tailed) na 0.000 






Sig (2 tailed) 0.000 na 
n 31 31 
 
Table 4.9: PSP matched plasma vs CSF samples from UCL correlation:  spearman rank 

















Figure 4.4: PSP matched plasma vs CSF samples from UCL correlation:  scatter plot 
depicting the spearman rank correlation. A) full scatter plot, B) data concentrated in the lower 

















Sig (2 tailed) na 0.338 






Sig (2 tailed) 0.338 na 
n 13 13 
 
Table 4.10: CBS matched plasma vs CSF samples from UCL correlation:  spearman rank 
statistical data obtained from IBM SPSS Statistics 21 package. 
 
 
Figure 4.5: CBS matched plasma vs CSF samples from UCL correlation:  scatter plot 
depicting the spearman rank correlation. 
 
 















Sig (2 tailed) na 0.000 






Sig (2 tailed) 0.000 na 
n 26 26 
 
Table 4.11: Healthy controls matched plasma vs CSF samples from UCL correlation:  























Figure 4.6: Healthy controls matched plasma vs CSF samples from UCL correlation:  
scatter plot depicting the spearman rank correlation. A) full scatter plot, B) data concentrated 






A significant correlation (p<0.05) between plasma and CSF levels of phosphorylated 
α-synuclein was found for individuals with PD/DLB, MSA and PSP, as well as in the 





The strong pathological relationship between α-synuclein and various 
neurodegenerative disorders, such as PD, MSA and DLB, has initiated a great deal 
of interest in the biological implications of this protein.  The discovery that α-synuclein 
can be detected in biological fluids, such as CSF and plasma, has led to many 
investigations as to whether α-synuclein has the potential to act as a biomarker. 
 
Studies comparing levels of CSF α-synuclein in the α-synucleinopathies versus other 
neurological disorders and healthy controls have been reported, with differing results 
(Table 4.12).   






Hong et al (2010) PD = 117 
AD = 50 
HC = 132 
Luminex Decreased levels 
in PD vs AD and 
HC 
Reesink et al 
(2010) 
DLB = 35 
AD = 63 
PD = 18 
HC = 35 
ELISA No significant 
difference 
Park et al (2011) PD = 23 
HC = 18 
ELISA No significant 
difference 
Shi et al (2011) PD = 126 
MSA = 32 
AD = 50 
HC = 137 
Luminex Decreased levels 











Aerts et al (2012) PD = 58 
MSA = 47 
DLB = 3 
PSP = 10 
CBD = 2 
ELISA No significant 
difference 
Tateno et al 
(2012) 
AD = 9 
DLB = 6 
PD = 11 
MSA = 11 
HC = 11 
ELISA Increased levels in 
AD vs HC 
 
Decreased levels 
in PD, DLB AND 
MSA vs AD 
Kang et al (2013) PD = 39 
HC = 63 
ELISA Decreased levels 
PD vs HC 
Van Dijk et al 
(2013) 
PD = 53 
HC = 50 
TR-FRET Decreased levels 
PD vs HC 
Wennstrom et al 
(2013) 
PD = 38 
DLB = 33 
AD = 46 
HC = 52 
ELISA Decreased levels 
in PD and AD vs 
AD and HC 
Parnetti et al 
(2014) 
PD = 44 
HC = 25 
ELISA Ratio of oligo:total 
synuclein 
decreased in PD vs 
HC 
 
Table 4.12: Summary of studies investigating the use of CSF total α-synuclein as a 
biomarker for neurodegenerative disorders: adopted and modified from Magdalinou et al, 
2014. 
 
Some studies reported no significant differences in the diseased groups investigated 
versus healthy controls (Aerts et al, 2012; Park et al, 2011; Reesink et al, 2010), 
whereas, most groups found decreased levels of CSF α-synuclein in PD compared to 
AD and healthy controls (Hong et al, 2010; Kang et al, 2013; Shi et al, 2011; 




increased levels of α-synuclein in CSF from AD patients compared to healthy 
individuals.   
 
Similarly, results from measuring α-synuclein in plasma have also differed (Table 
4.13). 
 






Lee et al (2006c) PD = 105 
MSA = 38 
HC = 51 
ELISA Increased levels in 
PD and MSA vs 
HC 
Li et al (2007) PD = 27 
HC = 11 
IP-WB Decreased levels 
in PD vs HC 
Duran et al (2010) PD = 95 
HC = 60 
ELISA Increased levels in 
PD vs HC 
Park et al (2011) PD = 23 
HC = 29 
ELISA No significant 
difference 
Shi et al (2010) HC = 95 
AD = 33 
PD = 117 
Luminex No significant 
difference 
 
Table 4.13: Summary of studies investigating the use of plasma total α-synuclein as a 
biomarker for neurodegenerative disorders: adopted and modified from Kasuga et al, 
2012. 
 
Lee et al (2006c) and Duran et al (2010) showed that levels of plasma α-synuclein 
are higher in PD and MSA patients compared to controls, whereas Li et al (2007) 
reported that levels are lower in PD.  Shi et al (2010) and Park et al (2011) found no 





The aforementioned studies all involved measuring levels of total α-synuclein, 
whereas, in this chapter, investigations have focussed specifically on the 
phosphorylated form of α-synuclein.  This particular interest in phosphorylated α-
synuclein stems from the finding that the protein aggregates found in PD, DLB or 
MSA brains are hyperphosphorylated at Ser129 (Fujiwara et al, 2002; Anderson et al, 
2006; Wakabayashi et al, 1998). Thus, Ser129 phosphorylated α-synuclein 
represents a ‘pathological’ form of the protein that might be particularly suitable as a 
biomarker.  Publications investigating the use of phosphorylated α-synuclein as a 
biomarker are relatively few (Foulds et al, 2011; Foulds et al 2013). Foulds et al 
(2011) showed that phosphorylated α-synuclein levels in plasma from PD patients 
were significantly higher than those in healthy controls.  Present data disagree with 
these previous findings, in that no significant difference in levels of plasma 
phosphorylated α-synuclein between diseased groups and healthy controls was 
found.  This discrepancy may be due to differences in the assay methodology.  
Foulds et al (2011 and 2013) used an ELISA for the quantification, utilising two 
different polyclonal antibodies.  Present assay was developed specifically for use 
with the Luminex analyser, with a monoclonal phosphospecific antibody for capture 
and a polyclonal detection antibody.  The different antibodies may be one possible 
reason for the difference in our results compared to those of Foulds et al (2011 and 
2013).  Another plausible reason may lie in differences in number of samples 
analysed.  Foulds et al (2013) analysed a total of 189 samples from PD patients and 
91 healthy controls, whereas only 79 plasma samples from PD patients and 94 
healthy control samples were analysed in the present study. 
 
Wang et al (2012) investigated the use of CSF phosphorylated α-synuclein in PD, 
MSA, PSP patients and healthy controls.  The quantification method used was the 




not commercially available.   They noted that phosphorylated α-synuclein levels in 
CSF do not appear to be a suitable biomarker, agreeing with present results. As well 
as phosphorylated α-synuclein, Wang et al (2012) measured total α-synuclein in CSF 
and found that the ratio between total α-synuclein : phosphorylated α-synuclein levels 
may serve as a better biomarker.    In chapter 6, it is investigated whether this can be 
achievable with plasma as opposed to CSF, since plasma would be a more easily 
accessible biological fluid for use as a biomarker. 
 
In addition to investigating whether phosphorylated α-synuclein in plasma and CSF 
has the potential to be a diagnostic marker, we were able to show that levels of 
phosphorylated α-synuclein in CSF correlated with levels in plasma.    A previous 
study in PD with longitudinally obtained samples showed that levels of α-synuclein in 
plasma are highly variable between individuals, i.e. some individuals are naturally 
high expressors and others are low expressors – this variability has been shown to 
be consistent over time in repeat samples taken from the same individual (Foulds et 
al, 2013).  From our study, we can conclude that this variability in α-synuclein levels 
amongst individuals also appears to be consistent between the CNS (CSF) and 
periphery (blood) and not confined to just one body fluid. From a biomarker point of 
view, this suggests that plasma is a suitable matrix for determining overall levels of α-
synuclein expression, and for highlighting differences in expression between 
individuals.  
 
Additionally, the positive correlation between plasma and CSF phosphorylated α-
synuclein levels suggests that levels in plasma could reflect pathological 
conditions/events taking place within the CNS. This would be helpful because plasma 
is much more accessible as a biological fluid for biomarker investigations than CSF, 




exchange of phosphorylated α-synuclein between CSF (brain) and blood. Shi et al 
(2014) and Sui et al (2014) used radiolabelled α-synuclein to show that this protein 
crosses the blood brain barrier (BBB), allowing its transportation in a bidirectional 
manner, i.e. blood to brain and brain to blood. The specific mechanisms involved in 
this transportation across the BBB are still unclear, but it may resemble the process 
implicated in the transportation of β-amyloid peptides.  Amongst the main 
components involved in the transportation of β-amyloid across the BBB is lipoprotein 
receptor related protein-1 (LRP-1) (Deane et al, 2009).  Interestingly enough, the 
study by Sui et al (2014) has shown a potential role for LRP-1 in the transportation of 
α-synuclein across the BBB also. In general, this supports the concept that plasma 
protein levels can potentially evidence changes occurring in the brain – but this would 




Chapter 5:    
Total α-synuclein and total DJ-1: 





5.1 Introduction  
 
The ability to multiplex different biomarkers is the main attractive feature offered by 
the Luminex technology.  One of the aims of this project was to develop a multiplex 
assay to quantify total α-synuclein, total DJ-1 and LRRK2 levels in human CSF and 
plasma samples from individuals with various neurodegenerative diseases and 
healthy controls.  These three markers have been predominantly linked to PD and 
other synucleinopathies, for which, well established commercial assays are not 
readily available for. Thus, multiplexing these markers was deemed to be a good 
starting point. Unfortunately, initial assay development experiments revealed that the 
LRRK2 assay components cross reacted with both the total α-synuclein and total 
DJ-1 assay components.  Thus, a duplex assay quantifying total α-synuclein and total 
DJ-1 was developed and validated for use with human plasma and CSF.  The 
LRRK2 assay was developed separately as a singleplex assay and is discussed in 
Chapter 7. 
 
To develop the duplex assay, a singleplex assay for the two analytes (total 
α-synuclein and total DJ-1) was first developed and then combined to form the 
duplex assay.   
 
This chapter describes the development of each individual singleplex and the series 
of experiments leading to the formation of the duplex assay. 
 
 
5.2 Total α-synuclein 
 
An ELISA for the quantification of total α-synuclein in human plasma and CSF has 
been established previously, utilising C211 mouse anti-α-synuclein mAb (Santa Cruz 





(Santa Cruz Biotech. Inc.)  as the detection component (Foulds et al, 2011).  In order 
to develop a total α-synuclein assay on the Luminex bead system, it was rational to 
start with the antibody pairings that worked in the ELISA system, where the C211 
mAb was coupled to beads and the FL140 pAb was biotinylated.  The ELISA assay 
did not require the FL140 pAb detection antibody to be biotinylated.  Instead, it 
utilised a goat anti-rabbit secondary antibody conjugated to horseradish peroxidase 
(HRP) plus TMB substrate complex as the detection system (Foulds et al, 2011).  
Unfortunately, the C211 mAb + FL140 pAb combination was not successful on the 
Luminex system.  This section reports the investigative steps taken which eventually 
led to the identification of the problem and allowed the development of a functional 
assay. 
 
5.3  Total α-synuclein Luminex assay troubleshooting 
 
C211 mouse anti-α-synuclein mAb (Santa Cruz Biotech. Inc.) was coupled to 
microspheres and FL140 rabbit anti-α/β/γ-synuclein pAb (Santa Cruz Biotech. Inc.)  
was biotinylated as per the procedures described in the Methods section.  The two 
components were then used to perform a Luminex assay using the in house 
recombinant α-synuclein protein at 600, 200, 66.7, 22.2, 7.4, 2.5, 0.82, 0 ng/ml, 
prepared in assay buffer (PBS/SM01).  This assay generated zero MFI signals.  The 
assay was repeated again to exclude the possibility of experimental error, but the 
same result was obtained.  In order to identify why the assay was not working, four 
questions were addressed: 
 
Q1:  Had the C211 mAb coupled to the beads successfully? 
Q2:  If the C211 mAb has coupled to the beads then does it still bind to α-synuclein? 
Q3:  Had the FL140 pAb conjugated to biotin successfully? 





In order to answer these questions the antibody coupling confirmation, antibody 
functionality, biotinylation confirmation and biotinylation functionality tests were 
conducted, respectively. 
 
The antibody coupling confirmation test used goat anti-mouse IgG conjugated to 
R-phycoerythrin.  The C211 anti-α-synuclein capture antibody was a mouse mAb, 
thus the anti-mouse IgG-PE would only bind and generate a signal in the presence of 
the C211 mouse anti-α-synuclein mAb.  Varying mass of antibody was coupled to 
beads; 0.5, 2, 4, 8 and 10 µg.  The results from this test are displayed in Figure 5.1: 
 
Figure 5.1: C211 anti-α-synuclein mAb bead coupling confirmation:  C211 mouse anti-α-
synuclein mAb (Santa Cruz Biotech. Inc.) were coupled at varying mass (µg) to Luminex 
beads.  Each bead set coupled with varying antibody mass (µg) was reacted with 4 µg/mL 
anti-mouse IgG-PE to show whether the C211 mouse mAb was present on the beads. 
 
These results suggested that C211 mouse anti-α-synuclein mAb was present on the 
beads.  0.5 μg of the antibody coupled to beads generated the best MFI signal, 





assay.  However, it was possible that the coupling process may have modified the 
antibody in a manner that destroyed its ability to bind to its target protein.  
 
In order to determine whether the coupled C211 mAb had retained its binding 
properties, the antibody coupling functionality test was performed, where biotinylated 
α-synuclein recombinant protein was reacted with each bead set coupled to varying 
mass of antibody.  The results are displayed in Figure 5.2:  
 
Figure 5.2: C211 mAb coupled to beads functionality test:  Beads coupled to 0.5, 2, 4, 8 
and 10 µg of C211 mAb were reacted with biotinylated α-synuclein.  Beads coated with 1% 
(w/v) BSA only and beads coated with anti-TDP43 mAb were used as controls for the assay.  
The level of α-synuclein binding by each bead set was quantified using the Luminex analyser. 
 
The beads coupled with C211 mAb were able to capture α-synuclein and thus were 
not the non-functional component. Therefore, the biotinylation of FL140 was 
assessed next.   
 
Two tests were performed simultaneously; biotin confirmation and biotin functionality.  





Biotin Confirmation Test:   Biotin Functionality Test: 
Biotinylated FL140 + Strep-EU   α-synuclein + Biotinylated FL140 + Strep-EU  











Figure 5.3: FL140 Biotin Confirmation and Functionality Test:   The biotinylation of 
FL140 pAb was confirmed by reacting the biotinylated FL140 pAb with Streptavidin-EU.  The 
functionality of biotinylated FL140 was assessed by reacting the pAb with recombinant α-
synuclein, followed by quantification of bound biotinylated FL140-protein complex via 
streptavidin-EU.  The figure displays the signals achieved for the confirmation and 
functionality tests.  The numbers in each “well spot” in the figure represent the signal. The 
colours of each well spot also indicate the intensity of the signal.  The “signal intensity bar” 
below the well spots shows that blue indicates low signal and red indicates a high signal. 
 
The high signal obtained in the biotin functionality test showed that FL140 pAb was 
conjugated to biotin.  The low signal generated from the biotin functionality test 
suggested that although biotin was present on the FL140 pAb, its ability to bind 
α-synuclein was compromised. 
 
The in house recombinant α-synuclein was used for all assays.  In order to ensure 
that the in house α-synuclein protein was not dysfunctional and to verify that the 
C211 mAb recognised the protein, a western blot was performed.  As a comparator, 
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commercial company (Zapaloid).  The results from this test showed that the in house 
protein was viable and that the C211 mAb binds to α-synuclein.  The data obtained 
are shown in Figure 5.4. 
 



















Figure 5.4: Western blot of α-synuclein protein:  C211 mAb was used as the primary 
antibody for detecting the presence of α-synuclein recombinant protein from our in house 
preparation and the protein provided from Zapaloid.  Lanes 1 to 5 are shown.  Each lane 
represents an increasing amount of protein; 25, 50, 100, 150 and 200 ng, respectively. 
α-synuclein runs at approximately 16 kDa on a western blot gel – the bands shown in this 
figure are at 16 kDa, thus representing the protein of interest - α-synuclein.     
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These troubleshooting exercises suggested that biotinylation of FL140 rendered the 
antibody inactive in terms of its ability to bind to α-synuclein.  Alternative antibodies 
supplied by Santa Cruz Biotechnology Inc. were biotinylated and tried in combination 
with C211 mAb coupled beads, but these generated the same negative results as the 
pairing with FL140 pAb. 
 
Potential detection antibodies from alternative manufacturers/vendors were sought.  
At the same time, alternative capture antibody and recombinant protein were 
purchased in order to assess various antibody pairing combinations.  The additional 
reagents tested were: 
 
 Syn211 mouse anti-α-synuclein mAb (Life Technologies-Invitrogen) 
 Biotinylated goat anti-α-synuclein pAb (R&D Systems) 
 Human α-synuclein recombinant protein (rPeptide) 
 Human α-synuclein recombinant protein (Merck Millipore) 
 
0.5 µg of the Syn211 mouse anti-α-synuclein mAb was coupled to Luminex beads.  
These antibody coupled beads and the previously 0.5 µg C211 mAb coupled beads 
were assayed with 1 µg/mL human α-synuclein recombinant proteins from rPeptide, 
Merck Millipore and our in house preparation, using the biotinylated goat anti-α-
synuclein pAb as the detection component.  The antibody and protein combinations 







Figure 5.5: Testing different antibody combinations:  Luminex beads coupled with 0.5 µg 
of Syn211 mouse anti-α-synuclein mAb (Life Technologies-Invitrogen) and 0.5 µg of C211 
mouse anti-α-synuclein mAb (Santa Cruz Biotech. Inc.) were used to detect α-synuclein levels 
in human α-synuclein recombinant proteins from rPeptide, Merck Millipore and our in house 
preparation.  1 µg/mL of each recombinant protein was used in the assay with 2 µg/mL 
biotinylated goat anti-α-synuclein pAb (R&D Systems) and 4 µg/mL streptavidin-RPE as the 
detection system for the assay.  The figure shows the mean (n=2) MFI signals achieved with 
the various antibody and protein combinations. 
 
It was found that the biotinylated detection pAb from R&D systems generated signals 
with both 0.5 µg of the Syn211 mouse anti-α-synuclein mAb and the 0.5 µg C211 
mAb coupled beads. 
 
In order to distinguish whether a higher MFI signal could be achieved, the Syn211 
mouse anti-α-synuclein mAb and C211 mAb were coupled to beads with an 







This data revealed that 1 μg Syn 211 mAb generated MFI signals of approximately 
8500 when assayed with 1 µg/ml of in house α-synuclein protein and 2 µg/mL of 
biotinylated goat anti-α-synuclein pAb.  The 1 μg C211 mAb coupled beads failed to 
generate signals as high as the 1 μg Syn211 mAb coupled beads.   
 
Therefore, the antibody combination of Syn211 mouse anti-α-synuclein mAb coupled 
beads with biotinylated detection pAb from R&D systems was chosen and taken into 
the assay optimisation step.  The in house α-synuclein recombinant protein 
preparation was used in all subsequent assays. 
 
5.4 Total α-synuclein Luminex assay optimisation 
 
The optimisation step involved assessing assay performance upon modification of 
various steps within the whole assay set up.  The aim of the assessment was to find 
the assay conditions that achieved optimal performance in terms of sensitivity, and 
reproducibility.    Altering two assay conditions were considered; capture phase and 
detection phase – this section details the findings from this investigation. 
 
5.4.1  Capture phase optimisation 
 
The mass of antibody used to couple beads was evaluated by a titration assay where 
data obtained from coupling 0.5 µg of Syn 211 mAb to beads was compared to 1, 1.5 












Figure 5.6: Syn211 mAb mass titration for bead coupling:  Luminex beads coupled with 
0.5, 1, 1.5 and 2 µg were assayed with 0, 10, 500 and 1000 ng/mL of in house α-synuclein 
recombinant protein prepared in assay buffer and 2 µg/mL biotinylated detection pAb (R&D 
systems) with 4 µg/ml streptavidin-RPE.  The figure shows the MFI signals obtained with each 
bead set at the varying α-synuclein recombinant protein concentrations. 
 
The data obtained indicated that increasing the amount (µg) of antibody during the 
coupling reaction does not make a significant difference to MFI signals when 
detecting α-synuclein.   Due to this reason, beads coupled with 1 µg of Syn211 mAb 
were used for the remaining optimisation experiments.   
 
Beads coupled with 1 µg of Syn 211 mAb were subjected to an experiment that 
tested the effect of increasing the capture step incubation from 2 h to an overnight 




















Figure 5.7: Increasing capture incubation step:  Luminex beads coupled with 1 µg of Syn 
211 mAb were assayed with 0, 10, 250 and 500 ng/mL of in house α-synuclein recombinant 
protein prepared in assay buffer.  2 µg/mL biotinylated detection pAb (R&D systems) and 4 
µg/mL of streptavidin-RPE was used.  The capture step incubation was increased from 2 h to 
an overnight incubation at 4
0
C, shaking.  The figure displays the MFI signals from the 
overnight experiment and the data obtained when performing the assay with the capture step 
incubation at 2 h. 
 
 
The difference in signal between 2 h and overnight capture step incubation was very 
small, however, an overnight incubation was preferred over the 2 h incubation and 
subsequent optimisation tests were performed with an overnight capture step. 
 
5.4.2  Detection phase optimisation 
 
The detection phase optimisation involved evaluating the effect of varying the 
biotinylated detection pAb (R&D systems) concentration and incubation as well as 
the streptavidin-RPE concentration and incubation.  The prospect of using less 






The detection pAb titration step involved testing 2, 1 and 0.5 µg/mL concentrations of 
the biotinylated pAb.  The signal to noise ratio was calculated for the data obtained 
by dividing the MFI signal obtained at 500, 250 and 10 ng/mL of α-synuclein protein 
by the MFI signal obtained at 0 ng/mL of protein.  The results from this test are 
depicted in Figure 5.8.   
 
 
Figure 5.8: Detection antibody titration test: Luminex beads coupled with 1 µg Syn 211 
mAb was assayed with 500, 250, 10 and 0 ng/mL of in house α-synuclein recombinant protein 
and incubated overnight at 4
o
C whilst shaking.  Biotinylated detection pAb was added at 2, 1 
and 0.5 µg/mL respectively and incubated for 1 h before reading on the Luminex analyser.  
The figure shows the signal to noise ratio at each protein concentration when 2, 1 and 0.5 
µg/mL of biotinylated detection pAb was reacted with the captured protein complex. 
 
The largest signal to noise ratio was obtained with the addition of 1 µg/mL of 
biotinylated detection antibody.  The effect of increasing the detection incubation step 
from 1 h to 4 h had no effect on the MFI signal achieved (data not shown).   For 
subsequent optimisation steps, the biotinylated detection pAb concentration used 






The streptavidin-RPE reagent was tested at 6 and 2 µg/mL and the data compared to 
the 4 µg/mL concentration.  The streptavidin incubation was extended to 1 h as 
opposed to 30 mins.  The data obtained from the reagent titration are displayed in 
Figure 5.9.  The increased incubation had no effect (data not shown). 
 
 
Figure 5.9: Streptavidin-RPE titration:  Luminex beads coupled with 1 µg of Syn 211 mAb 
were assayed with 0, 10, 250 and 500 ng/mL of in house α-synuclein recombinant protein 
prepared in assay buffer.  1 µg/mL biotinylated detection pAb (R&D systems) with varying 
concentrations of streptavidin-RPE was assessed.  The figure displays the signal to noise 
ratio calculated for each streptavidin-RPE concentration.  The signal to noise ratio was 
calculated from dividing the MFI signal achieved at 500 and 250 ng/mL α-synuclein protein by 
the MFI signal achieved from the 0 ng/mL protein concentration, respectively. 
 
Using 4 µg/mL of streptavidin-RPE with 1 µg/mL of biotinylated detection pAb 
generated the optimal signal to noise ratio. 
 
Findings from the assay optimisation steps showed that using 1 µg Syn 211 antibody 





shaking generated the best conditions for capturing the protein.  Reaction with 
1 µg/mL of biotinylated detection pAb for 1 h followed by incubation with 4 µg/mL of 
streptavidin-RPE for 30 mins was sufficient for detecting the captured protein.  These 
conditions were thus utilised for subsequent total α-synuclein assays. 
 
 
5.5 Total DJ-1 
 
The assay published by Hong et al (2010) involved coating Luminex beads with 
rabbit anti-DJ-1 mAb from Novus Biologicals Ltd. and biotinylated goat anti-DJ-1 pAb 
from R&D Systems as the detection component.  The same antibody pair was tested 
in our laboratory.  Unfortunately the assay performance was not comparable to the 
published method.  These results and the steps taken to improve the assay are 
displayed and discussed in this section. 
 
5.6  Total DJ-1 Luminex assay development 
 
0.5, 1 and 1.5 µg of rabbit anti-DJ-1 mAb (Novus Biologicals Ltd.) was coupled to 
Luminex beads.  Each coupled bead set was assayed with 2 µg/mL of biotinylated 
goat anti-DJ-1 pAb (R&D Systems) to measure MFI signals achieved in the presence 
of 1000, 500, 250 and 0 ng/mL of DJ-1 recombinant protein (Covance Inc.).  The MFI 
signals obtained with each bead set for the different DJ-1 protein concentrations are 








Figure 5.10:  Total DJ-1 Luminex assay using anti-DJ-1 mAb (Novus Biologicals Ltd.):   
Luminex beads coupled with 0.5, 1 and 1.5 µg of ant-DJ-1 mAb (Novus Biologicals Ltd.) were 
assayed with 0, 10, 500, 1000 ng/mL of DJ-1 recombinant protein (Covance Inc.) prepared in 
assay buffer.   2 µg/mL biotinylated anti-DJ-1 detection pAb (R&D systems) with 4 µg/ml 
streptavidin-RPE was used.  Figure shows MFI signals obtained with each bead set at varying 
DJ-1 protein concentrations. 
 
These data showed that signals with 0.5 µg of anti-DJ-1 mAb (Novus Biologicals Ltd.) 
coupled to Luminex beads generated the best MFI.  Hong et al (2010) state that their 
assay yielded a signal to noise ratio of 66 – the assay dynamic range is not provided 
but from the calibration graphs it appears that 175 ng/mL was their top calibrator.  
This was not achieved with our assay - the background signal was relatively high and 
the highest signal was fairly low, yielding a signal to noise ratio of approximately 30 - 
40.  The first approach to improve assay performance was to decrease the mass (µg) 
of anti-DJ-1 mAb used to couple Luminex beads to 0.25 µg.  The logic behind 
reducing the bead coating was based on the initial data (Figure 5.10) showing that as 
more anti-DJ-1 mAb is added the MFI is reduced.  The data from this experiment are 







Figure 5.11: Lowering anti-DJ-1 mAb (Novus Biologicals Ltd.) bead coupling:   
Luminex beads coupled with 0.25 and 0.5 µg of ant-DJ-1 mAb (Novus Biologicals Ltd.) were 
assayed with 0 and 1000 ng/mL of DJ-1 recombinant protein (Covance Inc.) prepared in 
assay buffer.  2 µg/mL biotinylated anti-DJ-1 detection pAb (R&D systems) with 4 µg/ml 
streptavidin-RPE was used.  The figure shows the MFI signals obtained with each bead set at 
the varying DJ-1 recombinant protein concentrations. 
 
Figure 5.11 shows that the MFI at 1000 ng/mL increases when decreasing the mass 
(µg) of anti-DJ-1 mAb (Novus Biologicals Ltd.) coupled to beads.  However, the 
background increases too, reducing the signal:noise ratio even further in comparison 
to data achieved with 0.5 µg coated beads.  The signal:noise ratio comparison is 







Figure 5.12: Lowering anti-DJ-1 mAb (Novus Biologicals Ltd.) bead coupling:   
Luminex beads coupled with 0.25 and 0.5 µg were assayed with 0 and 1000 ng/mL of DJ-1 
recombinant protein (Covance Inc.) prepared in assay buffer.  2 µg/mL biotinylated anti-DJ-1 
detection pAb (R&D systems) with 4 µg/ml streptavidin-RPE was used.  The figure shows the 
signal:noise ratio obtained with each bead set at the varying DJ-1 recombinant protein 
concentrations.  Signal:noise ratio was calculated by dividing the mean MFI signal at 1000 
ng/mL DJ-1 protein concentration by the MFI at 0 ng/mL. 
 
The signal:noise ratio with 0.5 µg beads was better in comparison to the 0.25 µg 
beads.  Thus, for subsequent assays, the 0.5 µg beads were used. 
 
The next approach to improve assay performance was to investigate the effect of 
decreasing biotinylated anti-DJ-1 goat pAb (R&D Systems) from 2 µg/mL to 0.5 
µg/mL – it was hypothesised that decreasing the detection antibody may reduce the 
background signals whilst maintaining the high MFI signal at the top DJ-1 
concentration and thus increase the signal:noise ratio.  Figure 5.13 show the data 







Figure 5.13: Lowering biotinylated anti-DJ-1 pAb (R&D Systems) concentration:  
Luminex beads coupled with 0.25 and 0.5 µg were assayed with 250, 62.5, 15.6, 3.9, 0.98, 
0.24, 0.06 and 0 ng/mL of DJ-1 recombinant protein (Covance Inc.) prepared in assay buffer.  
0.5 µg/mL of biotinylated anti-DJ-1 detection pAb (R&D systems) with 4 µg/ml streptavidin-
RPE were used.  The figure shows the signal:noise ratio obtained with each bead set at the 
varying DJ-1 recombinant protein concentrations. Signal:noise ratio was calculated by 
dividing the mean MFI signal at each DJ-1 protein concentration by the MFI at 0 ng/mL.  
 
These data showed that the signal:noise ratio was identical for both bead sets.  As 
shown in Figure 5.13, the signal:noise ratio achieved was approximately 30 – 35; no 
match to the 66 fold published in Hong et al (2010) paper. 
 
Alternative antibody pairings were explored; commencing the investigation with 
changing the capture antibody bound to the Luminex beads.  The antibody chosen 
was mouse anti-DJ-1 mAb (Covance Inc.).  0.25, 0.5, 1 and 1.5 µg of the antibody 
was coated to Luminex beads.  A Luminex sandwich assay was performed with each 
bead set using the biotinylated anti-DJ-1 pAb (R&D Systems) as the detection 







Figure 5.14:  Total DJ-1 Luminex assay using anti-DJ-1 mAb (Covance Inc.):  Luminex 
beads coupled with 0.25, 0.5, 1 and 1.5 µg of anti-DJ-1 mAb (Covance Inc.) were assayed 
with 0, 10, 500, 1000 ng/mL of DJ-1 recombinant protein (Covance Inc.) prepared in assay 
buffer.   2 µg/mL biotinylated anti-DJ-1 detection pAb (R&D systems) with 4 µg/ml 
streptavidin-RPE was used.  This figure shows MFI signals obtained with each bead set at 
varying DJ-1 protein concentrations. 
 
The MFI with anti-DJ-1 mAb from Covance Inc. in comparison to the anti-DJ-1 mAb 
from Novus Biological Ltd. as the capture reagent was shown to be markedly higher.  
The greatest MFI was achieved with beads coated with 1.5 µg of the Covance Inc. 
anti-DJ-1 mAb.  In light of this result, the anti-DJ-1 mAb from Covance Inc. and 
biotinylated anti-DJ-1 goat pAb from R&D Systems was chosen to take further into 










5.7  Total DJ-1 Luminex assay optimisation 
 
The Luminex assay for quantifying DJ-1 involved ensuring that the optimum mass of 
anti-DJ-1 mAb (Covance Inc.) was coupled to beads.  This was based on previous 
data (Figure 4.5) showing that as the anti-DJ-1 mAb mass (µg) increased, the MFI 
signals increased too.  Furthermore, the assays during the development phase used 
2 µg/mL of the biotinylated anti-DJ-1 goat pAb (R&D Systems) – it was interesting to 
see if we could use less detection antibody in order to generate an assay that was 
cost effective without compromising its performance.  
 
5.7.1  Increasing anti-DJ-1 mAb (Covance Inc.) bead coupling 
 
Increasing the mass (µg) of anti-DJ-1 mAb (Covance Inc.) from 1.5 µg to 2 and 3 µg 
was assessed.  The data obtained are shown in Figure 5.15: 
 
 
Figure 5.15: Increasing anti-DJ-1 mAb (Covance Inc.) bead coupling:  Luminex beads 
coupled with 1.5, 2 and 3 µg of ant-DJ-1 mAb (Covance Inc.) were assayed with 250, 62.5, 
15.6, 3.9, 0.98, 0.24, 0.06 and 0 ng/mL of DJ-1 recombinant protein (Covance Inc.) prepared 
in assay buffer.  2 µg/mL biotinylated anti-DJ-1 detection pAb (R&D systems) with 4 µg/ml 
streptavidin-RPE was used.  The figure shows the MFI signals obtained with each bead set at 





Increasing the mass of anti-DJ-1 mAb to couple Luminex beads did not increase the 
MFI, rather it decreased the signal, suggesting that beads coupled with 1.5 µg of 
capture anti-DJ-1 mAb was optimal.  For the remaining optimisation tests, 2 µg beads 
were tested alongside 1.5 µg beads, to see if changes in the detection phase of the 
assay affected assay performance in the form of higher signal:noise ratio. 
 
5.7.2  Detection antibody titration 
 
Luminex sandwich assay was performed with beads coated with 1.5 and 2 µg of the 
anti-DJ-1 mAb with decreasing concentrations of the biotinylated anti-DJ-1 goat pAb 
(R&D Systems).   1 and 0.5 µg/mL of biotinylated anti-DJ-1 pAb was tested and the 
data are shown in Figure 5.16: 
 
 
Figure 5.16: Detection antibody titration effect on signal:noise ratio: Luminex beads 
coupled with 1.5 and 2 µg of ant-DJ-1 mAb (Covance Inc.) were assayed with 250, 62.5, 15.6, 
3.9, 0.98, 0.24, 0.06 and 0 ng/mL of DJ-1 recombinant protein (Covance Inc.) prepared in 
assay buffer.  1 and 0.5 µg/mL biotinylated anti-DJ-1 detection pAb (R&D systems) with 4 
µg/ml streptavidin-RPE was used.  This figure shows the signal:noise ratio with each bead set 
at the varying DJ-1 recombinant protein concentrations.  Signal:noise ratio was calculated by 





The MFI signals achieved at all bead and detection antibody combinations were 
>11,000 at 250 ng/ml.  There was a difference in the background signal and this 
produced the marked difference in the signal:noise ratio for each bead/detection 
antibody combination. 
 
The optimisation data suggested that 2 µg beads with 0.5 µg/mL biotinylated anti-DJ-
1 detection antibody yield the best signal:noise ratio.  The effect of reducing the 
concentration of Streptavidin-RPE was not investigated since the plan was to include 
this assay with the α-synuclein assay as a multiplex panel.  Since 4 µg/mL was found 
to yield the best data for α-synuclein – this will have to be used for the DJ-1 assay. 
 
 
5.8  Duplex assay development: total α-synuclein and total DJ-1 
 
Three experiments were performed in order to test for cross reactivity between the 
total α-synuclein and total DJ-1 assays.  Details of these tests and the results are 
shown in this section.  Optimisation and validation of the duplex assay is also 
described in this section. 
 
5.8.1  Cross reactivity tests 
 
Out of the three cross reactivity tests, the first experiment involved checking for cross 
reactivity between the two sets of antibody coupled beads.  The second experiment 
tested whether there would be cross reactivity if the beads and detection antibody 
components were multiplexed.  The final test involved multiplexing all three assay 
components; the beads, protein standards and detection antibodies.  Figure 5.17, 




















Multiplexed  beads Multiplexed beads 
Multiplexed detection Abs Multiplexed detection Abs 
Multiplexed  beads 
Experiment 1 Experiment 2 Experiment 3
Figure 5.17: Luminex cross reactivity test: experimental steps taken to determine the 
presence of cross reactivity when multiplexing total α-synuclein and total DJ-1 Luminex 
assays.  Experiment 1; assay with multiplexed beads only.  Experiment 2; assay with 
multiplexed beads and multiplexed detection antibodies.  Experiment 3; assay with 
multiplexed beads, multiplexed detection antibodies and multiplexed protein standards.  
 
The results from these three cross reactivity tests showed that the two assays do not 






Figure 5.18: Luminex cross reactivity test results: MFI signals (n=2) obtained from 
experimental steps taken to determine the presence of cross reactivity when multiplexing total 
α-synuclein and total DJ-1 Luminex assays.  A) assay with multiplexed beads and multiplexed 
protein with only tαsyn detection antibody.  B)  assay with multiplexed beads and multiplexed 
protein with only DJ-1 detection antibody.  C) assay with multiplexed beads, multiplexed 
protein and multiplexed detection antibodies. 
 
In order to test whether diluting plasma samples x50 against a calibration curve in 
1% (v/v) plasma diluent, i.e. as was done with the phosphorylated α-synuclein assay 
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that the aforementioned conditions would be suitable for this duplex assay.  Results 
from the spike recovery experiment and other validation parameters are shown 
below. 
 
5.9  Duplex validation: plasma assay for total α-synuclein and total DJ-1 
 
As before, we have used the Lee et al (2006b) and Lee, (2009) papers for validating 
our assays: 
 
This section details the validation experiments performed and the data obtained. 
 
All assays were performed with a calibration curve generated in 1% (v/v) plasma 
diluent spiked with recombinant α-synuclein and recombinant DJ-1 at the following 
concentrations: 128, 64, 32, 16, 8, 4, 2, 1, 0.5 and 0 ng/mL. 
 
5.9.1  Spike Recovery 
 
A total of six patient samples were spiked with recombinant α-synuclein and 
recombinant DJ-1 at high (2000 ng/mL) and low (75 ng/mL) levels.  Each spiked 
sample was analysed alongside the sample without spike.   All samples were diluted 
x 50 with 1% (v/v) plasma diluent prior to analysis and analysed in triplicate.  The 
















      
0.00 na 1520 6.6 2000 76.0 
      
0.0 na 1739 4.5 2000 86.9 
      
4.2 36.7 1877 11.4 2004 93.7 
      
13.7 na 2271 1.3 2014 112.8 
      
0.00 na 2018 7.1 2000 100.9 
      
0.00 0.0 2047 1.9 2000 102.3 










      
0.00 na 68 12.2 75 90.4 
      
0.0 na 83 2.8 75 110.7 
      
4.2 36.7 75 6.6 79 94.5 
      
13.7 na 71 4.3 89 80.5 
      
0.00 na 87 8.8 75 115.3 
      
0.00 0.0 69 5.6 75 91.8 
 
Table 5.1: Total α-synuclein Plasma Spike Recovery: % recovery and precision (%CV) for 
six plasma samples spiked with 2000 and 75 ng/mL recombinant α-synuclein.  Mean n=3.  
 
The % recovery of total α-synuclein for the spiked samples ranged between 76.0% 
and 112.8% at the high level spikes with a precision between 1.3% and 11.4%.  The 











+ 2000 ng/mL 
spike (mean) 
CV% 




0.00 na 2117 3.9 2000 105.8 
Plasma 2 
0.50 na 1672 12.2 2001 83.6 
Plasma 3 
0.00 na 1982 5.8 2000 99.1 
Plasma 4 
18.00 13.6 1481 5.7 2018 73.4 
Plasma 5 
0.00 na 2089 7.1 2000 104.5 
Plasma 6 
0.00 na 2127 3.8 2000 106.3 





+75 ng/mL  spike 
(mean) 
CV% 




0.00 na 86 16.7 75 114.0 
Plasma 2 
0.00 na 90 14.2 75 120.0 
Plasma 3 
0.00 na 85 7.6 75 113.1 
Plasma 4 
17.50 20.2 89 3.4 93 96.0 
Plasma 5 
0.00 na 81 8.0 75 107.6 
Plasma 6 
0.00 na 78 2.7 75 103.6 
 
Table 5.2: Total DJ-1 Plasma Spike Recovery: % recovery and precision (%CV) for six 
plasma samples spiked with 2000 and 75 ng/mL recombinant DJ-1.  
 
The % recovery of total DJ-1 for the spiked samples ranged between 73.4% and 
106.3% at the high level spikes with a precision between 3.8% and 12.2%.  The low 








5.9.2  Parallelism 
 
Upon screening patient samples, levels of total α-synuclein and total DJ-1 levels 
were very low and not high enough to perform parallelism assessments.  One 
suitable sample was found.  The assessment involved analysing the sample at a 

















Plasma from Individual 1 
5 0.200 >128 na na >128 480 na 
10 0.100 117.17 2.93 2.50 1172  144.03 
20 0.050 44.37 2.15 4.85 887  84.8 
40 0.025 13.9 1.48 10.62 556  15.77 
80 0.013 6.08 0.20 3.25 486  1.25 
160 0.006 2.49 0.09 3.61 398  -17.02 
blank 0 0 0.00 na 0  na 
 
Table 5.3: Total α-synuclein Plasma Parallelism: Precision (%CV) and % Difference for 
one plasma sample Analysed at various dilutions with 1% (v/v) plasma assay diluent.  % 
difference calculated from the overall mean result of all dilutions from 1/40 onwards. Each 
sample analysed in triplicate. 
 
 
Figure 5.19: Total α-synuclein Plasma Parallelism: a plasma sample analysed at various 





















































Plasma from Individual 1 
5 0.200 10.9 0.24 2.20 55 112 -51.50 
10 0.100 8.56 0.08 0.94 86  -23.87 
20 0.050 5.15 0.43 8.41 103  -8.4 
40 0.025 2.5 0.11 4.27 101  -10.15 
80 0.013 1.67 0.06 3.46 133  18.54 
160 0.006 0.70 0.11 15.34 113  0.04 
blank 0.000 0 0.00 na 0  na 
 
Table 5.4: Total DJ-1 Plasma Parallelism: Precision (%CV) and % Difference for one 
plasma sample Analysed at various dilutions with 1% (v/v) plasma assay diluent.  % 
difference calculated from the overall mean result of all dilutions from 1/40 onwards. Each 
sample analysed in triplicate. 
 
 
Figure 5.20: Total DJ-1 Plasma Parallelism: a plasma sample analysed at various dilutions; 
1/5, 1/10, 1/20, 1/40 and 1/80, 1/60    
 
Parallelism for the sample was shown post x40 dilution of the plasma sample.  This 
result and the spike recovery assessment indicated that a dilution of x50 for the 
plasma samples was sufficient to yield relatively accurate data when using this assay 



































5.9.3  Dilutional Linearity 
 
A pooled plasma sample was spiked with 1500 ng/mL of recombinant α-synuclein 
and DJ-1 proteins.  This spiked sample was diluted 1/20, 1/40, 1/80, 1/160 and 1/320 
-   each diluted sample was analysed on the Luminex in triplicate. 
 









1/20 0.05 >ULOQ >ULOQ >ULOQ >ULOQ na na 
1/40 0.025 1073 1129 1171 1124 1500 -23.3 
1/80 0.0125 1230 1277 1252 1253 1500 -16.5 
1/160 0.00625 1315 1296 1309 1307 1500 -12.9 
1/320 0.003125 1347 1386 1347 1360 1500 -9.3 
 
Table 5.5: Total α-synuclein Plasma Dilutional Linearity: % Difference for a pooled plasma 
sample diluted at 1/20, 1/40, 1/80, 1/160 and 1/320, with 1% (v/v) plasma assay buffer.    
 









1/20 0.05 >ULOQ >ULOQ >ULOQ >ULOQ na na 
1/40 0.025 1626 1591 1691 1636 1500 9.1 
1/80 0.0125 1626 1536 1598 1587 1500 5.8 
1/160 0.00625 1581 1502 1469 1517 1500 1.2 
1/320 0.003125 1600 1600 1677 1626 1500 8.4 
 
Table 5.6: Total DJ-1 Plasma Dilutional Linearity: % Difference for a pooled plasma 
sample diluted at 1/20, 1/40, 1/80, 1/160 and 1/320, with 1% (v/v) plasma assay buffer.    
 
To further show the linearity of the dilutions, a regression plot for each analyte was 







Figure 5.21: Total α-synuclein Plasma Dilutional Linearity: pooled plasma sample 
underwent a series of dilutions.  Each diluted sample was assayed in the duplex Luminex 
assay.  Mean concentration yielded for each diluted sample was plotted in Microsoft Excel. 
 
 
Figure 5.22: Total DJ-1 Plasma Dilutional Linearity: pooled plasma sample underwent a 
series of dilutions.  Each diluted sample was assayed in the duplex Luminex assay.  Mean 
concentration yielded for each diluted sample was plotted in Microsoft Excel. 
y = 1114.4x + 1.1478 





























y = 1649.7x - 0.5086 




































The R2 value was 0.9984 and 0.9995 for total α-synuclein and total DJ-1, 
respectively, showing that the samples diluted in a linear fashion. 
 
This experiment was also used to assess hook effect for the assay.  The MFI signal 
for 1500 ng/mL of recombinant total α-synuclein and total DJ-1 did not reduce.  A 
reduction in the signal would have indicated a hook effect. 
 
5.9.4  Accuracy and Precision 
 
A total of six assays were performed on different dates to assess the accuracy and 
precision of the assay.  Five samples; ULOQ, HVS, MVS, LVS and LLOQ, were 
generated and used for this assessment.   
 
All samples were generated by spiking recombinant α-synuclein and recombinant DJ-
1 into neat blank plasma to yield a MFI assay reading in the region of 60, 40, 10, 1.5, 
0.5 ng/mL for both proteins, after the x50 assay dilution. 
 
Each sample was assayed in three wells on each assay plate.  Both Inter-assay and 
Intra-assay precision and accuracy has been determined.    
 
Tables 5.7 and 5.9 display the inter-assay data for total α-synuclein and total DJ-1.  








Assay Date ULOQ HQ MQ LQ LLOQ 
07-Dec-14 
52.2 39.2 9.9 1.4 0.43 
54.4 39.0 9.4 1.9 0.52 
61.7 39.2 9.0 1.57 0.41 
30-Jan-15 
62.3 43.5 10.0 1.56 0.52 
64.2 43.4 9.2 1.34 0.49 
73.5 33.4 9.8 1.46 0.57 
02-Feb-15 
62.1 41.0 10.3 1.59 0.51 
55.0 40.4 9.3 1.66 0.49 
54.3 41.8 10.4 1.68 0.54 
04-Feb-15 
59.6 36.4 9.6 1.38 0.52 
67.5 38.5 10.0 1.54 0.64 
59.4 40.2 9.9 1.56 0.57 
07-Feb-15 
59.1 38.5 10.2 1.51 0.60 
60.7 40.5 11.7 1.62 0.80 
62.0 36.6 10.3 1.25 0.78 
10-Feb-15 
60.8 42.5 10.3 1.78 0.56 
62.3 33.5 10.8 1.57 0.53 
62.5 40.6 10.6 1.57 0.61 
Inter-assay data 
Mean 60.7 39.4 10.0 1.55 0.56 
SD 5.007 2.923 0.636 0.155 0.101 
CV% 8.2 7.4 6.3 10.0 18.1 
% Difference/Bias 1.2 -1.6 0.4 3.5 12.1 
 
Table 5.7: Total α-synuclein Plasma Inter-assay Accuracy and Precision: ULOQ, HVS, 
MVS, LVS and LLOQ samples were analysed on the Luminex for the quantification of total α-
synuclein.  The precision was calculated using %CV (SD/mean %) and the bias was 













Assay Date Intra-assay data ULOQ HQ MQ LQ LLOQ 
07-Dec-14 
Mean 56.1 39.2 9.4 1.62 0.45 
SD 4.97 0.16 0.42 0.25 0.06 
CV% 8.9 0.4 4.4 15.7 12.9 
%Difference/Bias -6.5 -2.1 -5.5 8.2 -9.3 
30-Jan-15 
Mean 66.7 40.1 9.7 1.45 0.53 
SD 6.02 5.83 0.44 0.11 0.04 
CV% 9.03 14.53 4.58 7.58 7.7 
%Difference/Bias 11.1 0.3 -3.4 -3.1 5.3 
02-Feb-15 
Mean 57.1 41.1 10.0 1.64 0.51 
SD 4.31 0.73 0.63 0.05 0.03 
CV% 7.5 1.8 6.3 2.9 4.9 
%Difference/Bias -4.8 2.7 0.1 9.6 2.7 
04-Feb-15 
Mean 62.1 38.4 9.8 1.49 0.58 
SD 4.61 1.90 0.23 0.10 0.06 
CV% 7.4 5.0 2.4 6.6 10.5 
%Difference/Bias 3.6 -4.1 -1.7 -0.4 15.3 
07-Feb-15 
Mean 60.6 38.5 10.7 1.5 0.7 
SD 1.46 1.98 0.82 0.19 0.11 
CV% 2.4 5.1 7.6 13.0 15.2 
%Difference/Bias 1.0 -3.7 7.1 -2.7 45.3 
10-Feb-15 
Mean 61.9 38.9 10.6 1.6 0.6 
SD 0.90 4.74 0.22 0.12 0.04 
CV% 1.5 12.2 2.1 7.4 7.1 
%Difference/Bias 3.1 -2.8 5.6 9.3 13.3 
       
Intra-assay data Intra-CV% 6.1 6.5 4.6 8.9 9.7 
 
Table 5.8: Total α-synuclein Plasma Intra-assay Accuracy and Precision: ULOQ, HVS, 
MVS, LVS and LLOQ samples were analysed on the Luminex for the quantification of total α-
synuclein.  The precision was calculated using CV% (SD/mean %) and the bias was 
calculated using %difference ((observed-expected)/expected * 100). Intra assay precision 
was calculated from the average CV% from each individual assay. Intra assay bias was 














Assay Date ULOQ HQ MQ LQ LLOQ 
07-Dec-14 
51.9 41.4 10.5 1.59 0.55 
54.5 44.0 10.9 1.45 0.47 
55.3 39.4 10.8 1.3 0.44 
30-Jan-15 
60.9 41.1 9.6 1.31 0.57 
68.3 43.8 9.2 1.49 0.53 
59.7 41.8 9.5 1.47 0.65 
02-Feb-15 
65.1 46.1 8.6 1.55 0.47 
58.4 38.5 9.5 1.79 0.47 
59.5 43.9 10.7 1.46 0.53 
04-Feb-15 
58.3 37.1 9.4 1.63 0.51 
64.8 42.3 9.4 1.45 0.54 
60.1 39.4 9.8 1.63 0.57 
07-Feb-15 
59.6 38.5 10.5 1.69 0.69 
67.5 45.8 10.8 1.71 0.93 
63.7 41.5 9.7 1.48 0.83 
10-Feb-15 
64.9 44.3 10.6 1.13 0.66 
62.1 41.8 11.5 1.29 0.43 
68.8 42.4 10.3 1.53 0.50 
Inter-assay data 
Mean 61.3 41.8 10.1 1.50 0.57 
SD 4.766 2.560 0.743 0.167 0.134 
CV% 7.8 6.1 7.4 11.2 23.3 
% Difference/Bias 2.2 4.6 0.6 -0.2 14.9 
 
Table 5.9: Total DJ-1 Plasma Inter-assay Accuracy and Precision: ULOQ, HVS, MVS, 
LVS and LLOQ samples were analysed on the Luminex for the quantification of total DJ-1.  
The precision was calculated using %CV (SD/mean %) and the bias was calculated using 















Assay Date Intra-assay data ULOQ HQ MQ LQ LLOQ 
07-Dec-14 
Mean 53.9 41.6 10.7 1.45 0.49 
SD 1.77 2.35 0.20 0.15 0.06 
CV% 3.3 5.7 1.8 10.0 11.7 
%Difference/Bias -10.2 4.0 7.3 -3.6 -2.7 
30-Jan-15 
Mean 62.9 42.2 9.4 1.42 0.58 
SD 4.64 1.38 0.18 0.10 0.06 
CV% 7.4 3.3 1.9 6.9 10.5 
%Difference/Bias 4.9 5.6 -5.7 -5.1 16.7 
02-Feb-15 
Mean 61.0 42.8 9.6 1.60 0.49 
SD 3.59 3.91 1.03 0.17 0.03 
CV% 5.9 9.1 10.7 10.7 7.1 
%Difference/Bias 1.7 7.1 -4.0 6.7 -2.0 
04-Feb-15 
Mean 61.1 39.6 9.5 1.57 0.54 
SD 3.36 2.64 0.21 0.10 0.03 
CV% 5.5 6.7 2.2 6.6 5.6 
%Difference/Bias 1.8 -1.0 -4.7 4.7 8.0 
07-Feb-15 
Mean 63.6 41.9 10.3 1.6 0.8 
SD 3.93 3.66 0.55 0.13 0.12 
CV% 6.2 8.7 5.3 7.8 14.8 
%Difference/Bias 5.9 4.8 3.1 8.4 63.3 
10-Feb-15 
Mean 65.2 42.9 10.8 1.3 0.5 
SD 3.36 1.30 0.61 0.20 0.12 
CV% 5.1 3.0 5.6 15.3 22.2 
%Difference/Bias 8.7 7.1 7.7 -12.2 6.0 
       
Intra-assay data Intra-CV% 5.6 6.1 4.6 9.6 12.0 
 
Table 5.10: Total DJ-1 Plasma Intra-assay Accuracy and Precision: ULOQ, HVS, MVS, 
LVS and LLOQ samples were analysed on the Luminex for the quantification of total DJ-1.  
The precision was calculated using CV% (SD/mean %) and the bias was calculated using 
%difference ((observed-expected)/expected * 100). Intra assay precision was calculated from 
the average CV% from each individual assay. Intra assay bias was calculated from the 







The average inter assay precision for total α-synuclein was shown to be ≤ 18.1% with 
the bias ≤ 12.1%.  The inter assay precision for total DJ-1 was ≤ 23.3% and the bias 
≤ 14.9.   
 
The assay intra assay precision for total α-synuclein averaged at ≤ 9.7%, and the 
bias of the spiked known concentrations ranged from -9.3% to 15.3% (one assay 
yielded a bias of 45.3% at LLOQ, this could be due to sample preparation error).   
The intra assay precision for total DJ-1 was ≤ 12.0% and the bias ranged between -
12.2% and 16.7% (bias of 63.3 was obtained during one assay at the LLOQ, again 
this could be assigned to error in sample preparation). 
 
 
5.9.5  Limit of Detection 
 
As before, the method used to ascertain this limit entailed analysing a blank sample 
20 times, determining the mean value, and then using the mean + 3*SD as the LOD 
(Armbruster et al, 2008). 
 
The mean MFI reading from 20 replicates of the blank sample (1% (v/v) plasma) for 
the total α-synuclein assay was measured at 6.3 with a standard deviation of 0.6.  
Therefore, the mean MFI + 3*SD was calculated to be 8.08.  
 
The mean MFI reading from 20 replicates of the blank sample for the total DJ-1 was 
measured at 5.8 with a standard deviation of 0.7.  Therefore, the mean MFI + 3*SD 
was calculated to be 7.91. 
 
According to the “Elisa analysis” program (available at http://elisaanalysis.com/app), 





for the proposed minimum dilution of x 50 for the assay the LOD was calculated to be 
2.5 ng/mL (0.05 * 50). 
An MFI signal of 7.91 correlates to a concentration of 0.11 ng/mL of total DJ-1. This 
equals to 5.4 ng/mL LOD for the total DJ-1 assay after the x 50 MRD correction.   
 
5.10  Duplex validation: CSF assay for total α-synuclein and total DJ-1 
 
The duplex assay for use with CSF samples was validated using the same biomarker 
validation guidelines as used for the plasma assay (Lee et al, 2006b and Lee 2009).  
This section details the validation experiments performed and the data obtained. 
 
The assays developed so far into project involved using matrix-based diluents for the 
calibration curve preparation and sample dilution.  Unfortunately this was not 
possible for this duplex assay for use with CSF, due to the lack of sufficient volumes 
of blank CSF matrix.  As a result the accuracy of this assay was expected to be poor.   
 
All assays were performed with a calibration curve generated in PBS/SM01 assay 
buffer spiked with recombinant α-synuclein and recombinant DJ-1 at the following 
concentrations: 128, 64, 32, 16, 8, 4, 2, 1, 0.5 and 0 ng/mL.   All samples were 
diluted x5 with PBS/SM01 – this dilution was chosen based on acceptable spike 
recovery results (see section 5.10.1). 
 
5.10.1  Spike Recovery 
 
Six patient samples were analysed with 40 and 10 ng/mL of recombinant protein 
















CSF sample 1 
0.00 na 39.4 4.9 40 98.5 
CSF sample 2 
0.00 na 32.3 5.3 40 80.7 
CSF sample 3 
0.37 38.3 28.4 6.5 40 70.4 
CSF sample 4 
0.55 0.0 42.9 2.1 41 105.7 
CSF sample 5 
8.61 21.1 44.9 11.6 49 92.3 
CSF sample 6 










CSF sample 1 
0.00 na 10.8 11.8 10 108.5 
CSF sample 2 
0.00 na 7.7 2.7 10 77.4 
CSF sample 3 
0.37 38.3 7.4 14.7 10 71.4 
CSF sample 4 
0.55 18.9 9.9 0.4 11 94.2 
CSF sample 5 
8.61 21.1 19.5 0.4 19 104.6 
CSF sample 6 
6.45 0.0 17.3 6.4 16 105.5 
 
Table 5.11: Total α-synuclein CSF Spike Recovery: % recovery and precision (%CV) for 
six CSF samples spiked with 40 and 10 ng/mL recombinant α-synuclein.  Mean calculated 
from n=3.  
 
The % recovery of total α-synuclein for the spiked samples ranged between 70.4% 
and 105.7% at the high level spikes with a precision between 2.1% and 11.6%.   
The low spike recoveries ranged between 71.4% and 108.5% with a precision of 















CSF sample 1 
0.00 0.00 38.0 12.7 40 95.0 
CSF sample 2 
0.00 0.00 40.2 1.3 40 100.5 
CSF sample 3 
0.52 5.1 37.0 2.8 41 91.2 
CSF sample 4 
1.15 0.0 42.0 16.2 41 102.1 
CSF sample 5 
0.00 0.0 28.9 4.6 40 72.3 
CSF sample 6 










CSF sample 1 
0.00 0.00 7.7 3.1 10 77.3 
CSF sample 2 
0.00 0.00 10.0 5.4 10 100.0 
CSF sample 3 
0.52 5.1 9.4 10.3 11 89.3 
CSF sample 4 
1.15 10.4 10.6 10.2 11 94.6 
CSF sample 5 
0.00 0.0 7.4 3.0 10 73.7 
CSF sample 6 
0.00 0.0 11.2 21.5 15 74.6 
 
Table 5.12: Total DJ-1 CSF Spike Recovery: % recovery and precision (%CV) for six CSF 
samples spiked with 40 and 10 ng/mL recombinant DJ-1. Mean calculated from n=3.  
 
The % recovery of total DJ-1 for the spiked samples ranged between 72.3% and 
102.1% at the high level spikes with a precision between 2.8% and 16.2%.   







5.10.2  Dilutional Linearity 
 
Three individual CSF samples were spiked with up to 5000 ng/mL of recombinant α-
synuclein and DJ-1 recombinant proteins.  The spiked samples were diluted 1/10, 
1/20, 1/40, 1/80, 1/160 and 1/320 -   each diluted sample was analysed on the 
Luminex in triplicate.   Tables 5.13, 5.14 and Figures 5.23 and 5.24 represent data 
obtained for one of assessed samples. 
 









1/40 0.025 > ULOQ > ULOQ > ULOQ > ULOQ na Na 
1/80 0.0125 > ULOQ > ULOQ > ULOQ > ULOQ na Na 
1/160 0.00625 na 5314 6075 5694 5000 13.9 
1/320 0.003125 4086 4925 5171 4727 5000 -5.5 
1/640 0.001562 5818 5600 6131 5850 5000 17.0 
1/1280 0.000781 5261 4377.6 5504 5047 5000 0.9 
 
Table 5.13: Total α-synuclein CSF Dilutional Linearity: % difference for a CSF sample 
diluted at 1/20, 1/40, 1/80, 1/400, 1/160 and 1/320 with assay buffer. 
 
The % difference between the expected result and observed result was ≤17.0% - 






Figure 5.23: Total α-synuclein CSF Dilutional Linearity: A CSF sample underwent a series 
of dilutions.  Each diluted sample was analysed on the Luminex and results plotted using 
Microsoft Excel. 
 
The R2 value from the regression plot was 0.98 for this particular sample, further 
showing dilutional linearity.  
 









1/40 0.025 > ULOQ > ULOQ > ULOQ > ULOQ na Na 
1/80 0.0125 >ULOQ >ULOQ >ULOQ > ULOQ na Na 
1/160 0.00625 5059 4981 4501 4847 5000 -3.1 
1/320 0.003125 5043 5290 5158 5164 5000 3.3 
1/640 0.0015625 5888 5408 4832 5376 5000 7.5 
1/1280 0.00078125 4518 4915 5005 4813 5000 -3.7 
 
Table 5.14: Total DJ-1 CSF Dilutional Linearity: % difference for a CSF sample diluted at 
1/20, 1/40, 1/80, 1/400, 1/160 and 1/320 with assay buffer. 
 
y = 6452.4x - 2.0528 




































The % difference between the expected result and observed result was ≤ 7.5% - thus 
samples can be diluted up to 1280 times without compromising the final result.   
 
 
Figure 5.24: Total DJ-1 CSF Dilutional Linearity: A CSF sample underwent a series of 
dilutions.  Each diluted sample was analysed on the Luminex and results plotted using 
Microsoft Excel. 
 
The R2 value from the total DJ-1 regression plot was 0.995, further showing dilutional 
linearity.  
 
The additional two samples utilised for this assessment also yielded similar results 
for both proteins.  The % difference was ≤ 20% and R2 values were ≥ 0.995. 
y = 5296.5x + 0.4612 



































5.10.3  Accuracy and Precision 
 
As with previous assays, a total of six assays were performed on different dates to 
assess the accuracy and precision of the assay.  Five samples; ULOQ, HVS, MVS, 
LVS and LLOQ, were generated and used for this assessment.   
 
All samples were generated by spiking recombinant α-synuclein and recombinant DJ-
1 into neat blank CSF to yield a MFI assay reading in the region of 40, 20, 10, 5 and 
2 ng/mL for both proteins, after the x5 assay dilution (the actual spiked concentration 
was therefore, 200, 100, 50, 25 and 10 ng/mL) 
 
Each sample was assayed in three wells on each assay plate.  Both Inter-assay and 
Intra-assay precision and accuracy has been determined.   Subsequent tables 
display the data obtained for each protein: 
 
Tables 5.15 and 5.16 display the inter-assay data for total α-synuclein and total DJ-1 
respectively.  















Assay Date ULOQ HQ MQ LQ LLOQ 
07-Aug-15 
42.3 18.7 7.4 4.38 2.30 
36.7 14.2 10.7 4.8 1.12 
45.9 21.9 7.1 4.8 1.71 
12-Aug-15 
35.5 18.4 8.5 4.99 2.35 
35.6 20.5 9.3 4.69 1.58 
34.6 17.1 8.3 4.51 1.90 
14-Aug-15 
36.9 19.1 10.1 4.96 1.96 
36.6 19.5 11.2 4.4 1.83 
43.4 20.1 9.4 5.89 1.45 
21-Aug-15 
42.7 22.6 11.3 6.05 2.54 
45.3 18.8 9.1 5.02 2.11 
38.8 20.2 10.1 5.19 1.86 
28-Aug-15 
48.4 22.0 8.6 5.84 1.50 
43.1 17.1 12.3 5.78 2.17 
40.9 19.7 10.4 4.92 2.35 
Inter-assay data 
Mean 40.5 19.3 9.6 5.08 1.92 
SD 4.373 2.168 1.481 0.555 0.397 
CV% 10.8 11.2 15.5 10.9 20.7 
% Difference/Bias 1.1 -3.4 -4.3 1.6 -4.2 
 
Table 5.15: Total α-synuclein: CSF Inter-assay Accuracy and Precision: ULOQ, HVS, 
MVS, LVS and LLOQ samples were analysed on the Luminex for the quantification of total α-
synuclein in CSF.  The precision was calculated using %CV (SD/mean %) and the bias was 












Assay Date ULOQ HQ MQ LQ LLOQ 
07-Aug-15 
na 20.4 11.2 6.23 2.23 
44.2 17.9 12.2 5.54 1.76 
47.0 21.4 9.3 5.5 2.24 
12-Aug-15 
38.7 14.8 8.8 4.05 2.17 
36.4 18.0 8.6 4.63 1.84 
39.9 16.2 7.8 5.39 2.47 
14-Aug-15 
31.2 22.3 9.1 5.18 2.00 
na 19.1 13.5 4.57 2.13 
39.1 21.0 10.2 6.09 1.90 
21-Aug-15 
39.7 19.8 11.4 7.69 2.50 
37.5 19.9 11.0 7.7 2.85 
33.5 22.6 10.9 6.97 2.98 
28-Aug-15 
45.9 26.9 11.7 4.13 1.96 
45.8 20.5 11.4 5.55 2.78 
40.3 20.6 11.4 6.09 2.50 
Inter-assay data 
Mean 39.9 20.1 10.6 5.69 2.29 
SD 4.813 2.860 1.555 1.141 0.380 
CV% 12.1 14.2 14.7 20.1 16.6 
% Difference/Bias -0.2 0.5 5.6 13.7 14.4 
 
Table 5.16: Total DJ-1: CSF Inter-assay Accuracy and Precision: ULOQ, HVS, MVS, LVS 
and LLOQ samples were analysed on the Luminex for the quantification of total α-synuclein in 
CSF.  The precision was calculated using %CV (SD/mean %) and the bias was calculated 
















Assay Date Intra-assay data ULOQ HQ MQ LQ LLOQ 
07-Aug-15 
 
Mean 41.6 18.2 8.4 4.66 1.71 
SD 4.62 3.90 2.01 0.24 0.59 
CV% 11.1 21.4 24.0 5.2 34.5 
%Difference/Bias 4.1 -8.8 -16.2 -6.8 -14.5 
 
12-Aug-15 
Mean 35.2 18.7 8.7 4.73 1.94 
SD 0.56 1.75 0.55 0.24 0.39 
CV% 1.6 9.4 6.3 5.1 19.9 
%Difference/Bias -12.0 -6.7 -13.2 -5.4 -2.8 
 
14-Aug-15 
Mean 39.0 19.6 10.2 5.08 1.75 
SD 3.83 0.47 0.91 0.75 0.27 
CV% 9.8 2.4 8.9 14.8 15.2 
%Difference/Bias -2.6 -2.2 2.4 1.7 -12.7 
21-Aug-15 
Mean 42.3 20.5 10.2 5.42 2.17 
SD 3.27 1.91 1.09 0.55 0.34 
CV% 7.7 9.3 10.7 10.2 15.9 
%Difference/Bias 5.7 2.5 1.7 8.4 8.5 
28-Aug-15 
Mean 44.2 19.6 10.4 5.51 2.01 
SD 3.86 2.47 1.85 0.51 0.45 
CV% 8.7 12.6 17.7 9.3 22.3 
%Difference/Bias 10.4 -2.0 4.1 10.3 0.3 
       
Intra-assay data Intra-CV% 7.8 11.0 13.5 8.9 21.6 
 
Table 5.17: Total α-synuclein CSF Intra-assay Accuracy and Precision: ULOQ, HVS, 
MVS, LVS and LLOQ samples were analysed on the Luminex for the quantification of total 
DJ-1.  The precision was calculated using %CV (SD/mean %) and the bias was calculated 










Mean 45.6 19.9 10.9 5.76 2.08 
SD 2.02 1.79 1.52 0.41 0.27 
CV% 4.4 9.0 13.9 7.1 13.2 
%Difference/Bias 14.0 -0.5 8.9 15.1 3.8 
 
12-Aug-15 
Mean 38.3 16.3 8.4 4.69 2.16 
SD 1.74 1.58 0.50 0.67 0.32 
CV% 4.5 9.7 5.9 14.3 14.6 
%Difference/Bias -4.2 -18.4 -16.2 -6.2 8.0 
 
14-Aug-15 
Mean 35.1 20.8 10.9 5.28 2.01 
SD 5.64 1.63 2.25 0.76 0.12 
CV% 16.0 7.8 20.6 14.5 5.7 
%Difference/Bias -12.2 4.0 9.5 5.6 0.5 
21-Aug-15 
Mean 36.9 20.7 11.1 7.45 2.78 
SD 3.17 1.59 0.25 0.42 0.25 
CV% 8.6 7.7 2.2 5.6 8.9 
%Difference/Bias -7.8 3.7 10.8 49.1 38.8 
28-Aug-15 
Mean 44.0 22.7 11.5 5.3 2.4 
SD 3.24 3.68 0.18 1.01 0.42 
CV% 7.4 16.2 1.6 19.3 17.3 
%Difference/Bias 10.0 13.4 14.9 5.1 20.7 
       
Intra-assay data Intra-CV% 8.2 10.1 8.9 12.2 11.9 
 
Table 5.18: Total DJ-1 CSF Intra-assay Accuracy and Precision: ULOQ, HVS, MVS, LVS 
and LLOQ samples were analysed on the Luminex for the quantification of total DJ-1.  The 
precision was calculated using %CV (SD/mean %) and the bias was calculated using 
%difference ((observed-expected)/expected * 100).  
 
The average inter assay precision for total α-synuclein and total DJ-1 was shown to 
be ≤ 20.7% and ≤ 20.1%, respectively.   The bias based on the spiked known 





The intra assay precision for total α-synuclein and total DJ-1 averaged at ≤ 21.6%  
and ≤ 12.2%.  The bias of the spiked known concentrations ranged from -16.2% to 
10.4% for total α-synuclein and -18.4% to 20.7% for total DJ-1 (one assay yielded 
49.1% and 38.8% bias at the LQ and LLOQ respectively). 
 
5.10.4  Limit of Detection   
 
The mean MFI reading from 20 replicates of the blank sample for this assay was 83.0 
with a standard deviation of 5.15 for total α-synuclein and was 42.0 with a standard 
deviation of 5.15 for total DJ-1.  The mean MFI + 3*SD for total α-synuclein and total 
DJ-1 was 98.6 and 64.5, respectively.  
 
The “Elisa analysis” program (available at http://elisaanalysis.com/app), showed that 
a MFI signal of 98.6 correlates to a concentration of 0.35 ng/mL of total α-synuclein 
and 64.5 corresponds to 0.2 ng/mL of total DJ-1 protein.  Correcting these values for 
the proposed minimum dilution of x 5 for the assay, the LOD was calculated to be 





5.11  Discussion 
 
This chapter describes the development and validation of a duplex Luminex assay for 
quantifying total α-synuclein and total DJ-1 levels in human plasma and CSF.  
 
An ELISA for measuring total α-synuclein in human plasma and CSF was already 
developed in house.  The purpose of this project was to transfer this assay on to the 
Luminex platform.  Unfortunately, the antibodies used in the ELISA; C211 (capture 
antibody) and FL140 (detection antibody), did not perform well on the Luminex 
system.  This chapter detailed the troubleshooting experiments performed in order to 
determine why these antibodies may not have worked on the Luminex.  The 
troubleshooting tests indicated the biotinylated FL140 pAb as the problematic 
component.  The biotinylation confirmation test showed that biotin was present on the 
antibody, but the functionality test revealed that the biotinylated FL140 pAb was not 
binding to the α-synuclein protein sufficiently.  The biotinylation procedure involved 
attaching biotin molecules to lysine amino acid residues present on the antibody.  
Therefore, a plausible explanation for the biotinylation rendering the FL140 pAb 
inactive, may lie with the possibility that the antigen binding site of FL140 pAb 
contained lysine residues; modification of these residues may have reconfigured the 
antigen binding site, leading to its inactivity.  However, it was not possible to obtain 
the actual amino acid sequence of the Fab region of FL140 pAb, therefore it cannot 
be concluded definitively that it contains lysine residues.  Another possible 
explanation for the inactivity of FL140 pAb may be due to the buffer composition in 
which the antibody solution is provided – 1.0 ml PBS with 0.1% sodium azide and 
0.1% gelatin.  The antibody underwent manual Protein A/G purification followed by 
an ultra-filtration and desalting step, in order to make it suitable for biotinylation.  





such as gelatine and sodium azide which may have hindered the binding between 
FL140 pAb and biotin. 
 
The total DJ-1 assay was based on the assay described by Hong et al (2010).  The 
antibodies used by Hong et al (2010), transferred well on to the Luminex but this did 
not perform as well as the published method, i.e. our assay signal:noise ratio was 
much lower.  Changing the capture antibody improved the performance of this assay 
and generated a signal:noise ratio that matched the published method.  The reason 
why the capture antibody used by Hong et al (2010) did not perform as well in our 
laboratory may be due to the different types of beads used by Hong et al (2010).  
Their method utilised Liquichip activated beads (LiquiChip-Applications-
Handbook.pdf), whereas we used Bio-Rad carboxylated beads that required 
activating manually with EDC and NHS.  The activated beads are no longer 
available, thus it was not possible to test this possibility. 
 
Singleplex assays for total α-synuclein and total DJ-1 were initially established before 
combining the two assays to form the duplex assay.  Initially, the aim of the project 
was to develop a multiplex assay comprised of measuring total α-synuclein, total 
DJ-1 and LRRK2.  The LRRK2 assay components cross reacted with the other two 
assays (results of this cross-reactivity are displayed in Chapter 7) and thus LRRK2 
was removed from the multiplex assay. 
 
The duplex assay was validated as previously described in Chapter 3 using the 
acceptance criteria outlined in Table 3.14. The validation data obtained for the 
quantification of total α-synuclein and total DJ-1 in human plasma meet all the criteria 






The duplex assay for measuring total α-synuclein and total DJ-1 in human CSF also 
meet the acceptance criteria outlined in the summary table, except for the spike 
recovery experiments.  This was expected as we were unable to use blank CSF as 
the assay buffer for preparing calibrators and diluting samples.  The spike recovery 
experiments not meeting the acceptance criteria did not pose an issue with being 
able to use the assay and the data obtained from it.  The principle aim for developing 
this assay was to investigate differences in particular protein levels between samples 
taken from various neurodegenerative disease groups and healthy controls.  The 
high bias values for the protein levels in the samples anlaysed would be consistent 
for all samples, thus the data obtained from the various disease groups can still be 
compared to each other.    
 
The Luminex technology in theory should offer a more sensitive assay for quantifying 
analytes of interest when compared to the traditional ELISA.  An ELISA for 
measuring total α-synuclein in human plasma had already been developed in house.  
This in house assay yielded a LOD of 85 ng/mL (sample dilution factor corrected, 1.7 
* 50).  Thus, the Luminex assay has been found to be far more sensitive, displaying a 
LOD of  2.5 ng/mL (sample dilution factor corrected, 0.05 * 50). 
 
An assay for total DJ-1 has not been developed in house.  Waragai et al (2007), have 
measured total DJ-1 in human plasma using a commercial CircuLexTM Human DJ-1 
ELISA Kit (Cat. No. CY-9050, CyLex Co. Ltd. Nagano, Japan).  The kit claims to 
have a sensitivity of 0.92 ng/mL but there is no indication of the dilution factor used 
during sample analysis.  Thus, it cannot be definitively concluded that our Luminex 







Chapter 6:    
Total α-synuclein and total DJ-1: 




6.1  Introduction 
 
Chapter 5 described the development and validation of a duplex Luminex assay for 
quantifying total α-synuclein and total DJ-1, in human plasma and CSF.   
 
Here, this duplex assay has been used to analyse the same plasma and CSF 
samples that were tested for phosphorylated α-synuclein levels (see Chapter 4 
section 4.1).  It was not possible to analyse every single sample due to low sample 
volume.  Analysis of these samples allowed us to assess whether the levels of total 
α-synuclein and total DJ-1 show significant differences between the different disease 
groups.  Furthermore, it was also possible to investigate correlation relationships 
between: 
 
 Plasma total α-synuclein vs plasma total DJ-1 
 Plasma total α-synuclein vs plasma phosphorylated α-synuclein 
 Plasma total DJ-1 vs plasma phosphorylated α-synuclein 
 CSF total α-synuclein vs CSF total DJ-1 
 CSF total α-synuclein vs CSF phosphorylated α-synuclein 
 CSF total DJ-1 vs CSF phosphorylated α-synuclein 
 Plasma total α-synuclein vs CSF total α-synuclein 
 Plasma total DJ-1 vs CSF total DJ-1 
 






6.2  Total α-synuclein levels in plasma samples 
 
The IBM SPSS Statistics 21 package was used to analyse the total α-synuclein 
levels in plasma samples from GMNC and UCL.  The data were not normally 
distributed as per the Kolgomorov-Smirnov test; therefore the non-parametric 
Kruskal-Wallis (K-W) test (with post-hoc Mann-Whitney test when K-W was 
significant) was used in order to determine whether total α-synuclein levels were 
significantly different between the different disease groups.  The data from GMNC 
and UCL samples were initially analysed independently and a summary of that data 
is displayed in Tables 6.1 and 6.2.  Data from GMNC and UCL were then combined 
and the same statistical analysis was performed.  A summary of the combined data is 
displayed in Table 6.3. 
 






AD 42 198 12 553 
DLB 45 161 23 476 
PD 40 31 19 38 
MSA 14 27 11 32 
PSP 18 24 10 45 
CBD 12 96 20 240 
Healthy Controls 53 96 25 196 
 
Table 6.1: Total α-synuclein levels in plasma samples from GMNC data summary:  
mean, median and SD calculated using Microsoft Excel 2010.  Each sample was analysed in 
triplicate. 
 
The K-W test revealed that the levels of total α-synuclein were not significantly 










Healthy Controls 19 100 26 163 
MSA 20 177 45 262 
PD+DLB 18 122 4 273 
PSP+CBS 35 72 30 137 
 
Table 6.2: Total α-synuclein levels in plasma samples from UCL data summary:  mean, 
median and SD calculated using Microsoft Excel 2010.  Each sample was analysed in 
triplicate. 
 
Total α-synuclein levels between MSA, PD+DLB, PSP+CBS and healthy controls 
were also not significantly different (p=0.136 by K-W test). 
 






AD 42 198 12 553 
DLB 45 161 23 476 
PD 57 60 17 159 
MSA 34 115 21 213 
PSP+CBS 64 64 14 146 
Healthy Controls 72 97 26 166 
 
Table 6.3: Total α-synuclein levels in plasma samples from GMNC and UCL combined, 
data summary:  mean, median and SD calculated using Microsoft Excel 2010.  Each sample 
was analysed in triplicate. 
 
The p-value by K-W test for the combined data was 0.273, leading to the conclusion 
that total α-synuclein levels between the various neurodegenerative disorders tested 






6.3  Total DJ-1 levels in plasma samples 
 
The samples analysed for total α-synuclein were also analysed for total DJ-1.  The 
data was not normally distributed as per the Kolgomorov-Smirnov test.   Kruskal-
Wallis and Mann-Whitney tests using the IBM SPSS Statistics 21 package were 
therefore performed.  Table 6.4 summarises the data obtained with the samples 
analysed from GMNC. 
 






AD 42 28 11 37 
DLB 45 22 5 43 
PD 40 32 6 132 
MSA 14 27 16 32 
PSP 18 20 10 24 
CBD 12 25 5 64 
Healthy Controls 53 28 12 47 
 
Table 6.4: Total DJ-1 levels in plasma samples from GMNC data summary:  mean, 
median and SD calculated using Microsoft Excel 2010.  Each sample was analysed in 
triplicate. 
 
By K-W test it was revealed that there is a significant difference in plasma total DJ-1 
levels between AD, DLB, PD, MSA, PSP, CBD and healthy controls (p=0.017).   
 
Prior to performing Mann-Whitney tests on this (GMNC) data set, the data from UCL 
samples were tested via K-W.  Both datasets were then combined and tested via K-












Healthy Controls 19 8 3 11 
MSA 20 22 6 35 
PD+DLB 18 19 0 52 
PSP+CBS 35 7 2 11 
 
Table 6.5: Total DJ-1 levels in plasma samples from UCL data summary:  mean, median 
and SD calculated using Microsoft Excel 2010.  Each sample was analysed in triplicate. 
 
The K-W test with the UCL samples also showed a significant difference in plasma 
total DJ-1 levels between MSA, PD, DLB, PSP+CBS and healthy controls (p=0.021).    
 






AD 42 28 12 37 
DLB 45 23 5 43 
PD 58 28 3 113 
MSA 34 24 10 33 
PSP+CBS 65 14 4 31 
Healthy Controls 72 23 10 42 
 
Table 6.6: Total DJ-1 levels in plasma samples from GMNC and UCL combined, data 
summary:  mean, median and SD calculated using Microsoft Excel 2010.  Each sample was 
analysed in triplicate. 
 
K-W test on the combined data (GMNC and UCL) showed that total DJ-1 levels in 
plasma between AD, DLB, PD, MSA, PSP+CBS and healthy controls was 





Mann Whitney tests were performed on the combined (GMNC and UCL) data set, in 
order to find the specific groups that showed significant differences in levels of total 
DJ-1 in plasma.  Table 6.7 summarises the p-value data obtained from this test. 
 
 HC AD DLB MSA PD PSP+CBS 
HC - 0.274 0.265 0.558 0.004 0.024 
AD 0.274 - 0.058 0.738 0.001 0.004 
DLB 0.265 0.058 - 0.116 0.165 0.405 
MSA 0.558 0.738 0.116 - 0.005 0.013 
PD 0.004 0.001 0.165 0.005 - 0.412 
PSP+CBS 0.024 0.004 0.405 0.013 0.412 - 
 
Table 6.7: Mann Whitney p-values for total DJ-1 levels in plasma samples from GMNC 
and UCL combined data:  p-values <0.05 are shaded in grey. 
 
Significant differences were found between PD vs HC, PD vs AD and PD vs MSA. 
Furthermore, significant differences were also found between PSP+CBS versus HC, 
AD and MSA.  Receiver Operating Characteristic (ROC) curves were performed in 
order to assess whether the significant differences in plasma total DJ-1 levels 
between these disease groups indicate a diagnostic potential for plasma total DJ-1 
levels. 
 
The area under the curve (AUC) of ROC curves is a measure of how accurate a 
diagnostic test is.  Figure 6.1 displays the ROC curves for assessing the diagnostic 
values for PD against HC, AD and MSA.  Figure 6.2 presents the ROC curves 
showing the potential of plasma total DJ-1 to discriminate between PSP+CBS versus 

























Figure 6.1: ROC curves for assessing the diagnostic potential of plasma total DJ-1: 










PD vs AD  0.69 
 
PD vs HC 0.65 
 






PSP+CBS vs HC   0.61 
 
PSP+CBS vs AD  0.67 
 
























Figure 6.2: ROC curves for assessing the diagnostic potential of plasma total DJ-1: 
curves for PSP+CBS vs HC, PSP+CBS vs AD and PSP+CBS vs MSA with AUC of 0.61, 0.67 





An AUC of ≤ 0.5 is classified as being a “worthless” test and an AUC of 1.0 is classed 
as a perfect test.  The AUC for discriminating between PD, AD, HC and MSA are 
between 0.65 - 0.69.  The AUC for diagnosing between PSP+CBS against HC, AD 
and MSA are between 0.61 – 0.67.  Thus, we can conclude that plasma total DJ-1 
carries a fair potential as being a discriminatory diagnostic marker, but with need for 
considerable improvement.  
 
6.4  Correlation between total α-synuclein, total DJ-1 and phosphorylated α-
synuclein in plasma samples 
 
 
Plasma samples from GMNC and UCL were also analysed for levels of 
phosphorylated -synuclein (results discussed in Chapter 3).  The data from Chapter 
3 and the data displayed in this Chapter were combined to investigate the 
relationship between plasma levels of phosphorylated -synuclein, total -synuclein 
and total DJ-1. 
 
Combined data were checked for normality using the Kolgomorov-Smirnov test and 
found to be non-normally distributed.  Therefore, the Spearman rank correlation test 
was adopted to test for any correlation between the three different protein levels. 
 
The Spearman rank correlation test was first performed for the whole dataset, i.e. for 
all disease groups combined.  Table 6.8 and Figure 6.3 display this data. 
 
The correlation data for all disease groups was significant between all three protein 
levels (p = <0.005).  The data were therefore separated based on the various 
disease groups and then tested for correlation via the Spearman rank correlation 
test. Tables 6.9 to 6.15 and Figures 6.4 to 6.10 present the correlation test data for 










na 0.562 0.490 
Sig (2 tailed) na 0.000 0.000 
N 310 310 310 
 
Plasma tDJ-1   
Correlation 
coefficient 
0.562 na 0.286 
Sig (2 tailed) 0.000 na 0.000 





0.490 0.286 na 
Sig (2 tailed) 0.000 0.000 na 
N 310 310 310 
 
Table 6.8: GMNC and UCL plasma sample correlation; all disease groups: spearman 
























Figure 6.3: GMNC and UCL plasma sample correlation; all disease groups:  scatter plot 










Na 0.594 0.535 
Sig (2 tailed) Na 0.000 0.000 
N 42 42 42 
 
Plasma tDJ-1   
Correlation 
coefficient 
0.594 na 0.299 
Sig (2 tailed) 0.000 na 0.055 





0.535 0.299 na 
Sig (2 tailed) 0.000 0.055 na 
N 42 42 42 
 
Table 6.9: GMNC and UCL plasma sample correlation; AD only: spearman rank statistical 
























Figure 6.4: GMNC and UCL plasma sample correlation; AD only:  scatter plot depicting 










na 0.550 0.355 
Sig (2 tailed) na 0.000 0.008 
N 55 55 55 
 
Plasma tDJ-1   
Correlation 
coefficient 
0.550 na 0.234 
Sig (2 tailed) 0.000 na 0.083 





0.355 0.234 na 
Sig (2 tailed) 0.008 0.083 na 
N 55 55 55 
 
Table 6.10: GMNC and UCL plasma sample correlation; PD only: spearman rank 
























Figure 6.5: GMNC and UCL plasma sample correlation; PD only:  scatter plot depicting 










na 0.725 0.332 
Sig (2 tailed) na 0.000 0.026 
N 45 45 45 
 
Plasma tDJ-1   
Correlation 
coefficient 
0.725 na 0.294 
Sig (2 tailed) 0.000 na 0.050 





0.332 0.294 na 
Sig (2 tailed) 0.026 0.050 na 
N 45 45 45 
 
Table 6.11: GMNC and UCL plasma sample correlation; DLB only: spearman rank 













Figure 6.6: GMNC and UCL plasma sample correlation; DLB only: scatter plot depicting 










na 0.510 0.468 
Sig (2 tailed) na 0.002 0.006 
N 33 33 33 
 
Plasma tDJ-1   
Correlation 
coefficient 
0.510 na 0.107 
Sig (2 tailed) 0.002 na 0.554 





0.468 0.107 na 
Sig (2 tailed) 0.006 0.554 na 
N 33 33 33 
 
Table 6.12: GMNC and UCL plasma sample correlation; MSA only: spearman rank 













Figure 6.7: GMNC and UCL plasma sample correlation; MSA only:  scatter plot depicting 










na 0.443 0.618 
Sig (2 tailed) na 0.002 0.000 
N 45 45 45 
 
Plasma tDJ-1   
Correlation 
coefficient 
0.443 na 0.418 
Sig (2 tailed) 0.002 na 0.004 





0.618 0.418 na 
Sig (2 tailed) 0.000 0.004 na 
N 45 45 45 
 
Table 6.13: GMNC and UCL plasma sample correlation; PSP only: spearman rank 














Figure 6.8: GMNC and UCL plasma sample correlation; PSP only:  scatter plot depicting 










na 0.413 0.614 
Sig (2 tailed) na 0.088 0.007 
N 18 18 18 
 
Plasma tDJ-1   
Correlation 
coefficient 
0.413 na 0.645 
Sig (2 tailed) 0.088 na 0.004 





0.614 0.645 na 
Sig (2 tailed) 0.007 0.004 na 
N 18 18 18 
 
Table 6.14: GMNC and UCL plasma sample correlation; CBS only: spearman rank 













Figure 6.9: GMNC and UCL plasma sample correlation; CBS only:  scatter plot depicting 










na 0.629 0.587 
Sig (2 tailed) na 0.000 0.000 
N 72 72 72 
 
Plasma tDJ-1   
Correlation 
coefficient 
0.629 na 0.275 
Sig (2 tailed) 0.000 na 0.019 





0.587 0.275 na 
Sig (2 tailed) 0.000 0.019 na 
N 72 72 72 
 
Table 6.15: GMNC and UCL plasma sample correlation; HC only: spearman rank 












Figure 6.10: GMNC and UCL plasma sample correlation; HC only:  scatter plot depicting 




A significant correlation (p=<0.05) was found between plasma total α-synuclein and 
plasma total DJ-1 levels in all disease groups except CBS.  All disease groups also 
showed a significant positive correlation between plasma levels of total α-synuclein 
and phosphorylated α-synuclein.  Correlation between total DJ-1 and phosphorylated 
α-synuclein was statistically insignificant for AD, PD, DLB and MSA but significant in 
PSP, CBS and HC groups. 
 
6.5  Total α-synuclein levels in CSF samples 
 
CSF samples obtained from UCL were analysed for levels of total α-synuclein using 
the Luminex duplex assay.  Total α-synuclein levels for all samples analysed were 
below the assays limit of detection and were thus non detectable. 
 
6.6  Total DJ-1 levels in CSF samples 
 
Total DJ-1 levels were detectable in the CSF samples from UCL and underwent 
statistical analysis as per the plasma samples, i.e. K-W post Kolgomorov-Smirnov 
test.   
 
Tables 6.16 summarises the data. 
 
Disease group n 
tDJ-1 mean 
(ng/mL) 
tDJ-1  median 
(ng/mL) 
SD 
PD+DLB 17 2.4 2.0 1.4 
MSA 17 2.3 2.0 1.7 
PSP+CBS 28 1.3 1.3 0.8 
Healthy controls 19 2.5 1.6 1.9 
 
Table 6.16: CSF samples from UCL data summary:  mean, median and SD calculated 




Total DJ-1 levels in CSF were significant (p=0.021), as per K-W test.  In order to 
assess whether this significance was confined to a particular disease group or all 
disease groups, Mann-Whitney tests were performed.  The data from this test is 
summarised in Table 6.17. 
  
 HC PD+DLB MSA PSP+CBS 
HC na 0.59 0.86 0.011 
PD+DLB 0.59 Na 0.88 0.010 
MSA 0.86 0.88 na 0.024 
PSP+CBS 0.011 0.010 0.024 na 
 
Table 6.17: Mann Whitney p-values for total DJ-1 levels in CSF samples from UCL data:  
p-values <0.05 are shaded in grey. 
 
Total DJ-1 levels in CSF were significantly lower in PSP+CBS individuals compared 




6.7  Correlation between total α-synuclein, total DJ-1 and phosphorylated α-
synuclein in CSF samples 
 
The data obtained from analysing the CSF samples from UCL for total DJ-1 and total 
α-synuclein using the duplex assay, and phosphorylated α-synuclein using the 
singleplex assay described in Chapters 3 and 4, were combined and tested for 
correlation using the non-parametric Spearman rank test.   
 









 CSF tDJ-1   CSF pαsyn  
 




Sig (2 tailed) na 0.787 






Sig (2 tailed) 0.787 na 
N 89 89 
 
Table 6.18: UCL CSF sample correlation; all disease groups: spearman rank statistical 





Figure 6.11: UCL CSF sample correlation; all disease groups:  scatter plot depicting the 




There was no significant correlation between levels of total DJ-1, total α-synuclein 
and phosphorylated α-synuclein in CSF. 
 
6.8  Correlation between total DJ-1 in plasma versus matched CSF samples 
 
The availability of matched plasma and CSF samples from UCL, allowed us to 
investigate whether levels of plasma total DJ-1 and CSF total DJ-1 within a particular 
individual correlated.  This was initially determined by combining the data obtained 
for all individuals regardless of their disease group.  The data set was checked for 
normality using the Kolgomorov-Smirnov test and was found to be non-normally 
distributed.  Therefore, the Spearman rank correlation test was adopted to test for 
any correlation between the plasma and CSF data (Table 6.19; Figure 6.12). 
 
The correlation was insignificant between plasma total DJ-1 and CSF total DJ-1 
(p=0.514).   
 
 
 CSF tDJ-1 Plasma tDJ-1 
 




Sig (2 tailed) na 0.514 
N 81 81 
 




Sig (2 tailed) 0.514 na 
N 81 81 
 
Table 6.19: Matched plasma vs CSF samples from UCL tDJ-1 correlation:  spearman 









A correlation test for total α-synuclein was not possible due to levels being 
undetectable in CSF. 
 
6.9 Total α-synuclein: total DJ-1: phosphorylated α-synuclein ratio 
assessment 
 
Studies by Wang et al (2012) suggested that a ratio between total α-
synuclein:phosphorylated α-synuclein in CSF may serve as a better biomarker than 
the two proteins on their own.  In this study, we investigated whether this idea can be 
adopted for plasma and whether calculating a ratio with plasma total DJ-1 levels 




A ratio for each sample analysed was calculated for total α-synuclein:phosphorylated 
α-synuclein, total α-synuclein:total DJ-1 and phosphorylated α-synuclein:total DJ-1 
levels.  The non-parametric K-W test was performed for each ratio assessment to 
deduce if these values were significantly different between the disease groups and  
healthy controls.  Table 6.20 summarises the data found. 
 
Parameter assessed p-value by K-W test  
phosphorylated α-synuclein : total α-synuclein  0.345 
phosphorylated α-synuclein : total DJ-1 0.231 
total α-synuclein : total DJ-1 0.098 
 
Table 6.20: Plasma Ratio assessment: ratio calculated for each plasma sample anlaysed 
and p-value obtained from K-W test (n=311) 
 
 
The ratio assessment was carried out for the CSF samples that were analysed too.  
Only the ratio between phosphorylated α-synuclein:total DJ-1 was performed, due to 
total α-synuclein levels being non detectable with our assay.   The K-W test showed 
that there was a significant difference between the different disease groups.  Thus, 
Mann-Whitney tests were performed (see Table 6.21). 
 
 HC MSA PD+DLB PSP+CBS 
HC na 0.224 0.000 0.025 
MSA 0.224 Na 0.000 0.225 
PD+DLB 0.000 0.000 na 0.033 
PSP+CBS 0.025 0.225 0.033 na 
 
Table 6.21: CSF Ratio assessment: phosphorylated α-synuclein:total DJ-1 ratio Mann- 





Calculating the ratio between phosphorylated α-synuclein and total DJ-1 levels 
showed a significant difference between PD+DLB, PSP+CBS vs the control group, 
MSA vs PD+DLB and PSP+CBS vs PD+DLB. 
 
6.10 Longitudinal study: total α-synuclein and total DJ-1 
 
Plasma samples collected longitudinally (every 4 – 6 months for up to 4 years) for PD 
patients have been analysed using the duplex assay.  A total of six individuals were 
analysed.  Figures 6.13 and 6.14 display the data obtained for plasma total α-
synuclein and plasma total DJ-1, respectively. 
 
Figure 6.13: Longitudinal plasma total α-synuclein: longitudinal samples from six PD 
individuals analysed using the duplex assay.  Levels of total α-synuclein analysed at each 









Figure 6.14: Longitudinal plasma total DJ-1: longitudinal samples from six PD individuals 
analysed using the duplex assay.  Levels of total DJ-1 analysed at each time point and plotted 
against the duration of disease for each individual. 
 
 
There was not enough data in order to generate meaningful statistical data, but a 
spearman correlation test was performed on the data collected to see if the protein 
levels correlated with disease duration.    There was no significant difference for the 
total DJ-1 levels but there was a significant difference for total α-synuclein (p = 0.02).  
A correlation between total α-synuclein and total DJ-1 levels in the longitudinal 






This chapter summarised the data from the analysis of total -synuclein and total 
DJ-1 in plasma and CSF collected from individuals with different neurodegenerative 




































The role and scientific relevance of -synuclein, with regards to neurodegenerative 
disorders, has already been discussed (see chapter 4).  Table 4.12 of chapter 4, 
summarises the studies performed so far on plasma total -synuclein and its 
potential use as a diagnostic biomarker for neurodegenerative disorders.  Present 
data displayed in this chapter show that there was no significant difference in the 
levels of plasma total -synuclein between AD, PD, DLB, MSA, PSP and the control 
group.  These findings disagree with those published by Lee et al (2006c), Duran et 
al (2010), who reported increased levels in PD and MSA vs HC and  Li et al (2007) 
who found decreased plasma total -synuclein levels between PD and HC.  The 
disagreement may be attributed to the different analytical methodologies utilised by 
these various research groups i.e. ELISA and Western blot vs Luminex.  This 
argument is reinforced by the fact that the data presented here does agree with that 
presented by Shi et al (2012), and that both of these sets of results are dependent on 
the use of a Luminex bead based assay for sample analysis. 
 
Unfortunately, in the present study, total -synuclein levels were not detectable in 
CSF.  This may be due to the assay format utilised, since other research groups 
have reported successful detection of the molecule in CSF (see Chapter 4, Table 
4.11).  It is best practise to use a calibrator diluent that closely matches the samples 
to be analysed.  Unfortunately, for the CSF duplex assay, a matrix-based diluent was 
not available and this compromised the assay’s accuracy and may have resulted in 
matrix effects that affected the detection of total -synuclein in the CSF samples.  
Furthermore, in an attempt to decrease such matrix effects, the assay utilised here 
involved diluting the samples x5 prior to analysis.  Close examination of other 
research groups' methods of analysis reveals that the CSF samples were either 




for the present assay not detecting any total -synuclein in CSF is that the 
analyte/protein may have been diluted out to below the detection limit. 
 
The interest in DJ-1 has intensified as the role of oxidative stress in 
neurodegenerative disorders has become more apparent (Zondler et al, 2014; Ariga 
et al, 2013; Dias et al, 2013).  A few studies have already investigated the potential 
use of total DJ-1 in plasma and CSF as a biomarker.  Tables 6.22 and 6.23 
summarize the findings from other research groups, which show that no clear picture 
has yet emerged. 
 






Waragai et al 
(2007) 
PD = 104 
DLB = 30 
HC = 80 
ELISA  
Immunohistochemistry 
Increased levels in 
PD vs controls 
 
Increased levels in 
DLB vs controls 
Shi et al (2010) PD = 126 
AD = 33 
HC = 122 
 
Luminex No significant 
difference 
Maita et al (2008)* PD = 95 
HC = 70 
Others = 30 
ELISA No significant 
difference 
 
Table 6.22: Summary of studies investigating the use of total DJ-1 levels in plasma as a 














Waragai et al 
(2006) 
PD = 40 
HC = 38 
Immunoblot Increased levels in 
PD vs controls 
Hong et al (2010) PD = 117 
AD = 50 
HC = 122 
 
Luminex Decreased levels in 
PD compared to AD 
and controls 
Herbert et al (2014) PD = 43 
MSA = 23 
HC = 30 
ELISA Increased levels in 
PD vs controls and 
even higher in 
patients with MSA 
 
Table 6.23: Summary of studies investigating the use of total DJ-1 levels in CSF as a 
biomarker for neurodegenerative disorders 
 
The data presented in this chapter show that the median total DJ-1 levels in plasma 
are lower in PD patients in comparison to MSA, AD and the control groups.  This is 
also the case for the PSP versus MSA, AD and control groups.  This data does not 
agree with the other research groups.  However, Shi et al (2010), who used the 
Luminex methodology have noted in their publication that although there was no 
significant difference between the PD, AD and controls, there was a trend of total DJ-
1 levels being lower in the PD and AD groups compared to the controls.   
 
The observed decrease in plasma total DJ-1 levels in PD and PSP groups may be 
given two possible explanations.  Oxidative stress is a reputable reason for the 
degeneration of neurones observed in neurodegenerative disorders.  Organisms 
have developed adaptive responses to counteract the damage caused by oxidative 
stress (Dias et al, 2013).  The main role of DJ- 1 is to protect against oxidative stress.  
Thus, the low DJ-1 levels in individuals with PD and PSP, suggest that such 




oxidative stress.  There have been reports that α-synuclein aggregates contain large 
complexes of DJ-1 (Meulener et al, 2005), which is further supported by the findings 
that DJ-1 interacts with α-synuclein directly (Zondler et al, 2014).  Therefore the low 
levels may be due to the fact that the DJ-1 is sequestered within the aggregates in 
PD and PSP individuals.    
 
This is the first report in which the potential use of plasma total DJ-1 as a 
differentiation marker between MSA and other neurodegenerative disorders as well 
as healthy controls has been investigated.  This is therefore the first study to find that 
plasma total DJ-1 levels carry the potential to differentiate between patients with PD 
and MSA.  This is an important finding, since MSA and PD are both very clinically 
similar and a diagnostic tool to differentiate between the two would be highly 
advantageous.  However, based on the ROC analysis, there is still scope to improve 
the use of total DJ-1 as a diagnostic tool; one possible way of increasing the 
diagnostic value of total DJ-1 is to use it in conjunction with other markers or other 
methods of diagnosis. 
 
CSF total DJ-1 did not show a significant difference between the PD+DLB, MSA and 
control groups.  Studies by other research groups have reported contradictory 
results, with Herbert et al (2014) reporting high levels in PD as well as MSA patients 
compared to healthy controls and Hong et al (2010) publishing decreased levels in 
PD patients compared to AD and normal controls.  The disparity between current 
findings and Herbert et al (2014) may again be attributed to the different method of 
analysis utilised; it appears that research groups that have used an ELISA kit as their 
testing system have reported increased levels of DJ-1 in their test samples.  The 
difference between the data presented in this chapter and by Hong et al (2010), may 




Hong et al (2010) analysed 117 PD samples, 122 healthy controls and 50 AD 
samples, which is a much bigger sample pool compared to the number of CSF 
samples that were available for the study presented in this chapter.  CSF total DJ-1 
levels were found to be significantly lower in the PSP+CBS group versus the other 
diseased groups and healthy controls.  However, this significant data needs to be 
approached with caution due to the following reasons: 
 
 Low sample number representing each disease group. 
 The lack of a matrix based calibration diluent and sample diluent which 
compromised the assay accuracy (refer to chapter 5).  Using a matrix based 
diluent would have resulted in a less sensitive assay as evident from the other 
Luminex based assays developed and described in this thesis.  The 
concentrations of total DJ-1 measured in the CSF samples in this study are very 
close to the assay LOD (to recall LOD = 1 ng/mL).  If a matrix based calibration 
diluent was utilised for the assay, it is likely that a lot of the samples with currently 
quantifiable levels of total DJ-1 would be below detection limits, thus affecting the 
overall significance of the data. 
 
Wang et al (2012) mentioned the possibility of using the ratio between CSF total α-
synuclein and CSF phosphorylated α-synuclein as a diagnostic tool for differentiating 
between PD, MSA, PSP patients and healthy controls.   Present data unfortunately 
showed that this is not reproducible when using plasma as the sample matrix.  The 
data has shown that using the ratio between phosphorylated α-synuclein and total 
DJ-1 levels in CSF carry the potential of differentiating between healthy controls and 
those classified in the PD+DLB group and PSP+CBS group.  The ratio may also 
differentiate between MSA and PD+DLB as well as PSP+CBS vs the PD+DLB group.  
However, again this data regarding CSF total DJ-1 levels needs to be approached 




Correlation assessments with plasma levels of total α-synuclein, total DJ-1 and 
phosphorylated α-synuclein have shown positive correlations for all disease groups 
between phosphorylated α-synuclein vs total α-synuclein and total α-synuclein vs 
total DJ-1 (latter did not correlate in the CBS group).  Interestingly, phosphorylated α-
synuclein levels positively correlated with total DJ-1 levels within the PSP, CBS and 
HC groups but not in the AD, PD, DLB and MSA groups.  From these findings we can 
speculate that DJ-1 works in synergy with non-phosphorylated α-synuclein and not 
phosphorylated α-synuclein.  This is supported by findings from Zondler et al, (2014), 
whose research has found that DJ-1 interacts directly with α-synuclein monomers 
and oligomers.  CSF total DJ-1 and phosphorylated α-synuclein correlations were 
non-significant as was the correlation between plasma total DJ-1 and CSF total DJ-1, 
but this data may change as more CSF samples are analysed. 
 
The mini longitudinal study presented in this chapter was not large enough to make 
valid statistical statements.  However, it is worthy to note that the significant 
difference between the total α-synuclein levels and disease duration was consistent 
with a previous study performed by Foulds et al, 2013, where log transformed total α-
synuclein levels have been shown to potentially serve as a disease progression 
marker.  The significant correlation between the two protein levels in the longitudinal 
samples reinforces the significantly positive correlation found with the one off patient 












Mutations in LRRK2 are the leading cause of both inherited and sporadic PD.  Since 
its discovery in 2004, research has been directed at investigating the role of LRRK2 
in neurodegenerative disorders (ND), particularly in PD pathogenesis.  Fraser et al 
(2013) showed that LRRK2 is secreted into CSF and has been detected in urine.  No 
research has yet been reported with regards to the possible detection of LRRK2 in 
plasma.  One of the aims of this project was to determine whether LRRK2 could be 
detected in plasma and CSF and thus deduce if LRRK2 levels carry the potential of 
being a diagnostic marker. 
 
The first method developed for LRRK2 detection was the Luminex bead based assay 
system. Western blotting with immunoprecipitation and HPLC was also investigated.  
This chapter presents the development of the Luminex assay, the data obtained from 
western blotting and results from the HPLC investigation.  
 
7.2  Luminex assay 
 
Development of the Luminex assays for phosphorylated α-synuclein, total α-
synuclein and total DJ-1 showed that carrier free antibodies, i.e. containing no 
sodium azide or BSA, work best with this assay system.  With this in mind two 
antibodies were selected for the development of the LRRK2 assay: 
 
1. SIG39840; mouse monoclonal antibody; Covance (1 mg/mL) 
2. ab133474; rabbit monoclonal antibody; Abcam (0.01 mg/mL) 
 
Both antibodies were tested as a capture reagent and as a detection component, in 
order to deduce which combination worked the best.  Figure 7.1 displays the MFI 




Figure 7.1: Testing different antibody combinations:  Luminex beads coupled with 0.01 µg 
of each capture Ab were used to capture 1000, 100, 10, and 0 ng/mL of recombinant LRRK2.  
2 µg/mL of biotinylated detection Ab and 4 µg/mL of streptavidin-RPE were used as the 
detection system for the assay.  The figure shows the raw MFI signals achieved with the 
different antibody combinations. 
 
The Abcam antibody as the capture component and the Covance antibody as the 
biotinylated detection antibody generated data with the highest signal to noise ratio, 
due to the low background.  Thus, this combination was taken forward in order to 
optimise the assay. 
 
Optimisation experiments involved bead titration and DAb titration tests.   
 
Capture Abcam with Covance DAb
























The bead titration experiment involved using beads captured with 0.005, 0.01, 0.015 
and 0.02 µg of the Abcam LRRK2 antibody.  Each bead set was then assayed with 
recombinant LRRK2 protein and 2 µg/mL of the Covance anti-LRRK2 detection 
antibody.  Figure 7.2 display data obtained from the bead titration tests. 
 
 
Figure 7.2: Abcam LRRK2 antibody bead titration:  Luminex beads coupled with 0.005, 
0.01, 0.015 and 0.02 µg were assayed with 0, 10, 100 and 1000 ng/mL of recombinant 
LRRK2 protein 2 µg/mL biotinylated detection pAb (Covance) with 4 µg/ml streptavidin-RPE.  
The figure shows the MFI signals obtained with each bead set at the varying recombinant 
LRRK2 protein concentrations (n=2). 
 
Beads coupled with 0.005 µg of the capture component generated the best 
signal:noise data.  The DAb titration experiment was carried out using these beads.  
Beads coupled with 0.0025 µg of capture Ab were also tested in order to deduce 
whether using less capture antibody would further improve assay performance.  The 
DAb titration test was performed with 2 µg/mL and 1 µg/mL of DAb.  Figure 7.3 




































Figure 7.3: Covance LRRK2 antibody DAb titration:  Luminex beads coupled with 0.0025, 
and 0.005 µg of Abcam LRRK2 antibody were assayed with 1 and 2 µg/mL biotinylated 
Covance detection antibody with 4 µg/ml streptavidin-RPE, to detect 0, 10, 100 and 1000 
ng/mL of recombinant LRRK2 protein.   The figure shows the signal:noise ratio obtained with 
each bead set with varying DAb concentrations (n=2). 
 
The best data with regards to signal:noise ratio were obtained with using beads 
coupled to 0.0025 µg capture Ab, with 1 µg/mL biotinylated DAb.  Subsequent 
experiments were performed using these components.  
 
The original idea was to multiplex this LRRK2 assay with the duplex assay described 
in chapter 5.  The cross reactivity test was performed as described in section 5.8.1, 
where three tests were performed sequentially. Unfortunately, this LRRK2 assay 
cross reacted with the duplex assay.  Table 7.1 displays the data obtained from this 






















0.005 µg beads :  1 µg/mL DAb
0.005 µg beads :  2 µg/mL DAb
0.0025 µg beads :  1 µg/mL DAb





Table 7.1: Multiplex cross reactivity test: multiplex beads comprised of tαsyn, tDJ-1 and 
LRRK2 beads assayed with individual DAbs specific to each analyte for the detection of 
recombinant LRRK2.  The columns shaded blue indicate the cross reactivity data obtained 
when using the multiplexed beads with the LRRK2 biotinylated DAb. 
 
Due to cross reactivity between LRRK2 and the tαsyn/tDJ-1 assays, the LRRK2 
assay was used as a singleplex. 
 
Plasma and CSF samples were screened for the presence of LRRK2, using this 
newly developed Luminex assay   The samples screened were taken from healthy 
individuals as well as individuals with various neurodegenerative diseases.   
 
Figure 7.4 summarises the predicted concentrations of LRRK2 for the plasma 
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Figure 7.4: CSF LRRK2:  The newly developed Luminex assay was used to screen CSF 
samples.  Each sample was diluted x 5 and analysed in duplicate.  The bar chart shows the 




Figure 7.5: Plasma LRRK2:  The Luminex assay was used to analyse plasma samples.  









































The mean CSF LRRK2 was 0.25 ng/mL with std 0.15 and the median 0.225 ng/mL.  
For plasma LRRK2, the mean was 0.32 ng/mL with std 0.6 and median of 0.1 ng/mL.  
The LOD of this assay was deduced to be 0.1 ng/mL for CSF and plasma.  The 
values detected for most of the samples screened were lower than the LOD, 
however, one plasma sample showed a signal that was approximately 30 times 
above the LOD.  In order to deduce whether the Luminex signal for this sample was 
specific for LRRK2, a spike recovery test was performed. 
 
Blank sample 



















Table 7.2: Spike recovery:  The plasma sample with detectable levels of LRRK2 was spiked 
with 5 and 25 ng/mL of recombinant LRRK2 protein.  The sample with and without spike was 
analysed in triplicate. 
 
Spike recovery was 93% and 112% for 5 ng/mL and 25 ng/mL of LRRK2, 
respectively.  The additional increase in LRRK2 concentration upon spiking 
recombinant LRRK2 into the sample suggests that the value obtained without the 
spike is specific for the presence of LRRK2, and that the signal was not due to non-
specific binding.  If the original signal for the sample was due to non-specific binding, 












7.3  Western Blot 
 
The Luminex assay system has been reported to be more sensitive than the 
traditional ELISA technique (Baker et al, 2012).  However, there are no reports 
indicating how its performance compares with other techniques such as western 
blotting.  This section displays the data obtained from western blotting 15 plasma and 
CSF samples that were previously analysed with the Luminex technique.  
Unfortunately the western blot failed to reveal the presence of any LRRK2 in CSF or 
plasma.  
 
Additionally, the single sample that yielded a high signal for LRRK2 with the Luminex 
method was immunoprecipitated (IP) prior to western blotting.   Figure 7.6 displays 




Figure 7.6: LRRK2 IP plasma Western blot image:  Lane 1 represents the protein marker 
standard.  Lane 2 is recombinant LRRK2 spiked (0.5 µg/mL) in buffer, Lane 3 equates to 
recombinant LRRK2 spiked (0.5 µg/mL) into human plasma and Lane 4 represents the IP 
plasma sample. 
 





















The western blot data showed that recombinant LRRK2 can be detected via this 
technique.  There is a slight visible band at 250 kDa for the IP sample, that may 
represent a cleaved form of LRRK2.  Unfortunately, upon repeat this band was no 
longer present.  Thus, this band may have been a “spillover” from the neighbouring 
wells. 
 
7.4  High Performance Liquid Chromatography (HPLC) 
 
As with the western blot, there are no reports regarding the performance of HPLC 
versus the Luminex.  Therefore, the samples previously analysed with the Luminex 
and western blot methods were also analysed with the HPLC technique.  
 
Prior to analysing the samples, 1 µg recombinant LRRK2 protein was spiked into 
PBS and analysed, in order to determine whether the column utilised was suitable for 
the separation and identification of LRRK2, and, if so, at what time the spike 
corresponding to LRRK2 would show on the chromatogram (retention time).  The 
original column used for this purpose was C18 – this yielded no spike on the 
chromatogram.  Therefore a C4 column was tried, Figure 7.6, chromatograms A) and 
B) display the resulting chromatogram. 
 
The retention time for 1 µg recombinant LRRK2 was 28 mins.  The next step was to 
deduce whether this retention time for recombinant LRRK2 remained at 28 mins in 
plasma.  Thus, a blank plasma sample was spiked with 1 µg LRRK2 recombinant 
protein and analysed.  Figure 7.7, C) and D) show the chromatograms for the blank 






Figure 7.7: HPLC: Plasma LRRK2:  chromatograms obtained with A) PBS only, B) PBS 
spiked with 1 µg recombinant LRKK2, C) plasma only and D) plasma spiked with 1 µg 
recombinant LRRK2. The x-axis represents the retention time (RT). 
 
The retention time remained at 28 mins for recombinant LRRK2 in plasma.  Plasma 
samples analysed yielded chromatograms similar to that presented in Figure 7.7 













CSF samples were tested for the presence of LRRK2 via HPLC.  Figure 7.8 display 
the data obtained with CSF spiked with LRRK2 and an example chromatogram 

































Figure 7.8: HPLC: CSF LRRK2:  chromatograms obtained with A) PBS spiked with 1 µg 
recombinant LRKK2, B) CSF spiked with 1 µg recombinant LRKK2 and C) CSF only. The x-
axis represents the retention time (RT). The small peak in C) may represent LRRK2 but need 









7.5  Discussion 
 
This chapter described the initial experimental steps taken to investigate the potential 
role for LRRK2 as a biomarker for ND diseases.  In order to deduce whether LRRK2 
carries biomarker potential, it was important to find out if LRRK2 is actually present in 
biological fluids.  Research into the presence of LRRK2 in biological fluids has been 
minimal; Fraser et al (2013) have provided some evidence for the detection of 
LRRK2 in CSF and urine exosomes whilst researching the role of LRRK2 in relation 
to protein 14-3-3.  This chapter describes a method for detecting LRRK2 in plasma 
and CSF using the Luminex bead based system.  The detection methods used by 
Fraser et al (2013) are predominantly western blotting, which would be laborious and 
slow, and also less quantitative, when compared to the Luminex system. 
 
The samples screened in this investigation revealed that no CSF samples contained 
detectable LRRK2 and only one plasma sample gave a relatively high signal for 
LRRK2 - this particular sample was taken from an AD patient.  Presence of LRRK2 in 
plasma may follow the same pattern as α-synuclein in plasma – where levels vary 
greatly between individuals, i.e. some individuals are high expressors and others 
have low to non-detectable levels (Foulds et al, 2013).  However, more samples will 
need to be tested in order to infer this. 
 
LRRK2 was not detectable via the HPLC and western blot techniques, which 
suggests that the Luminex may be a more sensitive platform compared to these 
systems.  Future work can incorporate mass spectrometry to confirm and validate the 
detection of LRRK2 using the Luminex method.       
 
Despite this investigation not revealing substantial evidence for the presence of 




advance the research into detecting LRRK2 in plasma and CSF.  In addition to a 
biomarker being valuable as a diagnostic tool, it can also serve as an important tool 
for use in pharmaceutical research.  For instance, the Luminex detection method 
described in this chapter may prove to be useful in clinical trials where the detection 
of LRRK2 may act as a pharmacodynamic marker post therapeutic intervention. 
 
  
Chapter 8:    





The incidence rate of neurodegenerative disorders is increasing, thus, the need for 
accurate and early diagnosis is becoming more vital.  Many techniques are being 
investigated in order to improve early diagnosis of such diseases and allow the 
monitoring of disease progression to aid therapeutic strategies.  Techniques being 
investigated include, but are not limited to – neuroimaging, genetic variation studies 
and molecular markers. The latter is the topic presented in this thesis. 
 
Aβ1-42 and tau protein levels in CSF have been identified as biomarkers for AD and 
many studies have been conducted in order to promote their use in clinical settings 
(see e.g. Blenow et al, 2014; Menendez-Gonzalez, 2014).  Currently, no reliable 
markers have been found for other neurodegenerative disorders such as PD, DLB, 
MSA, FTLD and MND.  For the purpose of this project, some of the key proteins 
implicated in the pathogenesis of these neurodegenerative disorders were 
investigated as potential biomarkers, as shown in the table below: 
 
Neurodegenerative disease Protein(s) implicated 
AD β-amyloid (Aβ),  tau 





The original goal for this study was to investigate the potential of the above proteins 
as biomarkers, ultimately in a multiplex system.  Although studies on Aβ1-42 and tau 




this and other neurodegenerative disorders has been minimal.  Taking samples of 
CSF is a relatively invasive procedure, and there has been some debate regarding 
the safety and wellbeing of patients undergoing repeated lumbar punctures 
(Menendez-Gonzalez, 2014).  Thus, our main aim was to investigate the biomarker 
effectiveness of these proteins in plasma as opposed to CSF. 
 
Unfortunately, Luminex assays for Aβ1-42 and TDP-43 were not successful (data not 
included).  The antibodies against TDP-43 available for testing with the Luminex 
assay were very few.  In total only three antibodies were commercially available, and 
were tested as capture and detection components.  These antibodies did not 
generate an acceptable signal:noise ratio and were thus not investigated further.  A 
range of antibodies against Aβ1-42 were commercially available for testing on the 
Luminex, with antibody combinations generating acceptable Luminex MFI signals.  
However, the assay performance was not consistent, and, therefore, these assays 
did not pass the validation stage.   
 
Luminex assays for quantifying phosphorylated α-synuclein, total α-synuclein, and 
total DJ-1 in human plasma and CSF were successful.  ELISA assays have been 
deemed as the gold standard method for protein detection (Wilson, 2013).  However, 
based on the data obtained in this project, the Luminex assays have proved to be 
more sensitive than ELISA based assays.  The improvement in assay performance 
may be attributed to the use of microsphere beads in the Luminex technology.  
During ELISA, capture antibody is passively immobilised on to the walls of a 
microtitre well, leading to the possibility of unspecific hydrophobic binding.  The 
Luminex utilises beads onto which the capture antibody is chemically attached via 
covalent bonds – reducing the risk of such unspecific binding.  Additionally, the 
surface area of a microtitre plate compared to a well containing many beads is 




Luminex system (Baker et al, 2012).  High sensitivity and specificity as well as good 
accuracy and precision are desired features for assays used in biomarker research.  
The present project showed that the developed Luminex assays described in this 
thesis meet these requirements. 
 
A lot of biomarker research has been dedicated to α-synuclein; not surprising since 
α-synuclein is the major protein component involved in some important 
neurodegenerative disorders, namely PD, MSA and DLB.  Currently, results 
regarding the use of α-synuclein as a biomarker have been variable between 
different research groups (chapters 4 and 6 discuss these in detail).  This project 
assessed both total α-synuclein and its phosphorylated form.  Studies with 
phosphorylated α-synuclein have been minimal, especially in plasma.  Unfortunately, 
in this present study, neither total α-synuclein nor phosphorylated α-synuclein in CSF 
or plasma showed significant value as a differentiation marker.  Apart from 
differences in the methodology used for detection, and variation in sample number, a 
recent study published by Stewart et al (2015) suggests another plausible reason for 
the variation in results amongst research groups, especially regarding 
phosphorylated α-synuclein.  Stewart et al (2015) conducted a large scale 
longitudinal and cross-sectional study with phosphorylated α-synuclein in CSF 
samples collected from PD patients, and correlated the values with the disease stage 
for each individual.  Their research suggested that levels of phosphorylated 
α-synuclein follow a trend in which high levels of phosphorylated α-synuclein are 
detectable in patients at the very early stage of PD and low levels in those at the late 
stage.  This type of trend may be extended to other disease groups such as MSA 
and DLB and, furthermore, may also be applicable to studies with plasma.  Indeed, 
Foulds et al (2013) have recently reported that plasma total α-synuclein levels 




suggesting that consideration of stage of disease is also important for analysis of 
α-synuclein in plasma.  These two publications highlight a possible limitation in our 
study and stress the importance of obtaining disease stage and severity information 
from the samples analysed.  The possibility of the trend proposed by Stewart et al 
(2015) being replicated in plasma is strengthened by our finding that phosphorylated 
α-synuclein in CSF correlates with plasma phosphorylated α-synuclein.  This further 
supports the suggestion that plasma can reflect the environment of the brain and 
reinforces the use of plasma for biomarker studies as opposed to CSF, which would 
be preferred for practical reasons. 
 
Multiple factors have been associated with the onset of neurodegenerative disorders.  
Amongst these multiple factors, oxidative stress has been suggested as a possible 
cause.  In light of this and the fact that mutations in DJ-1 lead to early onset PD, its 
role as a biomarker was investigated.  The overall position of DJ-1 as a biomarker is 
similar to α-synuclein, where results so far are variable between research groups – 
though it is worthy to note that studies relating to DJ-1 have been less intense than 
those with α-synuclein.  The study conducted for this project revealed that DJ-1 does 
carry potential as a biomarker that can differentiate between PD and HC as well as 
between PD and MSA, with DJ-1 levels in plasma being significantly lower in PD.  
This is the first study in which the capability of DJ-1 in plasma to differentiate 
between these two clinically similar diseases (i.e. PD and MSA) has been assessed.  
However, the ROC curve analysis revealed that DJ-1 may not serve very well as a 
single diagnostic marker for PD vs HC, or PD vs MSA, but does hold promise as a 
biomarker, possibly if used in conjunction with other diagnostic techniques, and this 
is worth pursuing.   
 
Correlation studies with DJ-1 and α-synuclein also revealed some interesting insights 




DJ-1 levels and total α-synuclein levels in plasma show a positive correlation with 
one another, but DJ-1 levels do not correlate with phosphorylated α-synuclein.  Thus, 
individuals expressing low levels of DJ-1 also have low levels of total α-synuclein, 
and, conversely, high DJ-1 expressors also tend to show high total α-synuclein 
levels.  Since low DJ-1 levels are implicated in some diseased states, DJ-1 
interaction with α-synuclein may be neuroprotective, and the absence of DJ-1 may 
hinder this neuroprotection.  This leads to a possible therapeutic strategy, where 
levels of DJ-1 can be increased in those with low levels, to boost neuroprotection.  
 
Mutations in LRRK2 are the leading contributor to the genetic cause of late onset PD.  
Research into the role of LRRK2 in PD pathogenesis is ongoing and the potential of 
using LRRK2 therapeutics is being investigated (Lee et al, 2012).  In this project, 
several techniques have been explored in order to determine if LRRK2 is detectable 
in biological fluids such as CSF and plasma.  The data obtained from this project with 
recombinant LRRK2 indicate that techniques such as the Luminex, western blotting 
and HPLC can be adopted to detect LRRK2 in human plasma and CSF.  However, 
from the samples analysed within this study, it cannot be definitively concluded that 
LRRK2 is present and measurable in human CSF and plasma.  Analysis of more 
samples may provide a greater insight into the biomarker potential for LRRK2.  
Additionally, if LRRK2 based therapeutics are pursued, assays such as the Luminex 
LRRK2 assay described herein could prove to be a useful tool. 
 
Progress towards understanding and developing potential treatment strategies for 
neurodegenerative disorders has been rapid, but more research is still needed in 
order to understand the disease mechanisms.  The work presented in this thesis 
shows that research into biomarkers for diagnostic purposes for such diseases can 







1.   Expand on the multiplex assay 
Neurodegenerative disorders are multicausal with the possibility that factors leading 
to disease differ amongst those affected.  Thus, it would seem fitting to have multiple 
markers for diagnostic purposes.  The Luminex technology offers the possibility of 
developing a multiplex assay whereby multiple molecular markers can be measured 
simultaneously from a single sample.  These molecular markers can range from 
inflammatory markers to molecules similar to those discussed in this thesis.  As a 
follow on to the present study, other PD related molecules can be added to the 
existing multiplex assay, such as: 
 
 Parkin:  mutations in Parkin have been associated with the onset of autosomal 
recessive PD as well as sporadic PD.  Parkin is a component of the UPS and has 
a role as an ubiquitin E3 ligase, with its loss of function leading to PD 
pathogenesis.  Substrates for Parkin are still relatively unknown, but previous 
studies have revealed that α-synuclein may be a substrate, either directly or 
indirectly (Dawson et al, 2010). Previous studies at Lancaster (Foulds. P, 2008 
PhD thesis) have suggested that Parkin is present in human blood plasma. 
 Oxidized DJ-1:  the role of DJ-1 has been covered in detail in this thesis.  The 
mechanism of action for DJ-1 involves its cysteine residue at position 106 being 
oxidised.  Thus, levels of oxidised DJ-1 in CSF and plasma can be measured in 
order to investigate its potential as a biomarker (Saito, 2014).  
 Glucocerebrosidase:  mutations in the glucocerebrosidase gene have revealed 
them to be an important risk factor for PD.  The protein is involved in the 
lysosomal degradation pathway and its loss of function leads to PD pathogenesis.  




investigated; therefore including this protein in the multiplex panel may provide 
interesting information regarding its value as a biomarker as well as its 
mechanism of action and interaction with other proteins. 
 An attempt to modify the LRRK2 assay once more antibodies are commercially 
available can be attempted, in order to multiplex it in with the other molecules.  
 
Additionally, the assay panel can be expanded to include markers relevant to various 
neurodegenerative disorders other than PD, for example: 
 
 TDP-43:  a RNA/DNA binding protein that is the major component found in the 
protein inclusions associated with FTLD-U and MND.  As mentioned previously, a 
Luminex assay for TDP-43 has been attempted but the major drawback was the 
poor availability of antibodies.  Therefore, if more antibodies become available 
the development of this assay can be revisited.  
 
 FUS:  another RNA/DNA binding protein that has been linked to the MND-FUS.  
Like TDP-43, mutations in FUS lead to the formation of FUS aggregates, thus 
may be worth pursuing as a potential biomarker candidate. 
 
 Neurofilament: neurofilament proteins are a predominant feature of neuronal 
axons and have a key role in the growth and maintenance of nerve cells.  Recent 
studies by Lu et al (2015) have shown that levels of neurofilament light chain 
protein (NF-L) can differentiate between MND and healthy controls.  Furthermore, 
serum NF-L levels are higher in FTD patients than in healthy controls.  Therefore, 
adding this to the Luminex multiplex panel may serve to discriminate FTD or 





 Neurogranin:  this is a postsynaptic protein that is a member of the calpactin 
family and is involved in calcium signalling (Represa et al, 1990).  It is expressed 
exclusively in the brain and specific to the dendritic spines (Chang et al, 1997).  
Neurogranin levels in CSF from AD pateints have been shown to be higher in 
comparison to cognitively normal individuals (Thorsell et al, 2010; Kvartsberg et 
al, 2015; Kester et al, 2015).  Cortical neurones expressing neurogranin have 
also been shown to degenerate in the late stages of PD (McKeith et al, 2005b) 
and Koob et al, 2014 have shown that neurogranin binds to α-synuclein, thus 
making it a potential biomarker for further investigation. 
 
 Synaptotagmin: a synaptic vesicle protein that has been found to be raised in AD 
patients versus controls (Davidsson et al, 1996).  More recently, Sesar et al, 2016 
has shown a siginificant association between SNPs in SYT11, which codes for 
the protein synaptotagmin XI. 
 
 Synaptosomal associated protein-25 (SNAP-25):  this protein is an important 
component of the membrane-fusion SNARE complex which is essential for 
mediating synaptic communication (Jahn et al, 1999).  Increased levels of CSF 
SNAP-25 in AD patients have been found in comparison to control groups 
(Brinkmalm et al, 2014). 
 
2.  Longitudinal sample analysis 
 
Longitudinal plasma samples from 198 PD patients, with samples collected at 10-11 
visit points over a period of 4 years, have already been collected as part of a 
previous study (Foulds et al, 2013) and are available for testing.  These valuable 




molecules carry potential as early diagnostic markers for PD, or markers of disease 
progression.   
 
Moreover, some PD patients develop dementia as the disease progresses.  Thus, a 
study with these longitudinal samples and the multiplex assay may reveal a marker 
that can help to identify those people who will ultimately progress on to develop 
dementia. 
 
Demographic data, such as disease stage, disease severity as per the UPDRS and 
Hoehn and Yahr scores, and information regarding medication, is also available for 
this longitudinal cohort of patients with PD.  Information such as this will allow 
interesting correlation studies to reveal possible relationships between molecular 
markers and disease severity – similar to those investigated by Stewart et al (2015). 
 
Furthermore, a whole blood sample was also taken from the enrolled PD patients.  
This whole blood sample can be used for genomic studies that can show if any of the 
patients have abnormal mutations or particular gene polymorphisms.  The genomic 
data can be compared against the molecular marker data and assessed for any 
corresponding relationships. 
 
3.  Mass spectrometry   
This technique can be developed and used alongside the Luminex multiplex assay in 
order to validate/confirm the data obtained from the latter.  Samples would need to 
undergo special treatment in order to deplete them of high abundance proteins, such 
as albumin.  Post treatment, these samples can be fractionated by HPLC and then 
analysed using mass spectrometry.  Alternatively, if the protein of interest generates 
an acceptable band via the western blot technique, the mass spectrometry method 
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1. Microspheres diluted 1 in 20 in PBS+ 0.05% (v/v) tween 20 (PBST), vortex to 
remove doublets 
 
2. Prepare the standards in serial dilution in assay buffer (SM01:PBS) 
 
 
3. Pre wet 96-well filter microplate with 200µl PBST and use vacuum manifold to 
aspirate wash solution. Blot filter plate dry with paper towel.   
 
4. Add 20 µl diluted microspheres to each well (Total 5,260 Beads/well) 
 
 
2. Add 200 µl PBST to each well. Aspirate plates via the vacuum manifold and 
blot dry on paper towel 
 
3. Pipette 50 µl of diluted standard or sample per well. Agitate on a microplate 
shaker for 2 hrs at room temperature and covered with aluminium foil  
 
 
4. Agitate on a microplate shaker overnight at 4oC, covered with aluminium foil  
 
 
5. Following incubation aspirate and blot filter plate dry with paper towel  
 
6. Wash plate with 200µl PBST and use vacuum manifold to aspirate wash 
solution. Blot filter plate dry with paper towel. (Repeat 2 times) 
 
 
7. Add 50 µl/well diluted biotinylated secondary antibody in assay buffer 
(SM01:PBS) and agitate on a shaker covered with aluminium foil for 1 hr at 
room temperature in the dark. 
 
 
8. Add 50 µl/ well Streptavidin  diluted at 4ug/ml in PBST, agitate on a shaker 
covered with aluminium foil for 30 mins at room temperature in the dark 
 
 
9. Following incubation, aspirate and blot filter plate dry with paper towel 
 
10. Wash plate  3 times with 200µl PBST using vacuum manifold  
 
 
11. Resuspend beads in 125 µl of Luminex sheath fluid and agitate on a shaker 
for 1 min, at high speed 
 
12. Read plate in Luminex 200 machine 
 
